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ABSTRACT 
Cardiovascular disease (CVD) is the leading cause of mortality among US adults, and 
African Americans have a higher burden of CVD morbidity and mortality than any other racial 
group. Identification of novel CVD biomarkers is essential to better identify at-risk individuals, 
advance precision medicine, and inform efforts to reduce CVD burden. DNA methylation 
(DNAm) is an epigenetic mechanism that captures genetic influences as well as imprints of 
lifestyle and environmental exposures throughout the life course. DNAm patterns may help 
identify biological mechanisms contributing to CVD pathogenesis. This dissertation explores the 
effects of DNAm and DNAm-based epigenetic age acceleration (EAA) on cardiometabolic risk 
factors, atherosclerosis, CVD incidence, and target organ damage from hypertension (TOD) in 
African American participants from the Genetic Epidemiology Network of Arteriopathy 
(GENOA). In Aim 1, we used univariate and multivariate linear mixed models to assess the 
epigenome-wide association between DNAm sites (CpGs) and measures of TOD in the heart 
(left ventricular mass index (LVMI) and relative wall thickness (RWT)), kidneys (estimated 
glomerular filtration rate (eGFR) and albuminuria), and brain (white matter hyperintensity). 
LVMI, RWT, and albuminuria were each associated with one CpG in univariate models, and 
seven CpGs were associated with TOD measures in the multivariate (pleiotropy) model (false 
discovery rate (FDR) < 0.1). Mendelian randomization analysis provided evidence of a causal 
pathway between three CpGs and eGFR. In Aim 2, we assessed the associations between four 
measures of EAA, 10 cardiometabolic risk factors, and CVD incidence. We then evaluated 
 xvi 
whether EAA improved the predictive accuracy of two clinically-used CVD risk scores: the 
Framingham risk score (FRS) and the Atherosclerotic Cardiovascular Disease risk equation 
(ASCVD). Increased biological aging, as assessed by EAA, was associated with worse 
cardiometabolic risk profile, but the associations between each of the four EAA measures 
differed across cardiometabolic risk factors. GrimAge acceleration (GrimAA) was associated 
with CVD incidence (hazard ratio per 5-year increase 1.47, 95% CI: 1.05 – 2.01, P = 0.024) after 
adjusting for traditional CVD risk factors. GrimAA improved model fit over clinical risk scores 
using likelihood ratio tests (P = 0.013 for FRS, P = 0.008 for ASCVD), did not improve C 
statistics (P > 0.05), and marginally improved net reclassification index (NRI) which assesses 
reassignment of risk categories (NRI = 0.055, 95% CI: 0.040 – 0.071 for FRS; 0.029, 95% CI: 
0.006 – 0.064 for ASCVD). In Aim 3, we evaluated in prospective analyses whether EAA 
measures, previously identified atherosclerosis-associated CpGs, and methylation risk scores 
(MRSs) derived from these CpGs are associated with single- or multi-site atherosclerosis 
(coronary artery calcification (CAC), abdominal aorta calcification (AAC), and ankle-brachial 
index (ABI)). One and six CpGs were associated with AAC and multi-site atherosclerosis, 
respectively (FDR < 0.1). Both a 5-year increase in GrimAA as well as a one unit increase in the 
MRS for carotid artery plaque were associated with a 1.6-fold increase in AAC and 0.7 units 
increase in multi-site atherosclerosis (score range: 0-12) after adjusting for CVD risk factors 
(Bonferroni-adjusted P < 0.05). Together, these studies support the premise that DNAm plays an 
important role in CVD and TOD and is a promising biomarker that may improve risk assessment 
in African Americans. 
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Chapter 1.  Introduction 
1.1 Overview 
Health disparities are preventable differences in the indicators of health across different 
population groups.1 In the United States, African Americans bear a disproportionate burden of 
disease, death, and disability for a number of health outcomes, most notable of which are 
cardiovascular diseases (CVDs).2 A number of underlying factors contribute to CVD disparities 
including biological, social, and environmental risk factors. Disparities in cardiovascular health 
have been persistent over the last few decades despite the overall declining trends in CVD across 
all groups.3 African Americans ages 18-49 are two times as likely to die from CVD as non-
Hispanic Asian or Pacific Islander individuals.4 Similar disparities exist in the prevalence of 
cardiovascular risk factors and are most pronounced in hypertension, which is associated with 
structural and functional changes in the end organs like the kidneys, eyes, brain, peripheral 
arteries, and heart.5 African Americans over 20 years of age have the highest prevalence of 
hypertension, estimated to be 41% higher than non-Hispanic whites.6  
1.1.1 Clinical Cardiovascular Diseases 
Collectively, CVD includes coronary heart disease (CHD), transient ischemic attack or 
stroke, heart failure, and peripheral arterial disease. CVD is the number one cause of death in the 
US and it is estimated that 9% of the US adult population has heart disease.7 Estimates from the 
National Health and Nutrition Survey (NHANES, 2013-2016) show the prevalence of total CVD 
to be approximately 10.5% among African American adults, with CVD accounting for about 
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30% of the deaths.7 African Americans have a greater burden in the onset of stroke, peripheral 
vascular disease, and heart failure, but not CHD.3,7 Nevertheless, cardiovascular mortality 
remains higher in African Americans compared to whites.8  
CHD clinically manifests as stable angina, unstable angina, or myocardial infarction 
(heart attack). CHD alone contributed to more than 45% of the total deaths attributable to CVD, 
equivalent to approximately 1 of every 7 deaths in the United States in 2011.9 CHD prevalence is 
estimated to be 7.7% in white males, 7.2% in African American males, 6.1% in white females, 
and 6.5% in African American females (NHANES 2013-2016).7 Although CHD prevalence is 
not significantly higher in African Americans compared to whites, African Americans have 
higher overall CVD mortality.3 Analysis of data from the Atherosclerosis Risk in Communities 
(ARIC) study shows that the rate of CHD decline between 1987-2000 for African Americans 
males is only about half the rate for white males (-3.2%/year vs. -6.5%/year) and about two 
thirds the rate for white females (-4.0%/year in African American females vs. 5.8%/year in white 
females).10 Longitudinal follow-up in the ARIC, the Cardiovascular Health Study (CHS), and the 
REasons for Geographic And Racial Differences in Stroke (REGARDS) study show that African 
American males have similar risks of fatal CHD, lower risk of nonfatal CHD, and higher CHD 
case-fatality compared to whites after adjustment for social determinants of health and 
cardiovascular risk factors.11  
Stroke, another major cardiovascular disease, ranks 5th in the causes of death in the US.12 
It is estimated that 7.8 millions of adults in the US have had a stroke.13 The prevalence of stroke 
using NHANES (2013-2016) is 3.1% in African American males, 2.4% in white males, 3.8% in 
African American females, and 2.5% in white females.7 Disparities are also most notable in 
stroke mortality despite overall national trends of decreased mortality and incidence.3,14-16 In 
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adults ages ≥ 45 years, African American males had 54% higher age-adjusted stroke death rates 
than white males, and African American females had a 30% higher death rate than white 
females.14  
1.1.2 Subclinical Cardiovascular Disease and Atherosclerosis 
Atherosclerosis, a precursor for CVD, is a chronic inflammatory condition that develops 
over several decades.17-19 It is a complex process where calcification of the intimal layer of the 
arterial wall occurs as a result of an inflammatory response to lipid accumulation and focal 
plaque formation.20 Intimal calcium deposition is often seen in the coronary arteries surrounding 
the heart and peripheral arteries. Atherosclerotic lesions can lead to diminished blood flow to the 
organs that presents as cardiac ischemia or claudication.  Atherosclerotic plaque rupture leads to 
arterial occlusion with subsequent blood flow interruption that manifests as heart attack, stroke 
or limb ischemia.17,21-23  
Atherosclerosis starts early in life with lesions starting as only fatty streaks consisting of 
monocyte derived macrophages and T lymphocytes.17,24 A number of factors may induce and 
promote atherogenesis such as endothelial dysfunction, elevated low-density lipoproteins, and 
hypertension. The continued inflammation results in further activation and migration of 
macrophages and lymphocytes and an increase in cytokines, chemokines and other growth 
factors. Through these continued cycles of inflammation and migration of cells, the fatty streak 
becomes enlarged and changes into a fibrous plaque with a necrotic core.17 Calcification of the 
plaque may ensue where macrophages in the plaque promote osteogenic differentiation and 
calcium deposition.22 Continued calcification may then stabilize the plaque and provide a wall 
between the plaque and the blood pool, which may decrease the risk of plaque rupturing.22  
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One imaging modality for the quantification of atherosclerosis in the coronaries and aorta 
is noninvasive computed tomography (CT) scans. The Agatston score is used to quantify the sum 
of the total calcified area and maximum density calcification.22,25 For individual lesions, the 
Agatston score is derived by multiplying the lesion area with a density weighting factor (DWF) 
in Hounsfield units (HU) units. The DWF is derived from the maximal CT attenuation within a 
given calcified lesion and reflects increasing categories of Hounsfield units (Hu) (DWF: 130 to 
199 HU = 1; 200 to 299 HU = 2; 300 to 399 HU = 3; and ≥ 400 HU = 4).26 Hence, the Agatston 
score is weighted upward for greater CAC density.27 The scores for all lesions is then summed 
over all lesions to determine the total Agatston score.26 
𝐴𝑔𝑎𝑡𝑠𝑡𝑜𝑛 𝑠𝑐𝑜𝑟𝑒𝑙𝑒𝑠𝑖𝑜𝑛 = 𝐴𝑟𝑒𝑎 × 𝐷𝑊𝐹 
𝐴𝑔𝑎𝑡𝑠𝑡𝑠𝑜𝑛 𝑠𝑐𝑜𝑟𝑒𝑡𝑜𝑡𝑎𝑙 =  ∑ 𝐴𝑔𝑎𝑡𝑠𝑡𝑜𝑛 𝑠𝑐𝑜𝑟𝑒𝑙𝑒𝑠𝑖𝑜𝑛 
Both coronary artery calcium (CAC) and abdominal aorta calcium (AAC) have been found to be 
independent predictors of CVD incidence and mortality.28-30 Calcification in the peripheral 
arteries can be assessed using the ankle-brachial index (ABI), which is calculated as the ratio of 
systolic blood pressure at the ankles divided by the brachial pressure. Previous studies have 
reported ABI to be a robust predictor of peripheral arterial disease and mortality.31-33 Abnormally 
high ABI (>1.3) suggests the presence of calcified vessels that may not compress normally 
which may occur in the setting of underlying diabetes or end-stage kidney disease.34 
Despite having a higher burden of CVD and traditional risk factors, African Americans 
have a lower prevalence of CAC and AAC.35-40 In about 6,800 MESA participants, the relative 
risk of CAC in African Americans compared to whites was 0.78 (95% CI 0.74–0.82) after 
adjusting for socioeconomic and clinical risk factors.41 African Americans, however, are more 
likely to have carotid atherosclerosis and a higher carotid intima media thickness (IMT). In the 
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same MESA sample, African Americans were found to have the highest common carotid IMT 
compared to other racial groups.42 Finally, African Americans have a higher prevalence of 
peripheral arterial disease that was not explained by traditional and novel risk factors.7,43,44 
1.1.3 Cardiac and Renal Target Organ Damage of the Heart, Kidneys, and Brain  
Among African Americans, the prevalence of hypertension is estimated to be the highest 
in the world, and although awareness and treatment rates are higher than those of other racial 
groups, control of high blood pressures remains lower in African Americans compared to 
whites.45 In this dissertation we defined hypertension as having an average systolic blood 
pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg, or current anti-hypertensive 
medication use, following previously established guidelines. More recent guidelines by the 
American College of Cardiology/American Heart Association (ACC/AHA) apply a lower 
threshold: a systolic blood pressure ≥ 130 mmHg or a diastolic blood pressure ≥ 80 mmHg.46 
Hypertension over time contributes to structural and functional changes in organ systems, 
referred to as target organ damage (TOD). High blood pressure causes reduced arterial plasticity 
and endothelial wall damage, which in turn triggers the deposition of lipids in the wall lesions, 
leading to atherosclerotic plaque build-up and the subsequent obstruction of these vessels.5,47 As 
the vascular resistance increases, the systolic function is increased to maintain adequate organ 
perfusion.5,47 Renal injury occurs when the regulatory mechanisms of the kidneys are unable to 
maintain flow and pressure, resulting in an increase in glomerular hypertension, permeability, 
and proteinuria.5 In the heart, the remodeling of the myocardium ensues as the cardiac muscle 
adapts to the increased resistance in the circulation. This results in hypertrophy and increased 
myocardial thickness that eventually reduces relaxation of the heart muscle.5 In the brain, small 
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vessel disease is associated with decreased blood flow and hypoperfusion and results in lesions 
seen in the white matter.5 
TOD in the heart can be quantified using echocardiography imaging, which provides 
precise measurements of the dimension of the heart such as left ventricular mass and relative 
wall thickness. In the kidneys, TOD can be assessed using glomerular filtration rate and 
albuminuria. Hyperintensity of the white matter on brain MRI is often used to assess TOD in the 
brain. Compared to whites, epidemiological studies have shown that African Americans have 
greater left ventricular mass 48,49, higher incidence of chronic kidney disease, higher incidence of 
end stage renal disease,50,51 and more severe white matter hyperintensity burden,52,53 a trend that 
is in parallel to their higher hypertension burden. 
While subtle TOD may start as asymptomatic in the early course of hypertension, more 
severe organ damage typically happens after long periods of uncontrolled hypertension.54 
Clinical endpoints of TOD include symptomatic chronic kidney disease, systolic and diastolic 
dysfunction, dementia and transient ischemic attack. Further complications can lead to end-stage 
renal disease, myocardial infarction, and stroke.54 These thrombotic effects of hypertension 
leading to clinical events are facilitated by damage to the vessel wall, hypercoagulability, and 
abnormal blood flow.54 In addition, the well documented cardio-renal interactions, where chronic 
dysfunction of one organ may induce dysfunction in the other, can further contribute to the 
progression of TOD into more pronounced clinical and cardiovascular events.55 
1.2 Risk Factors for Cardiovascular Diseases and Target Organ Damage 
Surveillance data from NHANES and the Behavioral Risk Factor Surveillance System 
(BRFSS) show that marked disparities exist in both measured and self-reported cardiovascular 
risk factors which contribute to disparities in cardiovascular health.1 These include traditional 
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risk factors such as hypertension, type 2 diabetes mellitus, dyslipidemia, and obesity as well as 
adverse health behaviors such as smoking, poor diet quality, and physical activity.1,3 In addition, 
there is emerging evidence that social and socioeconomic factors such as educational attainment, 
built-environment, neighborhood environment, access to care, psychosocial stress, and 
discrimination are important factors that contribute to the disparities in cardiovascular 
morbidities and mortality.56  
The age adjusted prevalence of high blood pressure among adults ages ≥ 20 years 
between 2013 and 2016 was 46% for the total US population, 57.6% among African American 
males, 53.2% among African American females, 46.7% among white males, and 38.8% among 
white females.7 The prevalence of diabetes between 2013 and 2016 was 9.8% for the total 
population, 14.7% and 13.4% in African American males and females, and 9.4% and 7.3% in 
white males and females, respectively.7 Longitudinal evidence from the Coronary Artery Risk 
Development in Young Adults (CARDIA) study showed that the higher risk of diabetes onset 
among African Americans appears to be mediated by biological, neighborhood, psychosocial, 
socioeconomic, and behavioral factors.57 Prevalence estimates of dyslipidemia (defined as 
having total cholesterol levels ≥ 240 mg/dl, low density lipoprotein (LDL-C) ≥ 160 mg/dl, high 
density lipoprotein (HDL-C) ≤ 40 mg/dl, or use of lipid-lowering medications) in African 
Americans are comparable to or lower compared to whites.3,7 These prevalence estimates 
contradict with those based on incidence data, where African Americans have a higher rate of 
dyslipidemia that is more pronounced at older ages.58 This discrepancy could be partially 
explained by the higher rates of CVD mortality attributed to dyslipidemia among African 
Americans compared to whites.3 Obesity, defined as body mass index (BMI) ≥ 25 kg/m2, is also 
higher in African Americans across the age spectrum.3 In adults ages ≥ 20 years, the prevalence 
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of obesity in African American males was 37.0% compared to 35.8% in white males, and 55.3% 
in African American females compared to 37.8% in white females.7 Smoking exposure, as both 
active and secondhand smoke, is a strong risk factor for CVD in all groups with no differential 
magnitude of effect or rates of smoking in African Americans compared to whites.3,59 However, 
compared to whites, African Americans have lower quit rates and are more likely to be exposed 
to secondhand smoke.3 Finally, adherence to dietary and activity recommendations remains 
difficult and below target in all racial group including African Americans.3  
1.3 Genetics and Epigenetics in Cardiovascular Disease and Target Organ Damage 
1.3.1 Genetics of Cardiovascular Disease and Target Organ Damage 
In addition to the risk factors discussed above, family history and genetics may also 
contribute to the increased burden of CVD in African Americans. A number of independent loci 
have been identified for cardiovascular diseases in African Americans, including those 
associated with hypertension60,61 and left ventricular mass.62 However, most identified genetic 
loci explain only a small portion of the variance of complex diseases, including CVD.63 Hence, 
despite the role of genetic predisposition and family history in CVD and its risk factors, social 
and environmental conditions are likely to be the most important determinants in CVD risk and 
disparities.1,64  
1.3.2 The Emerging Role of Epigenetics in Health and Disease  
Epigenetic mechanisms are modulated by lifestyle and environmental factors over the life 
course and can capture the influences of early and long-term exposures on health. Their effect is 
translated into changes in gene expression and they are recognized as a molecular bridge 
between the environment and disease.65  Epigenetic markers may be important biomarkers of 
early disease onset and progression and can reveal important information on biological 
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mechanisms and pathways underlying morbidities. Combined with other genetic and phenotypic 
information, epigenetic markers could be used to provide precise characterization of individual 
risk for health conditions, including CVD.   
Currently recognized epigenetic mechanisms include DNA methylation (DNAm), histone 
modifications, and higher order chromatin structure.66 DNA methylation is the covalent addition 
of a methyl group to a cytosine of a cytosine-guanine pair, also known as a CpG site.67 It is the 
most studied and best understood epigenetic mechanism and is a useful biomarker because it can 
be relatively stable over time yet susceptible to change in response to environmental stimuli.66 
Histone modifications are energy dependent post translational processes of nucleosomal 
histones. These modifications include acetylation, methylation, phosphorylation, ubiquitylation, 
and sumoylation and are differently associated with gene activity, gene silencing, or insulation 
between active and inactive gene regions.66 Lastly, higher order chromatin structure involves 
nucleosomal compaction near the nuclear membrane (heterochromatin) or nucleosomal 
accessibility (euchromatin).66 The higher order chromatin structure also partitions the genome 
into regions that are topologically associated resulting in enhancer-promoter interaction.66,68 
1.3.3 Epigenetic clocks 
Epigenetic clocks are novel measures of biological aging that are based on DNA 
methylation. They are added to a growing list of biological aging measures which are used to 
describe the biological aging process beyond chronological age.69 Aging in essence is defined as 
the progressive functional decline that is the leading risk factor for major human morbidities 
including cardiovascular disorders and neurodegenerative diseases.70 The concept of biological 
aging is based on the observation that individuals of the same chronological age do not age 
biologically at the same pace.71 Hence the different trajectories of age-related decline can be 
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better captured by measures of biological aging than chronological age. Biological aging 
measures can be divided into molecular biomarkers, such as epigenetic clocks and telomere 
length, or phenotypic or physiological markers which include clinical measures such as blood 
pressure, grip strength, and lipids.69 Understanding the aging process and pathophysiological 
processes underlying age-related conditions may lead to innovative prevention and therapeutic 
targets. 
The earliest generation of epigenetic clocks, developed by Horvath72 and Hannum73 were 
trained to select CpG sites associated with chronological age using penalized regression models. 
The Horvath measure, based on 353 CpGs, is a multi-tissue measure derived using DNA 
methylation from 8000 samples from 82 publicly available datasets.72 The datasets had 
representation of four racial/ethnic groups; mainly whites, Hispanics, African Americans, and to 
a lesser extent East Asians.72 The Hannum measure, based on 71 CpGs, is derived using DNA 
methylation in whole blood from a sample of 426 whites and 230 Hispanics.73 For both 
measures, the acceleration is based on residuals from a model regressing epigenetic age against 
chronological age. Modified versions of these measures also account for confounding by blood 
cell composition. 74. Intrinsic epigenetic age acceleration (IEAA) is the residual resulting from a 
multivariate regression model of Horvath epigenetic age on chronological age and white blood 
cell counts (naive CD8+ T cells, exhausted CD8+ T cells, plasmablasts, CD4+ T cells, natural 
killer cells, monocytes, and granulocytes) imputed from methylation data. Extrinsic age 
epigenetic age acceleration (EEAA) is based on the residuals from a model of biological age 
calculated using the Hannum measure after incorporating an up-weighted count of three cell 
types known to change with age: naïve cytotoxic T cells, exhausted cytotoxic T cells, and 
plasmablasts.  
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The second generation of the epigenetic aging measures, including PhenoAge and 
GrimAge, account for physiological dysfunction among individuals of the same chronological 
age in their selection of CpGs. PhenoAge was developed using NHANES III as the training 
sample where a proportional mortality hazard penalized regression model was used to narrow 42 
biomarkers to 9 biomarkers and chronological age.75 The 9 selected biomarkers were then used 
to derive phenotypic age. PhenoAge was then derived by regressing phenotypic age on blood 
DNA methylation data from the Invecchiare in Chianti, Aging in the Chianti Area (InCHIANTI) 
study. This produced an estimate of DNAm PhenoAge based on 513 CpGs, and PhenoAge was 
further validated in multiracial cohorts (Women’s health initiative (WHI), Jackson Heart Study 
(JHS), Normative Aging Study (NAS) and Framingham Heart Study (FHS). GrimAge was 
derived by first defining DNA methylation-based surrogate markers of 88 plasma proteins and 
smoking pack-years.76 Out of those, only 12 of the plasma proteins were correlated with the 
surrogate measure (r >0.35). Next, time-to-death due to all-cause mortality was regressed on 
chronological age and the DNA methylation-based biomarkers for the 12 plasma proteins and 
smoking.76 An elastic net regression selected 7 surrogate plasma protein and smoking pack-years 
in addition to chronological age and sex. GrimAge, based on 1030 CpGs, was then derived as the 
linear combination of these covariate values and transformed to be in units of years. GrimAge 
was trained on samples from the FHS and validated in an independent FHS cohort, WHI, JHS, 
and INChianti.76 For both GrimAge and PhenoAge, an acceleration measure is derived as the 
residual from a model regressing the epigenetic aging measure against chronological age.  
1.3.4 Epigenetics of Cardiovascular Diseases and Target Organ Damage 
Epidemiological studies of DNA methylation signatures measured in proxy tissues, such 
as blood, typically employ an epigenome wide approach where differential DNA methylation at 
 12 
individual CpGs is examined in relation to the exposure or outcome of interest. Given the 
immune system involvement and inflammatory responses underlying atherosclerosis and TOD, 
DNA methylation patterns in white blood cells are suitable proxy tissue to study the epigenetic 
signature of the onset and progression of these outcomes. Other methodological approaches, such 
as adaptation of approaches similar to polygenic risk scores to access more variance of complex 
trait, i.e. methylation risk scores, are still limited in use. This is mostly because DNA 
methylation data is more sensitive to confounding by age and tissue and it is difficult to find 
appropriate external weights.77 Conversely, epigenetic age acceleration measures have been used 
more extensively and have been shown to be robust markers of aging and a number of aging 
related diseases.  
To date, a limited number of studies have examined the association between genome 
wide DNA methylation and hypertension and TOD in the kidneys.78,79 More studies have 
examined the genome-wide DNA methylation signatures of subclinical CVD80 and clinical 
CVD.81-84 However, a majority of these studies were in cohorts of European ancestry and/or were 
cross-sectional. Other studies have examined the association between epigenetic age acceleration 
and TOD, 85,86 CVD, and their risk factors86-97, but the overall evidence remains inconclusive 
likely due to heterogeneity in study design, outcomes, and the epigenetic aging measures used. In 
two recent studies of participants of European ancestry, GrimAge acceleration was found to be 
associated with CVD incidence beyond traditional risk factors.86,96 It remains unclear whether 
similar association exits in African Americans. 
1.4 Motivation for further studies 
CVD disparities in the US remain pervasive, and the causes of these disparities are 
complex and elusive. Epigenetic mechanisms are increasingly recognized as important genomic 
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regulators that may influence or be biomarkers of CVD disease risk and progression. Identifying 
and quantifying key epigenetic modifications may help to improve risk stratification of CVD and 
its risk factors. Furthermore, epigenetic studies can help identify underlying disease mechanisms 
and key regulatory processes and gene-environment interactions that may occur over long 
periods of time and contribute to CVD risk.65 Further studies are needed to better characterize 
these associations, replicate previous findings and increase representation of highly burdened 
populations. As such, this dissertation will explore the effects of DNAm and DNAm-based 
epigenetic age acceleration (EAA) on cardiometabolic risk factors, atherosclerosis, CVD 
incidence, and target organ damage (TOD) from hypertension in African American participants 
from the Genetic Epidemiology Network of Arteriopathy (GENOA). 
1.5 The Genetic Epidemiology Network of Arteriopathy (GENOA) study 
The Genetic Epidemiology Network of Arteriopathy (GENOA) is a community-based 
study in Rochester, MN and Jackson, MS that aims to identify genes influencing blood 
pressure98. In the first phase of GENOA (Phase I: 1996 – 2001), sibships with at least two adults 
with clinically diagnosed essential hypertension before age 60 were recruited, and all siblings in 
the sibships were invited to participate regardless of hypertension status [20]. Exclusion criteria 
included secondary hypertension, alcoholism or drug abuse, pregnancy, insulin-dependent 
diabetes mellitus, or active malignancy.  
In Phase I, a total of 1,583 non-Hispanic whites (Rochester, MN) and 1,854 African 
Americans (Jackson, MS) were enrolled. In the second phase (Phase II: 2001 – 2005), all 
participants were invited for a second examination. Eighty percent of African Americans (N = 
1,482) and 75% of non-Hispanic whites (N = 1,213) from Phase 1 returned. At Phase III (2009-
2011), 752 African Americans returned for a third examination. Demographic information, 
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medical history, clinical characteristics, lifestyle factors, and blood samples were collected in 
each phase. 
This dissertation will focus on African American participants who had their DNA 
methylation measured in whole blood samples collected at Phase I (N = 1,106) and/or Phase II 
(N = 304). For these participants, genomic DNA was extracted from stored peripheral blood 
leukocytes using AutoGen FlexStar (AutoGen, Holliston, MA) and DNA methylation was 
measured using the Infinium MethylationEPIC BeadChip. The methods of DNA methylation 
processing have been previously described.99 Following quality control, a total of 1,100 samples 
from Phase I and 294 from Phase II were available for analysis. 
 
1.6 Specific Aims and Hypotheses 
The specific aims and hypotheses for this dissertation are as follows: 
Aim 1 
To assess the longitudinal association between epigenome-wide DNA methylation and five 
measures of target organ damage (TOD) in GENOA African Americans. 
Sub aims 
1. To identify CpGs associated with five measures of TOD in the heart (left ventricular 
mass index and relative wall thickness), kidneys (estimated glomerular filtration rate and 
albuminuria), and brain (white matter hyperintensity) using univariate and multivariate 
regression.  
2. To explore whether DNA methylation at the identified CpGs is associated with proximal 
gene expression.  
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3. To evaluate the causal relationship between the identified CpGs and TOD using 
Mendelian randomization. 
Hypothesis 1: We hypothesize that a number of CpGs will be associated with measures of 
TOD, with evidence of differential proximal gene expression and causality.  
Aim 2 
To investigate whether four epigenetic age acceleration measures (IEAA, EEAA, PhenoAA, and 
GrimAA) are associated with ten cardiometabolic risk factors and CVD incidence in GENOA 
African Americans.  
Sub aims 
1. To assess the cross-sectional association between four epigenetic age acceleration 
measures and ten cardiometabolic markers of hypertension, insulin resistance, and 
dyslipidemia. 
2. To investigate whether four epigenetic age acceleration measures are associated with 
CVD incidence and improve predictive accuracy over two clinical CVD risk scores 
(Framingham risk score (FRS) and the atherosclerotic cardiovascular disease (ASCVD) 
risk equation). 
Hypothesis 2: We hypothesize that increased epigenetic age acceleration, indicative of faster 
biological aging, will be associated with a worse cardiometabolic risk profile and higher 
CVD incidence, and will improve prediction of CVD incidence over the FRS and/or the 
ASCVD risk scores. 
Aim 3 
To evaluate whether four epigenetic age acceleration measures (IEAA, EEAA, PhenoAA, and 
GrimAA), previously identified CpGs for atherosclerosis, and/or methylation risk scores (MRSs) 
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derived from these CpGs are associated with single- or multi-site atherosclerosis in GENOA 
African Americans. 
Sub aims  
1. To assess the associations between four epigenetic age acceleration measures and single- 
or multi-site atherosclerosis (coronary artery calcification, abdominal aorta calcification, 
and ankle-brachial index). 
2. To evaluate the associations between previously-identified CpGs for atherosclerosis, both 
individually and aggregated into MRSs, and single- or multi-site atherosclerosis 
(coronary artery calcification, abdominal aorta calcification, and ankle-brachial index). 
3. To characterize the temporal stability of the potential epigenetic biomarkers for 
atherosclerosis (four epigenetic age acceleration measures and MRSs) using longitudinal 
measures of DNA methylation.  
Hypothesis 3: We hypothesize that increased epigenetic age acceleration and previously-
identified CpGs for atherosclerosis, both individually and aggregated into MRSs, will be 
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Chapter 2.  Epigenome-wide Association Study Identifies DNA Methylation Sites 
Associated with Target Organ Damage in Older African Americans 
2.1 Abstract 
Target organ damage (TOD) manifests as vascular injuries in the body organ systems 
associated with long standing hypertension. DNA methylation in peripheral blood leukocytes can 
capture inflammatory processes and gene expression changes underlying TOD. We investigated 
the association between epigenome-wide DNA methylation and 5 measures of TOD (estimated 
glomerular filtration rate (eGFR), urinary albumin-creatinine ratio (UACR), left ventricular mass 
index (LVMI), relative wall thickness (RWT), and white matter hyperintensity (WMH)) in 961 
African Americans from hypertensive sibships. A multivariate (multi-trait) model of eGFR, 
UACR, LVMI, and RWT identified 7 CpGs associated with at least one of the traits 
(cg21134922, cg04816311 near C7orf50, cg09155024, cg10254690 near OAT, cg07660512, 
cg12661888 near IFT43, and cg02264946 near CATSPERD) at FDR q<0.1. Adjusting for blood 
pressure attenuated the association for cg04816311, and further adjustment for body mass index 
and type 2 diabetes attenuated the association for 3 additional CpG sites (cg21134922, 
cg09155024, and cg10254690). Although DNA methylation was associated with cis-gene 
expression for some CpGs, no significant evidence of mediation by gene expression was 
detected. Mendelian randomization analyses suggested causality between three CpGs and eGFR 
(cg04816311, cg10254690, and cg07660512). We also assessed whether the identified CpG sites 
were associated with TOD in 614 African Americans in the Hypertension Genetic Epidemiology 
Network (HyperGEN) study. Out of the 3 CpG sites available for replication, cg04816311 was 
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significantly associated with eGFR (p=0.0003), LVMI (p=0.0003), and RWT (p=0.002). This 
study found evidence of an association between DNA methylation and TOD in African 
Americans and highlights the utility of using a multivariate-based model that leverages 




More than 40% of US adults have hypertension, with African Americans having higher 
prevalence than that of any other racial group.1 According to the 2011-2014 National Health and 
Nutrition Examination Survey, the prevalence of hypertension was 59% in African American 
men and 56% in African American women, compared to a prevalence of 47% and 41% in non-
Hispanic White men and women.1 Due to long standing hypertension, target organ damage 
(TOD) manifests as subclinical or clinical changes to the micro and macro vascular systems of 
the heart, brain, eyes, and kidneys.2 Oxidative stress, endothelial dysfunction, extracellular 
matrix formation, and innate and adaptive immune cells activation and invasion are some of the 
mechanisms recognized to play a role in TOD onset and progression.2,3 Previous research 
indicates that measures of TOD are independent and strong predictors of cardiovascular 
morbidity and mortality and all-cause mortality.4-7 However, there are gaps in our knowledge 
about the progressive effects of hypertension over the life course and which risk factors 
contribute to the development of subclinical changes and symptomatic diseases related to TOD. 
African Americans are especially susceptible to manifestations of target organ damage from 
hypertension leading to a higher risk of adverse cardiovascular and renal outcomes and 
mortality.8,9 Previous studies have shown that African Americans have greater left ventricular 
mass,10,11 higher incidence of chronic kidney disease, and end stage renal disease compared to 
non-Hispanic Whites.12,13 Better understanding of the pathogenesis of TOD could elucidate and 
improve our prediction of related morbidities and mortality, especially in populations with the 
highest burden of hypertension. 
A complex interplay of genetics and the environment contributes to the risk of TOD.  
Heritability studies point to a substantial genetic component, with heritability estimates ranging 
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from 0.17 to 0.76.14-18 Familial clustering patterns in Framingham Heart Study reveal that 
individuals who have at least one parent with TOD had an increase in the odds of any type of 
TOD, even after controlling for hypertension status.19 Epigenetic mechanisms may shed light on 
the ways that genetics, the environment, and traditional risk factors contribute to the progression 
of TOD.20,21 To date, only a handful of well-powered epigenome-wide association studies 
(EWAS) have investigated the association between DNA methylation and blood pressure or 
related organ damage.22-24  
In this study, we investigated the association between DNA methylation, interrogated in 
peripheral blood leukocytes, and 5 TOD measures in a cohort of older African Americans using 
longitudinally collected data. We hypothesized that biological pathways involved in the 
association between DNA methylation and TOD could be unique to each trait or could act in a 
pleiotropic manner. Hence, to gain a better understanding of these biological mechanisms, we 
employed both univariate (single-trait) and multivariate (multi-trait) models. Additionally, we 
assessed whether the effects of CpG sites on TOD were mediated by the expression of nearby 
genes and we used Mendelian randomization (MR) to investigate causality. 
2.3 Methods 
Study sample 
Genetic Epidemiology Network of Arteriopathy (GENOA) is a community-based study 
in Rochester, MN and Jackson, MS that aims to identify genes influencing blood pressure 25. In 
the first phase of GENOA (Phase I: 1996 – 2001), sibships with at least two adults with clinically 
diagnosed essential hypertension before age 60 were recruited, and all siblings in the sibship 
were invited to participate regardless of hypertension status [20]. Exclusion criteria included 
secondary hypertension, alcoholism or drug abuse, pregnancy, insulin-dependent diabetes 
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mellitus, or active malignancy. In Phase I, a total of 1,583 non-Hispanic whites (Rochester, MN) 
and 1,854 African Americans (Jackson, MS) were enrolled. In the second phase (Phase II: 2001 
– 2005), all participants were invited for a second examination. Eighty percent of African 
Americans (N = 1,482) and 75% of non-Hispanic whites (N = 1,213) from Phase 1 returned. 
Demographic information, medical history, clinical characteristics, lifestyle factors, and blood 
samples were collected in each phase.  
This study includes African American participants who had their DNA methylation 
profiles measured in whole blood samples collected at Phase I. Measures of TOD were collected 
at Phase II and/or in an ancillary study of brain magnetic resonance imaging (MRI) conducted 
shortly after Phase II. Gene expression profiles were measured from lymphoblastoid cell lines 
made from blood samples collected after Phase 1 (median time from Phase 1 was 5.8 years). A 
total of 961 participants who had DNA methylation measurements at Phase I and returned for 
Phase II were included in the current study. Written informed consent was obtained from all 
participants and approval was granted by participating institutional review boards (University of 
Michigan, University of Mississippi Medical Center, and Mayo Clinic). 
Target organ damage measures 
Five TOD measurements were selected for the current analyses. Two traits, estimated 
glomerular filtration rate (eGFR) and urinary-albumin-creatinine ratio (UACR), measured 
diminishing kidney function. Left ventricular mass index (LVMI) and relative wall thickness 
(RWT) captured structural remodeling of the heart. White matter hyperintensity (WMH) 
captured altered areas of white matter in the brain using MRI. eGFR, UACR, LVMI, and RWT 
were assessed at Phase II. WMH was assessed in an ancillary study shortly after Phase II.  
Estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR) 
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Blood was drawn on the morning of the study visit after an overnight fast of at least 8 
hours. Serum creatinine was assessed with enzymatic assays on a Hitachi 911 Chemistry 
Analyzer (Roche Diagnostics, Indianapolis, IN). The CKD-EPI formula was used to calculate the 
estimated glomerular filtration rate (eGFR).26 A first-morning sample urine was collected on the 
morning of the study visit. Urine creatinine and urine albumin were assessed with enzymatic 
assays on a Hitachi 911 Chemistry Analyzer (Roche Diagnostics, Indianapolis, IN).  
Left ventricular mass index (LVMI) and relative wall thickness (RWT) 
Left ventricular mass (LVM) was estimated as previously described.27 Briefly, Doppler, 
two-dimensional (2D) and M-mode (2D-guided) echocardiograms were performed following a 
standardized protocol.28 Measurements were made at the echocardiography reading center using 
a computerized review station equipped with a digitizing tablet and monitor overlay used for 
calibration and quantification (Digisonics, Inc., Houston, Texas). LVM was calculated using 
end-diastolic dimensions by an anatomically validated formula and LVMI was derived by 
indexing LVM to the height raised to the power of 2.7.29 RWT was calculated as twice the 
posterior wall thickness divided by the left ventricular internal dimension.28 
White matter hyperintensity (WMH) 
Brain magnetic resonance imaging was performed using Signa 1.5 T MRI scanners (GE 
Medical Systems, Waukesha, WI, USA) and images were processed at Mayo Clinic.30 Total 
brain and WMH volume in the corona-radiata and periventricular zone were determined from 
axial fluid-attenuated inversion recovery (FLAIR) images.31 Brain scans with cortical infarctions 
were excluded from the analyses because of the distortion of the WMH volume estimates that 
would be introduced in the automated segmentation algorithm. For additional details, see Smith 
et al.32 Models assessing WMH were adjusted for total intracranial volume (TIV).  
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Methylation measures 
Genomic DNA from 1,106 African American participants from Phase I was extracted 
from stored peripheral blood leukocytes using AutoGen FlexStar (AutoGen, Holliston, MA). 
Bisulfite conversion was done using with the EZ DNA Methylation Kit (Zymo Research, Irvine, 
CA) and then DNA methylation was measured using the Infinium MethylationEPIC BeadChip. 
IDAT files were imported using the Minfi R package33 and sex mismatches and outliers were 
excluded using the shinyMethyl R package.34 Probes with detection p-value < 10-16 were 
considered to be successfully detected35 and both samples and probes that failed a detection rate 
of at least 10% were removed. Samples with incomplete bisulfite conversion identified using the 
QCinfo function in the ENmix R package36 were removed. Sample identity was checked using 
the 59 SNP probes included in the EPIC BeadChip and mismatched samples were removed. 
Afterwards, the Noob method was used for individual background and dye-bias normalization.37 
Since two types of probes were present on the EPIC BeadChip (Infinium I and Infinium II), we 
used the Regression on Correlated Probes (RCP) method to adjust for the probe-type bias in the 
data.38 Cross-hybridizing probes and those on sex chromosomes were removed using DMRcate 
R package.39  
Methylation beta values were changed to M-values using logit transformation 
(𝑙𝑜𝑔2[𝐵𝑒𝑡𝑎 1 − 𝐵𝑒𝑡𝑎⁄ ]).
40 Sample plate, sentrix ID and sample row were identified as batch 
effect variables using principle variance component analysis. White blood cell type proportions 
within the blood sample were estimated using Houseman’s method.41 Methylation M-values 
were adjusted for white blood cell type counts and batch effects using linear mixed modeling and 
the residuals were added to the mean. After quality control, a total of 1,100 participants remained 
for further analysis.  
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Gene expression measures 
Gene expression levels in GENOA African American participants were measured in 
Epstein-Barr virus (EBV) transformed lymphoblastoid cell lines using the Affymetrix Human 
Transcriptome Array 2.0. The Affymetrix Expression Console provided by Affymetrix was used 
for array quality control and all array images passed visual inspection. Affymetrix CEL files 
were normalized using the Robust Multichip Average algorithm in the Affymetrix Power Tool 
software.42 The Brainarray custom CDF version 19 was used to map the probes to genes43 and 
Combat44 was used to adjust batch effects and other technical covariates. A total of 17,616 
autosomal protein coding genes were available for analysis. A total of 1,205 samples remained 
after quality control. 
Genotyping and imputation information for MR analysis 
GENOA African American samples were genotyped on the Affymetrix® Genome-Wide 
Human SNP Array 6.0 platform, Illumina® Human1M-Duo, or Human660W-Quad BeadChips. 
Participants were excluded if they had a missing SNP call rate ≥ 0.05 or were an outlier ≥ 6 
standard deviations (SD) from the mean of the first 10 genome-wide principal components from 
genotype data. SNPs were excluded if they had unknown chromosomal location, < 95% call rate, 
or minor allele frequency less than 0.01. Imputation was performed separately by chip 
(Affymetrix or Illumina) using the 1000 Genomes Phase3 v5 reference panel and post-
imputation comparison between the two groups revealed no substantial differences in genotype 
and allele frequencies. SNPs with imputation quality < 0.8 were removed before MR analysis. 
Covariates 
Height was measured by stadiometer and weight by electronic balance. Body mass index 
(BMI) was calculated as weight in kilograms divided by the square of height in meters. Resting 
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systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured by a random 
zero sphygmomanometer and a cuff appropriate for arm size. The second and third of three 
readings, after the participant sat for at least 5 minutes, were averaged for analysis.45 Information 
on current anti-hypertensive medication use was collected. Smoking was categorized as current, 
former, or never smokers. Type 2 diabetes (T2D) was defined as fasting serum glucose 
concentration >126 mg/dl or self-reported physician-diagnosed diabetes and current anti-diabetes 
medication use (insulin or hypoglycemic agents).  
Statistical analyses 
Epigenome-wide association analysis of TOD 
TOD traits were rank-based inverse normalized to ensure they follow a Gaussian 
distribution and outliers at 4 standard deviations from the mean were removed. Analyses were 
performed using the multivariate linear mixed model implemented in the Genome-wide Efficient 
Mixed Model Association (GEMMA) software.46 Random effects in the linear mixed models 
were used to adjust for familial relationship by using the genetic relatedness matrix. SNP-based 
heritability (h2) of the TOD traits was additionally estimated using GEMMA.47 TOD traits were 
investigated individually using univariate (single-trait) linear mixed models and jointly using a 
multivariate (multi-trait) linear mixed model. The multivariate method tests a hypothesis of a 
given CpG being associated with at least one of the TOD traits. We hypothesized that given the 
correlation between the TOD traits and potentially similar underlying biological mechanisms, 
some CpG sites will have true pleiotropic effects on the different TOD traits and using this 
approach will provide a better model fit. Additionally, using a multivariate approach will 
increase our statistical power, even if the methylation sites are not associated with all of the TOD 
traits at the univariate level.47 The multivariate model included eGFR, UACR, LVMI and RWT 
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as outcome variables. WMH was not included as the sample size is significantly smaller (N = 
539). Following multivariate regression, we tested the association between the significant sites 
identified in the multivariate model and WMH.  
Univariate and multivariate models were adjusted for age at trait measurement, sex, time 
between measurements, smoking status, and 4 genetic principal components (PCs) (model 1).        
The minimally adjusted multivariate model (model 1) was considered our main analysis model.  
For significant CpG sites identified in the main analysis model, we examined the scatterplots of 
the CpGs against TOD to identify and potentially remove any extreme outliers or leverage 
points. We investigated attenuation of effects for the CpG sites identified in the main analysis by 
adjusting for SBP, DBP and antihypertensive medication use (model 2) and T2D status and BMI 
(model 3). To account for multiple comparisons, the Benjamini-Hochberg procedure was applied 
to control the false discovery rate (FDR) at a threshold of q<10%.48  
Illumina documentation was used to annotate significant CpG sites with functional and 
regulatory features that mapped their genomic location relative to CpG islands and nearby genes. 
Additionally, we examined any overlap with regulatory elements reported by the Encyclopedia 
of DNA Elements (ENCODE)49 and the Functional ANnoTation Of the Mammalian genome 
(FANTOM).50  
Mediation of CpG-TOD associations by gene expression levels 
For significant CpG sites identified in the main analysis model, we selected genes within 
a 250 Kb range with expression levels associated with the corresponding CpG at p-value < 0.1 
for formal mediation analysis. Linear mixed models were adjusted for familial relationship, age, 
sex, time between the measures, and 4 genetic PCs. UACR was natural log transformed as 
ln(UACR+1). The mediation R package was then used to test for mediation by proximal gene 
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expression levels between each CpG site and TOD association.51,52 To account for multiple 
testing, an FDR q < 0.1 was applied across all CpG-mediator-TOD associations. 
Mendelian randomization analysis of CpG-TOD associations 
To assess whether the significant CpG sites identified contributed causally to TOD 
measures, we performed one-sample Mendelian randomization (MR) analysis. We opted to use 
one-sample MR given the limited availability of public methylation quantitative trait locus 
(mQTL) databases and TOD genome wide association studies (GWAS) in participants of African 
ancestry. After excluding SNPs with minor allele frequency < 0.05, instrumental variables (IV) 
were drawn from SNPs within ± 1 Mb of each corresponding significant CpG site. RVTEST was 
used to assess the CpG-SNP association and identify eligible SNPs (FDR q < 0.1).53 Clumping 
for independence using the Phase 3, version 5 of the 1000 Genomes dataset for Africans (AFR), 
at r2 of 0.1 and physical distance threshold of 100kb, was done using PLINK v1.07.54 Causal 
estimates were obtained using the inverse-variance weighted (IVW) model in the 
MendelianRandomization R package55 for each TOD trait. UACR was natural log transformed as 
ln(UACR+1). Models were adjusted for familial relationship, age at baseline, sex, and 4 genetic 
PCs. A p-value < 0.05 was used. Additionally, we applied the MR Egger test to examine 
pleiotropy because IVW MR is invalid in the presence of horizontal pleiotropic effects of IVs.56 
Finally, since both the IVW and Egger methods rely on summary data, we also calculated the 
causal estimates for the significant results using two-stage least squares regression.57 
Replication analysis 
 For the 7 CpG sites identified in the multivariate model 1 in GENOA, we sought to test 
the association between each CpG site and each TOD trait univariately in 614 African Americans 
from the Hypertension Genetic Epidemiology Network (HyperGEN) study. Like GENOA, 
 35 
families in HyperGEN were selected if sibships had ≥2 siblings who had been diagnosed with 
hypertension before age 60. DNA methylation was assayed from peripheral blood leukocytes 
(buffy coat) using the Infinium HumanMethylation450 BeadChip (450K). Further details about 
HyperGEN can be found in the Supplemental Text. 
2.4 Results 
Descriptive statistics 
Sample characteristics are described in Table 1. The mean age of the participants was 
57.7 years at baseline and the majority of the participants were females. The mean follow-up 
time between phases was approximately 5 years. Mean SBP and DBP was 137.8 mmHg and 79.3 
mmHg, respectively. Of the sample, about 12% were current smokers and 60% were never 
smokers. TOD heritability estimates ranged between 0.214 for WMH and 0.523 for LVMI. TOD 
traits were significantly correlated at p-value < 0.05 (r range: -0.21 to 0.36, Table S1) with the 
exception of WMH and UACR (r=0.08). 
Epigenome-wide association analysis of TOD 
Results from the minimally adjusted univariate and multivariate (4-trait: eGFR, UACR, 
LVMI, and RWT) epigenome-wide association analyses are shown in Table 2. The 
corresponding QQ plots are shown in the Figure S1.  RWT, LVMI, and UACR models each 
identified a single CpG site at FDR q < 0.1, while no site reached the statistical significance 
threshold for eGFR.  Our initial analysis identified 8 significant CpG sites associated with TOD 
at FDR q < 0.1 for our main multivariate model. However, upon inspection of scatterplots, we 
identified one CpG site (cg07235511) with an outlier that drove the association. This site was 
excluded from our report of findings, leaving a total of 7 CpG sites in the minimally adjusted 
model (model 1).  
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We extended the multivariate model 1 by adjusting for SBP, DBP, antihypertensive 
medication use, BMI, and T2D status. Table 3 shows the results of the adjusted models for the 7 
CpG sites previously identified in model 1 (q<0.1). Adjusting for hypertension (Model 2) 
attenuated the association for one CpG site (cg04816311) while the remaining 6 CpG sites 
remained significant. Adjustment for BMI and T2D further attenuated the association for 3 more 
CpG sites (cg21134922, cg09155024, and cg10254690). In addition, one new CpG site was 
found significant at the same threshold (Model 3, cg02204965, p-value = 5.02 × 10-7, FDR q = 
0.098).  
We next performed follow-up analysis for the 7 identified CpG sites from multivariate 
Model 1 to: [1] assess their association with the individual TOD traits univariately, [2] identify 
which combination of traits were driving the multivariate association, and [3] examine the 
association between the identified CpG sites and WMH. The results of the univariate models for 
each of these sites with each TOD trait are shown in the Table S2. In model 1, 4 of the 7 
identified sites were significantly associated with two TOD traits using a Bonferroni adjusted 
cutoff of p-value < 0.007, while the other 3 were associated with only LVMI. Both cg04816311 
and cg12661888 had a consistent effect in which increased methylation was associated with 
worse TOD outcomes (higher UACR, lower eGFR and/or higher LVMI). To aid in the clinical 
interpretation of the results, equivalent linear mixed models were run for each significant CpG 
site identified in the main analysis model and each of the TOD traits without normalization 
(Table S3). Individual TOD values were calculated at the mean - 1SD and mean + 1SD M-value 
methylation levels for each CpG site. Adjusting for SBP, DBP, and antihypertensive medication 
use did not substantively change the results from Model 1, except that cg02264946 became 
associated with RWT in addition to LVMI. Further adjustment for BMI and T2D attenuated the 
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association between cg04816311 and LVMI but not UACR. None of the 7 CpG sites identified 
were associated with WMH at p-value < 0.05 (Table S4). 
Bioinformatic characterization of CpG sites and mediation of CpG-TOD associations by 
gene expression levels 
We characterized significant CpG sites bioinformatically and by examining their 
association with proximal gene expression. Five out of the 7 sites identified in the multivariate 
model were located in DNase hypersensitivity sites (Table S5), but no overlap was found with 
any FANTOM sites. Gene expression was derived from cell lines created from blood samples 
that were taken a minimum of 1.9 years after methylation measurement. Within the identified 
range of ± 250 Kb of the 7 CpG sites identified, a total of 14 genes were marginally associated 
with nearby CpG methylation levels at p-value < 0.1 (Table 4). These genes were selected for 
the mediation analysis. Methylation at the examined CpG sites was associated with decreased 
expression of the SAFB2, UNCX, MORN3, HPD, and OAT genes as well as a number of long 
noncoding RNA molecules. Formal mediation analyses did not identify mediation by gene 
expression for any of the CpG-TOD traits associations at FDR q < 0.1; however, post hoc power 
calculation showed that statistical power for the mediation analysis was low (<50%).   
Mendelian randomization analysis of CpG-TOD associations 
 Table 5 shows the results of inverse-variance weighted models to assess whether the 
identified CpG sites were casually associated with each of the TOD traits. For 4 of the 7 CpG 
sites, we identified significant independent SNPs within ±1 Mb that had a CpG-SNP FDR q < 
0.1 (Table S6). eGFR was inversely influenced by methylation at cg10254690 near OAT (effect 
estimate = -5.75 mL/min/1.73m2 and p-value = 0.027) and cg07660512 (effect estimate = -14.91 
mL/min/1.73m2 and p-value = 0.042).  Methylation at cg04816311 near C7orf50 positively 
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influenced eGFR (effect estimate = 8.84 mL/min/1.73m2 and p-value = 0.014). The effect 
estimates were consistent in direction, but of greater magnitude, than those estimated by our 
baseline association analysis at the univariate level. Figure S2 (A-C) shows the plots of these 
causal estimates using the IVW method, which shows an overall consistent effect of the SNPs. 
The MR Egger test suggested no evidence of horizontal pleiotropy for all CpGs with the 
exception of the effect of cg10254690 on eGFR, where the MR Egger test showed no evidence 
of causality. Effect estimates and standard errors using two stage least squares regression were 
slightly larger than with the summary methods, but the p-values were similar (Table S7). The 
associations were only significant at a p-value threshold of 0.05, and none would reach statistical 
significance if corrected for multiple testing.   
Replication analysis 
 Sample characteristics of the HyperGEN replication cohort are shown in Table S8. 
HyperGEN participants were younger than GENOA participants with a mean age of 48.4 (SD = 
11.1) years. Mean BMI and antihypertensive medication use were similar in both cohorts. 
HyperGEN had a lower percentage of diabetic participants and a higher percentage of smokers. 
Both UACR and LVMI were higher in HyperGEN compared to GENOA. Out of 7 CpG sites 
significant at FDR q < 0.1 in GENOA, only 3 sites (cg04816311, cg09155024, and cg10254690) 
were present on the 450K chip used in HyperGEN. Table S9 shows the univariate associations 
for each of the 3 CpG sites with each of the 4 TOD traits. In the minimally adjusted model 
(Model 1), cg04816311 was associated with eGFR, LVMI, and RWT at p-value < 0.05. Effect 
directions were consistent in that increased methylation was associated with increased TOD: 
higher LVMI in both cohorts, higher RWT in HyperGEN, and higher UACR in GENOA. 
However, it was also associated with lower eGFR in HyperGEN (an indicator of less TOD). The 
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second CpG, cg09155024 was not associated with any of the TOD measures in HyperGEN. The 
third CpG, cg10254690, which was associated with LVMI in GENOA, had the same beta 
coefficient direction in HyperGEN but did not reach statistical significance (p-value = 0.18). 
2.5 Discussion  
 The study identified 7 CpG sites associated with 4 TOD measures in a cohort of older 
African Americans using a multivariate approach. The multivariate model had more power to 
detect significant CpG sites than the univariate models which detected a single CpG site for 3 of 
the TOD traits. This is in line with evidence from the literature on the power gains associated 
with multivariate over standard univariate analyses in genetic studies.46,47,58-60 Testing the 
significant CpG sites identified in the multivariate model at the univariate level showed that not 
all of the sites reached statistical significance. While counterintuitive, this is expected as 
unassociated traits in the multivariate analysis increase power if they are correlated with the 
associated trait.46,47 Our initial hypothesis was that DNA methylation would have the same 
direction of effect across the different TOD traits; however, our findings show that this may not 
be true for all CpG sites. None of the sites identified were associated with WMH, which may 
indicate a different underlying mechanism for that trait or may be due to the relatively low 
variability of WMH in this sample. 
Five out of the 7 sites identified in the multivariate model were located in DNase 
hypersensitivity sites, which are regions of chromatin that are not highly condensed, rendering 
the chromatin exposed and accessible for transcription. After adjusting for hypertension-related 
covariates, 6 of these associations remained significant, and 3 remained significant when BMI 
and T2D were included. Although there was evidence for an association between the identified 
CpG sites and cis-gene expression, including both protein coding and long non-coding RNA 
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molecules, none were statistically significant in formal mediation analyses. MR analysis 
provided some evidence of causality between at least two CpG sites and eGFR. 
The CpG site that was identified in GENOA and replicated in HyperGEN, cg04816311 
near C7orf50, was previously reported to be associated with T2D in Mexican-Americans and 
sub-Saharan Africans.61,62 cg04816311 was also associated with BMI in African Americans.63 
The direction of effect reported in the study by Meeks et al. showed that hypermethylation was 
observed at cg04816311 among T2D cases compared to the controls.62 In our study, a change in 
M-value methylation (mean -1SD to mean +1SD) was associated with approximately 13 mg/g 
increase in UACR and 2.6 g/height2.7 increase in LVMI in GENOA. In the model adjusting for 
BMI and T2D, the methylation effect was attenuated and was no longer significant. Genetic 
variants in this locus were also found to be associated with lipid levels,64 blood pressure,65,66 and 
longevity67 in GWAS studies.  
Methylation at the cg10254690 site, which maps near the OAT gene promoter region, was 
associated with significantly decreased expression of OAT. Additionally, MR analysis using 
IVW suggested a causal effect equivalent to approximately 6 mL/min/1.73m2 units decrease in 
eGFR for each 1 unit M-value increase in DNA methylation. The OAT gene codes for ornithine 
aminotransferase, a key mitochondrial enzyme found in the liver, intestine, brain, and kidney that 
converts arginine and ornithine into glutamate and GABA.68 Ornithine is involved in the urea 
cycle and synthesis of nitric oxide (NO). It is an important messenger molecule that regulates 
blood vessel dilation and has other thrombotic and inflammatory effects.69,70 Studies suggest that 
OAT is involved in controlling the proliferation of several cell lines, including vascular smooth 
muscle cells, and it acts as a modulator of collagen synthesis and of extracellular matrix 
formation.68,71 In addition, there is evidence that OAT is involved in metabolic reprogramming in 
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activated T-cells by providing ornithine and α-KG.72 One previous study found a nominal 
association between DNA methylation at cg10254690 and cortisol stress reactivity,73 and genetic 
variants in OAT were also associated with diastolic blood pressure.74 
Other genes identified in the multivariate model were IFT43 and CATSPERD. IFT43, 
near cg12661888, encodes a subunit of the intraflagellar transport complex A, a multi-protein 
complex involved in in cilia assembly and maintenance. This subunit is essential in regulating 
the Sonic Hedgehog signaling pathway, which is involved in regulating the growth, 
differentiation, and patterning of cells, especially during embryonic development.75 CATSPERD, 
near cg02264946, encodes an auxiliary subunit of sperm calcium channel pore-forming proteins 
required for the motility of spermatozoa and male fertility.76 cg03042953 near SSBP3, a single-
stranded DNA-binding protein 3, was only significant for the RWT trait model. Genetic loci in 
the SSBP3 locus were associated with P wave duration,77 blood urea nitrogen,78 and BMI.79,80 
The single trait model for UACR identified cg04816311 near C7orf50, which was also 
significant in the multivariate outcome model. cg21134922, found significant for LVMI, was not 
near a gene.  
Changes in methylation may not affect the expression of the genes immediately proximal 
to the CpG site, and CpG regulatory effects could be more distal or in trans (i.e. affecting genes 
on different chromosomes).81 When we evaluated whether CpG sites were associated with 
transcriptional changes, a number of genes within the range of 250 Kb showed decreased 
expression levels with increasing methylation. Previous literature identified DNA sequence 
variants in one of these genes, UNCX near cg04816311, to be associated with eGFR and other 
kidney-related traits in GWAS studies.82,83 However, our study did not identify any significant 
mediation effects using formal mediation analysis. This could be attributed to the lack of 
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statistical power and/or the different cell types used for the methylation-gene expression 
measures (EBV-transformed lymphocytes cell line for gene expression versus peripheral blood 
leukocytes for DNA methylation). There is conflicting evidence on whether the methylation 
patterns of these cell lines are similar, whether the EBV transformation preserves the gene 
expression profile, and whether that translates to a similar gene expression profile in both.84-87 
This study is among the very few studies that assessed the association between DNA 
methylation and TOD. To the best of our knowledge, it the first study to employ a pleiotropy-
informed analysis to examine epigenome-wide DNA methylation sites associated with correlated 
TOD traits. However, this study has a number of limitations. First, although we employed a 
longitudinal design, it is difficult to rule out reverse causality, especially for TOD traits where 
disease onset and duration is difficult to detect. In addition, although MR analyses allowed us to 
characterize the direction of the association, findings did not reach statistical significance when 
accounting for multiple testing, which could be attributed to small sample size and low power. 
None of the sites identified in this study replicated epigenome-wide significant CpG sites from 
the limited epigenome-wide studies available for TOD traits.22-24  
In conclusion, our study addresses an important gap in the literature on the role of DNA 
methylation in TOD in African Americans. CpG sites mapped to important genes that can further 
our understanding of biological mechanisms underlying these conditions. Future studies are 
needed to replicate these findings and further investigate gene expression and epigenetic profiles 
in more relevant tissue types such as the kidney and the heart, in addition to investigating the 
associations in different racial and ethnic groups. Findings from such research may direct future 
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Table 2-1: Characteristics of participants in GENOA African Americans1 (N = 961) 
 Mean (SD) or 
N (%) 
h2 heritability  
(95% CI) 
 Female 685 (71.3%)  
Age  (years) 62.7 (9.7)  
Age at phase I (years) 57.7 (10.3)  
Time between phases I and II 5.2 (1.3)  
BMI  (kg/m2) 31.8 (6.8)  
Systolic blood pressure (mmHg) 137.8 (21.1)  
Diastolic blood pressure (mmHg) 79.3 (11.1)  
Antihypertensive medication use   
     No 284 (29.6%)  
     Yes 662 (68.9%)  
     Missing 15 (1.6%)  
Smoking status   
    Current 118 (12.3%)  
    Former 257 (26.7%)  
    Never 571 (59.4%)  
    Missing 15 (1.6%)  
Diabetes status2   
    No 653 (68.0%)  
    Yes 289 (30.1%)  
    Missing 19 (2.0%)  
Estimated glomerular filtration rate (eGFR, 
mL/min/1.73m2) 
89.9 (21.2) 0.31 (0.113 – 0.50) 
Urine albumin-to-creatinine ratio (UACR, 
mg/g) 
48.4 (192.9) 0.49 (0.301 – 0.68) 
Left ventricular mass index (LVMI, g/height2.7) 39.1 (10.3) 0.52 (0.352 – 0.70) 
Relative wall thickness (RWT) 0.32 (0.05) 0.30 (0.123 – 0.46) 
White matter hyperintensity (WMH, cm3) 9.49 (8.0) 0.21 (0 – 0.43) 
Total intracranial volume (cm3) 1373 (134.7)  
SD: Standard deviation; CI: Confidence interval; BMI: Body mass index  
Sample sizes for target organ damage measures: eGFR (n=940), UACR (n=943), LVMI (n=910), RWT 
(n=915), WMH (n=539) 
1 Measured at phase II unless stated otherwise 




Table 2-2: Statistically significant CpG sites associated with TOD traits at FDR q < 0.1 using univariate and multivariate models in 
GENOA African Americans 
  
Chr: chromosome; FDR: false discovery rate; UACR: urinary albumin to creatinine ratio; LVMI: left ventricular mass index; RWT: relative wall 
thickness; eGFR: estimated glomerular filtration rate 
Model 1 is adjusted for age at phase II, sex, time between measurement, smoking status, and 4 genetic principal components 
1 Multivariate model includes eGFR, UACR, LVMI, and RWT as outcome measures 
2 Within 1500 kb of the gene start site (promoter region) 
  
 Model 1 – univariate 
Outcome 
measure 
CpG site Gene Chr 
Relation to 
CpG site 
Relation to gene p-value FDR q Beta (SE) 
RWT cg03042953 SSBP3 1 Island Body 9.53 × 10-8 0.072 1.361 (0.253) 
LVMI cg21134922  5   1.59 × 10-8 0.013 0.663 (0.116) 
UACR cg04816311 C7orf50 7 North Shore Body 5.52 × 10-8 0.044 0.513 (0.094) 
     Model 1 – multivariate 1 
     Beta (SE) for each TOD trait   






eGFR UACR LVMI RWT p-value FDR 
cg21134922  5   -0.035 (0.106) 0.124 (0.118) 0.663 (0.117) 0.004 (0.113) 6.54 × 10
-7 0.044 
cg04816311 C7orf50 7 North Shore Body 0.178 (0.089) 0.492 (0.097) 0.390 (0.098) 0.093 (0.094) 1.06 × 10-7 0.042 
cg09155024  10   0.188 (0.057) -0.070 (0.063) -0.042 (0.064) 0.269 (0.060) 3.35 × 10
-7 0.044 




-0.154 (0.064) -0.044 (0.071) -0.359 (0.070) -0.062 (0.068) 2.75 × 10-7 0.065 
cg07660512  12   -0.527 (0.162) -0.795 (0.179) -0.003 (0.182) -0.242 (0.173) 2.62 × 10
-7 0.044 
cg12661888 IFT43 14  Body -0.306 (0.072) 0.259 (0.080) -0.117 (0.081) 0.019 (0.077) 4.68 × 10
-7 0.053 
cg02264946 CATSPERD 19  Body 0.236 (0.125) 0.203 (0.137) -0.489 (0.137) 0.341 (0.132) 6.16 × 10
-8 0.042 
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Table 2-3: Adjusted multivariate models for statistically significant CpG sites from Model 1 in GENOA African Americans 
FDR: false discovery rate; SE: standard error; eGFR: estimated glomerular filtration rate; UACR: urinary albumin to creatinine ratio; LVMI: left 
ventricular mass index; RWT: relative wall thickness 
Model 2 is adjusted for age at phase II, sex, time between measurement, smoking status, 4 genetic principal components, systolic blood pressure, 
diastolic blood pressure and antihypertensive medication use  
Model 3 is adjusted for Model 2 variables plus body mass index and type 2 diabetes status  
Results with a significant FDR q < 0.1 are in bold font 
1 Multivariate model includes eGFR, UACR, LVMI, and RWT as outcome measure
   Model 2 – multivariate1  Model 3 – multivariate1 
   Beta (SE) for each TOD trait    Beta (SE) for each TOD trait  
CpG site Gene  eGFR UACR LVMI RWT p-value FDR   eGFR UACR LVMI RWT p-value FDR  


















6.52 × 10-4 0.9119 


















1.49 × 10-2 0.9904 


















3.03 × 10-6 0.2885 


















3.08 × 10-4 0.8776 


















8.00 × 10-8 0.0363 


















6.21 × 10-7 0.0981 


















9.19 × 10-7 0.0363 
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Table 2-4: Associations between statistically significant CpG sites from multivariate Model 1 
and nearby gene expression (± 250 Kb, p-value < 0.1) in GENOA African Americans 
CpG site Gene Protein Type Beta SE p-value 
cg04816311  AC073957.1 LncRNA -0.156 0.050 0.002 
AC073094.1 LncRNA -0.183 0.060 0.003 
AC091729.2 LncRNA -0.127 0.057 0.026 
UNCX Protein-coding -0.108 0.058 0.063 
cg10254690 OAT Protein-coding -0.163 0.057 0.005 
cg07660512  MORN3 Protein-coding -0.096 0.044 0.031 
AC079360.1 LncRNA -0.060 0.028 0.035 
HPD Protein-coding -0.085 0.043 0.050 
cg02264946 AC011444.1 LncRNA -0.095 0.044 0.030 
SAFB2 Protein-coding -0.147 0.073 0.045 
SE: standard error 
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Table 2-5: Mendelian randomization results showing the inverse-variance weighted effects of multiple SNPs used as instrumental 
variables in the association of CpG sites and TOD traits in GENOA African Americans 
TOD trait  Chr CpG site 
Independent 
SNPs with CpG-


















5 cg21134922 6 8.718 6.2 -3.432 20.869 0.16 
7 cg04816311 15 8.844 3.584 1.819 15.868 0.014 
10 cg10254690 10 -5.752 2.594 -10.836 -0.669 0.027 




5 cg21134922 6 0.075 0.485 -0.876 1.026 0.877 
7 cg04816311 15 0.285 0.254 -0.213 0.783 0.261 
10 cg10254690 10 0.359 0.222 -0.076 0.793 0.106 
12 cg07660512 13 -0.57 0.571 -1.69 0.55 0.319 
Left ventricular mass 
index (LVMI), 
g/height2.7 
5 cg21134922 6 6.292 3.299 -0.173 12.757 0.056 
7 cg04816311 15 1.816 1.919 -1.946 5.578 0.344 
10 cg10254690 10 -2.485 1.378 -5.186 0.216 0.071 
12 cg07660512 13 -5.694 3.689 -12.925 1.537 0.123 
Relative wall 
thickness (RWT) 
5 cg21134922 6 0.004 0.016 -0.027 0.036 0.780 
7 cg04816311 15 0.015 0.009 -0.002 0.031 0.084 
10 cg10254690 10 -0.002 0.007 -0.015 0.011 0.798 
12 cg07660512 13 0 0.02 -0.04 0.039 0.994 
Chr: chromosome; SE: standard error 
1The causal effect estimate is the pooled estimate calculated using inverse-variance weighted models from the Mendelian randomization analyses 




2.8 Supplementary Material 















Estimated glomerular filtration rate 
(eGFR) 
    
Urinary albumin-creatinine ratio 
(UACR) 
-0.20****    
Left ventricular mass index (LVMI) -0.15**** 0.17****   
Relative wall thickness (RWT) -0.18**** 0.09** 0.36****  
White matter hyperintensity (WMH) -0.21**** 0.08 0.14** 0.11* 
p-value < 0.0001 ‘****’, p-value < 0.001 ‘***’, p-value < 0.01 ‘**’, p-value < 0.05 ‘*’ 
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Table SM 2-2: Univariate associations between CpG sites1 and each TOD trait in GENOA African Americans1 
 
CpG site 
eGFR  UACR  LVMI  RWT 
 







cg21134922 -0.008 0.104 9.42E-01  0.142 0.115 2.20E-01  0.663 0.116 1.59E-08  0.009 0.112 9.36E-01 
cg04816311 0.179 0.086 3.66E-02  0.513 0.094 5.52E-08  0.389 0.098 8.01E-05  0.100 0.094 2.86E-01 
cg09155024 0.181 0.056 1.19E-03  -0.077 0.062 2.14E-01  -0.043 0.063 5.01E-01  0.264 0.060 1.29E-05 
cg10254690 -0.149 0.062 1.74E-02  -0.030 0.069 6.61E-01  -0.362 0.070 2.64E-07  -0.059 0.068 3.85E-01 
cg07660512 -0.443 0.159 5.43E-03  -0.754 0.175 1.79E-05  -0.009 0.181 9.60E-01  -0.248 0.172 1.50E-01 
cg12661888 -0.317 0.070 6.10E-06  0.246 0.077 1.54E-03  -0.117 0.081 1.49E-01  0.016 0.077 8.38E-01 







cg21134922 0.007 0.103 9.45E-01  0.104 0.110 3.47E-01  0.608 0.110 3.84E-08  0.000 0.111 9.97E-01 
cg04816311 0.184 0.085 3.07E-02  0.452 0.089 5.38E-07  0.310 0.093 8.36E-04  0.069 0.092 4.53E-01 
cg09155024 0.171 0.055 2.11E-03  -0.103 0.059 8.08E-02  -0.065 0.060 2.75E-01  0.242 0.059 4.81E-05 
cg10254690 -0.156 0.062 1.24E-02  -0.025 0.066 7.01E-01  -0.346 0.066 1.88E-07  -0.059 0.066 3.73E-01 
cg07660512 -0.473 0.158 2.81E-03  -0.779 0.166 3.27E-06  0.004 0.170 9.80E-01  -0.281 0.169 9.58E-02 
cg12661888 -0.327 0.069 2.62E-06  0.223 0.074 2.57E-03  -0.136 0.076 7.41E-02  -0.006 0.076 9.34E-01 







cg21134922 0.035 0.103 7.36E-01  0.080 0.106 4.53E-01  0.411 0.101 4.98E-05  -0.025 0.110 8.23E-01 
cg04816311 0.157 0.085 6.46E-02  0.271 0.087 1.96E-03  0.142 0.085 9.48E-02  -0.019 0.092 8.38E-01 
cg09155024 0.166 0.056 2.89E-03  -0.120 0.057 3.59E-02  -0.019 0.055 7.26E-01  0.240 0.059 5.22E-05 
cg10254690 -0.159 0.062 1.03E-02  -0.007 0.064 9.06E-01  -0.225 0.060 2.10E-04  -0.038 0.066 5.63E-01 
cg07660512 -0.473 0.157 2.66E-03  -0.684 0.161 2.50E-05  0.097 0.156 5.32E-01  -0.233 0.168 1.66E-01 
cg12661888 -0.335 0.069 1.31E-06  0.211 0.071 3.11E-03  -0.122 0.069 7.86E-02  -0.004 0.075 9.61E-01 
cg02264946 0.226 0.122 6.34E-02  0.267 0.124 3.19E-02  -0.325 0.118 5.94E-03  0.392 0.128 2.32E-03 
SE: standard error; eGFR: estimated glomerular filtration rate; UACR: urinary albumin to creatinine ratio; LVMI: left ventricular mass index; RWT: relative wall thickness 
Model 1 is adjusted for age at phase II, sex, time between measurements, smoking status, and 4 genetic principal components 
Model 2 is adjusted for Model 1 variables plus systolic blood pressure, diastolic blood pressure and antihypertensive medication use  
Model 3 is adjusted for Model 2 variables plus body mass index and type 2 diabetes status  
Results significant at Bonferroni adjusted p-value are in bold font  
1 Only CpG sites that were statistically significant in multivariate Model 1 were included in this analysis 
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Table SM 2-3: Predicted change in TOD associated with CpG sites1 using linear mixed models and TOD modeled without 
normalization in GENOA African Americans1 
CpG site 









cg21134922 1.61 (0.27) -0.215 2.698 3.328 0.001 
cg04816311 1.10 (0.33) 2.160 13.111 2.559 0.004 
cg09155024 4.41 (0.50) 3.453 -2.438 0.024 0.012 
cg10254690 -4.01 (0.45) -2.778 -0.427 -2.871 -0.002 
cg07660512 -0.51 (0.18) -3.209 -12.176 -0.049 -0.004 
cg12661888 4.11 (0.40) -5.214 6.786 -0.967 0.002 
cg02264946 5.01 (0.23) 2.110 3.246 -2.096 0.008 
SD: standard deviation; eGFR: estimated glomerular filtration rate; UACR: urinary albumin to creatinine ratio; LVMI: left ventricular mass index; 
RWT: relative wall thickness 
Estimates are calculated from linear mixed regression models of DNA methylation (M-values) on each of the TOD traits after adjusting for age at 
phase II, sex, time between measurements, smoking status, 4 genetic principal components, and pedigree information as a random effect. Shown 
values of TOD were calculated based on the difference in predicted TOD between those with less (-1SD) and those with more (+1SD) from mean 
DNA methylation M-values. 
Results significant at Bonferroni adjusted p-value in the univariate Model 1 are in bold font 
1 Only CpG sites that were statistically significant in multivariate Model 1 were included in this analysis 
2 UACR was log-transformed, results shown were calculated using exponentiated coefficients 
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Table SM 2-4: Association between CpG sites1 and white matter hyperintensity in GENOA African Americans1 
CpG site Beta SE p-value 
cg21134922 -0.203 0.130 0.118 
cg04816311 0.195 0.104 0.063 
cg09155024 -0.039 0.067 0.554 
cg10254690 -0.116 0.077 0.131 
cg07660512 -0.028 0.192 0.884 
cg12661888 -0.026 0.085 0.757 
cg02264946 0.131 0.150 0.383 
SE: standard error 
Model is adjusted for age at white matter hyperintensity measurement, sex, time between measurements, smoking status, 4 genetic principal 
components, and total intracranial volume 
1 Only CpG sites that were statistically significant in multivariate Model 1 were included in this analysis 
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1 Only CpG sites that were statistically significant in multivariate Model 1 were included in this analysis 
  









Table SM 2-6: Independent SNPs identified as instrumental variables at FDR q < 0.1 for Mendelian randomization analyses in 
GENOA African Americans 
Chromosome CpG site Number of 
SNPs 
rs ID1 












































1 Independent based on clumping (r2=0.1 and physical distance threshold=100kb) using the Phase 3, version 5 of the 1000 Genomes dataset for 
Africans (AFR) and CpG-SNP FDR q < 0.1 
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Table SM 2-7: Significant Mendelian randomization results with causal estimates of CpG sites and TOD traits calculated using the 
two-stage least squares regression method in GENOA African Americans 
TOD trait  Chr CpG site 
Independent SNPs 
with CpG-SNP 










filtration rate (eGFR), 
mL/min/1.73m2 
7 cg04816311 15 11.836 4.591 0.010 
10 cg10254690 10 -6.764 3.011 0.025 
12 cg07660512 13 -15.879 8.251 0.055 
Chr: chromosome; SE: standard error 
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Table SM 2-8: Characteristics of participants in HyperGEN (N = 614) 
 Mean (SD) or N (%) 
Female 409 (66.6%) 
Age (years) 48.4 (11.1) 
BMI (kg/m2) 32.4 (8.2) 
Systolic blood pressure (mmHg) 131.6 (23.6) 
Diastolic blood pressure (mmHg) 75.5 (12.6) 
Antihypertensive medication use  
     No 175 (28.6%) 
     Yes 438 (71.5%) 
     Missing 1 (0.0%) 
Smoking status  
    Current 193 (31.4%) 
    Former 149 (24.3%) 
    Never 262 (42.7%) 
    Missing 10 (1.6%) 
Diabetes status1  
    No 492 (80.1%) 
    Yes 122 (19.9%) 
    Missing 0 (0.0%) 
Estimated glomerular filtration rate (eGFR, mL/min/1.73m2) 92.1 (21.9) 
Urine albumin-to-creatinine ratio (UACR, mg/g) 81.6 (403.3) 
Left ventricular mass index (LVMI, g/height2.7) 45.0 (16.1) 
Relative wall thickness (RWT) 0.3 (0.1) 
SD: Standard deviation; CI: Confidence interval; BMI: Body mass index  
Sample sizes for target organ damage measures: eGFR (N=613), UACR (N=606), LVMI (N=611), RWT (N=613)  
1 Defined as glucose level ≥ 126 mg/dL or taking diabetes medication
 63 
 
      
 Table SM 2-9: Univariate associations between CpG sites1 and each TOD trait in HyperGEN 
Model 1 is adjusted for age at phase II, sex, smoking status, 4 genetic principal components, and family (random) 
Model 2 is adjusted for Model 1 variables plus systolic blood pressure, diastolic blood pressure and antihypertensive medication use  
Model 3 is adjusted for Model 2 variables plus body mass index and type 2 diabetes status 
Results significant at p-value <0.05 are in bold font  
1 Only CpG sites that were statistically significant in multivariate Model 1 in GENOA were included in this replication analysis  
 
CpG site 
eGFR  UACR  LVMI  RWT 
 






 cg04816311 0.473 0.131 3.07E-04  0.141 0.139 0.32  0.402 0.004 3.33E-04  0.422 0.137 2.13E-03 














cg04816311 0.496 0.132 1.78E-04  0.051 0.131 0.69  0.244 0.123 4.63E-02  0.349 0.133 8.62E-03 














cg04816311 0.502 0.135 2.08E-04  -0.008 0.130 0.54  0.070 0.113 0.54  0.337 0.135 1.27E-02 



















B: Urinary albumin-creatinine ratio (UACR) C: Relative wall thickness (RWT) 
D: Left ventricular mass index (LVMI) E: Multivariate model (eGFR, UACR, RWT, LVMI) 
A: Estimated glomerular filtration rate (eGFR) 
Figure SM 2-1: QQ plots of the association between DNA methylation and TOD using univariate and multivariate model 1 in 
GENOA African Americans 
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Figure SM 2-2: Mendelian randomization (MR) scatter plots of estimated glomerular filtration rate (A-C). Causal estimates are based 


















































































































SNP effect on cg10254690 
B 
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Chapter 3.  Epigenetic Age Acceleration in African Americans Associates with 
Cardiometabolic Risk Factors and Clinical Cardiovascular Disease Risk Scores 
3.1 Abstract 
Cardiovascular disease (CVD) is the leading cause of mortality among US adults. African 
Americans have higher burden of CVD morbidity and mortality compared to any other racial 
group. Identifying biomarkers for clinical risk prediction of CVD offers an opportunity for 
precision prevention and earlier intervention. Using linear mixed models, we investigated the 
cross-sectional association between four measures of epigenetic age acceleration (intrinsic 
(IEAA), extrinsic (EEAA), PhenoAge (PhenoAA), and GrimAge (GrimAA)) and ten 
cardiometabolic markers of hypertension, insulin resistance, and dyslipidemia in 1,100 primarily 
hypertensive African Americans from sibships in the Genetic Epidemiology Network of 
Arteriopathy (GENOA). We then assessed the association between epigenetic age acceleration 
and time to self-reported incident CVD using frailty hazard models and investigated CVD risk 
prediction improvement compared to models with clinical risk scores (Framingham risk score 
(FRS) and the atherosclerotic cardiovascular disease (ASCVD) risk equation). After adjusting for 
sex and chronological age, increased epigenetic age acceleration was associated with higher 
systolic blood pressure (IEAA), higher pulse pressure (EEAA and GrimAA), higher fasting 
glucose (PhenoAA and GrimAA), higher fasting insulin (EEAA), lower low density cholesterol 
(GrimAA), and higher triglycerides (GrimAA). A five year increase in GrimAA was associated 
with CVD incidence with a hazard ratio of 1.54 (95% CI 1.22–2.01) and remained significant 
after adjusting for CVD risk factors. The addition of GrimAA to risk score models improved 
 67 
model fit using likelihood ratio tests (P = 0.013 for FRS and P = 0.008 for ASCVD), but did not 
improve C statistics (P > 0.05). Net reclassification index (NRI) showed small but significant 
improvement in reassignment of risk categories with the addition of GrimAA to FRS (NRI: 
0.055, 95% CI 0.040–0.071) and the ASCVD equation (NRI: 0.029, 95% CI 0.006–0.064). 
Epigenetic age acceleration measures are associated with traditional CVD risk factors in an 
African American cohort with a high prevalence of hypertension. GrimAA was associated with 




Cardiovascular disease (CVD) is the leading cause of mortality among US adults.1 
African Americans have the highest CVD morbidity and mortality burden, a trend which has 
been consistent over the last few decades.2 Underlying this higher CVD prevalence is a greater 
burden of a number of risk factors, including hypertension, type 2 diabetes, and obesity.3-5 Yet a 
focus on established risk factors and their management has failed to fully reduce the excess CVD 
burden among African Americans. Identification of novel biomarkers that go beyond traditional 
ones may help better identify at-risk individuals, advance precision medicine, and inform efforts 
to reduce CVD burden.  
Epigenetic aging, based on DNA methylation (DNAm) at CpG dinucleotides, is a novel 
measure of biological aging that offers the opportunity to identify molecular markers of disease 
risk. The first generation of epigenetic aging measures, the HorvathAge 6 and HannumAge 7 
epigenetic clocks, were trained on chronological age and are estimated based on 363 and 71 CpG 
sites selected using elastic net regression modeling, respectively. HorvathAge was trained using 
multi-tissue samples from children and adults, while HannumAge was trained using a single 
tissue (whole blood) from adults. Modified versions of these two measures were later derived to 
account for confounding by blood cell composition: intrinsic epigenetic age acceleration (IEAA) 
based on HorvathAge explicitly adjusts for blood cell composition, and extrinsic epigenetic age 
acceleration (EEAA) based on the HannumAge is a composite measure that includes a weighted 
average of cell counts known to vary strongly with age.8 PhenoAge, a more recent measure 
based on whole blood from adults, was estimated using 513 CpG sites and was trained on a 
composite clinical measure of phenotypic age that is based on chronological age and nine 
biomarkers including albumin, creatinine, serum glucose, white blood cell counts.9 The 
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biomarkers were selected for their association with the hazard of mortality using a Cox penalized 
regression model. GrimAge is another recent measure constructed based on the linear 
combination of 1030 CpG sites that represent DNAm-based surrogate measures for a number of 
plasma proteins and smoking pack-years.10 Like PhenoAge, it is based on whole blood from 
adults. In addition to chronological age, both PhenoAge and GrimAge account for physiological 
dysfunction among individuals of the same chronological age in their selection of CpGs. For 
each of these measures, epigenetic age acceleration is defined as the discrepancy between 
epigenetic age and chronological age. These four epigenetic age acceleration measures are 
hypothesized to be capturing different aspects of aging and are based mostly on unique CpG 
sites.11 
A growing body of literature has examined the association between epigenetic age 
acceleration and CVD and its risk factors, such as blood pressure and lipids, but the overall 
evidence remains inconclusive likely due to heterogeneity in study design, the specific outcomes 
examined, and the epigenetic aging measures used.12-21 PhenoAge and GrimAge are more 
recently developed measures, and so validation of their associations and comparisons to the first-
generation measures are in early stages. Two recent studies in participants of European ancestry 
show that GrimAA outperforms other measures in its association with CVD incidence after 
adjusting for CVD risk factors,21,22 and additional studies report similar findings with all-cause 
mortality.21-24 Yet it is unclear whether epigenetic age acceleration measures could be used to 
improve CVD prediction in a clinical setting.  
In this study, we investigated the relationship between four epigenetic age acceleration 
measures and ten cardiometabolic markers of hypertension, insulin resistance, and dyslipidemia 
in 1,100 primarily hypertensive African Americans in the Genetic Epidemiology Network of 
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Arteriopathy (GENOA) study. We additionally assessed the association between four epigenetic 
age acceleration measures and incident CVD. Finally, we examined whether epigenetic age 
acceleration measures can improve the predictive accuracy of two clinically-used CVD risk 
scores: the Framingham risk score (FRS)25 and the more recently developed atherosclerotic 
cardiovascular disease (ASCVD) risk equation.26  
3.3 Methods 
Study sample  
Genetic Epidemiology Network of Arteriopathy (GENOA) is a community-based study 
in Rochester, MN and Jackson, MS that was established to identify genes influencing blood 
pressure and development of target organ disease.44 In the first phase of GENOA (Phase I: 1996 
– 2001), sibships with at least two adults with clinically diagnosed essential hypertension before 
age 60 were recruited, and all siblings in the sibship were invited to participate regardless of 
hypertension status. Exclusion criteria included secondary hypertension, alcoholism or drug 
abuse, pregnancy, insulin-dependent diabetes mellitus, or active malignancy. In Phase I (i.e. 
baseline), a total of 1,583 non-Hispanic whites (Rochester, MN) and 1,854 African Americans 
(Jackson, MS) were enrolled. In the second phase (Phase II: 2001 – 2005), all participants were 
invited for a second examination. Eighty percent of African Americans (N = 1,482) and 75% of 
non-Hispanic whites (N = 1,213) from Phase 1 returned. At Phase III (2009-2011), 752 African 
Americans returned for a third examination. This study includes African American participants 
who had their DNA methylation profiles measured in whole blood samples collected at Phase I. 
Demographic information, medical history, clinical characteristics, lifestyle factors, and blood 
samples were collected in each phase. Written informed consent was obtained from all 
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participants and approval was granted by participating institutional review boards (University of 
Michigan, University of Mississippi Medical Center, and Mayo Clinic). 
DNA methylation and epigenetic age acceleration measures 
The methods of DNA methylation processing have been previously described.45 Briefly, 
genomic DNA from 1,106 African American participants from Phase I and 304 from Phase II 
was extracted from stored peripheral blood leukocytes using AutoGen FlexStar (AutoGen, 
Holliston, MA). Sex mismatches and outliers were excluded using the shinyMethyl R package,46 
probes with detection P-value < 10-16 were considered to be successfully detected47 and both 
samples and probes that failed a detection rate of at least 10% were removed. The Noob method 
was used for individual background and dye-bias normalization48 and the Regression on 
Correlated Probes method was used to adjust for the probe-type bias in the data.49 White blood 
cell type proportions within the blood sample were estimated using Houseman’s method.50  
After quality control, a total of 1,100 samples from Phase I and 294 from Phase II were 
available for assessment of epigenetic age acceleration; however, only Phase I measures were 
included in this study. Methylation beta values were uploaded to the online Horvath epigenetic 
age calculator to calculate DNAm Age.51 Four measures of epigenetic age (HannumAge, 
HorvathAge, PhenoAge and GrimAge) were estimated for the current analysis. IEAA based on 
the Horvath measure, are the regression residuals after adjusting for chronological age and blood 
cell count.6-8 EEAA was calculated using the Hannum epigenetic age after incorporating 
weighted averages of three white blood cell types (naïve cytotoxic T cells, exhausted cytotoxic T 
cells, and plasmablasts).7,8 PhenoAge and GrimAge are considered to be extrinsic measures of 
aging because they capture both cell intrinsic methylation changes as well as extracellular 
changes in blood cell composition.9,10,31 We also estimated 7 DNAm based surrogate plasma 
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proteins (adrenomedullin (ADM), beta-2-microglobulin, cystatin C, GDF-15, leptin, 
plasminogen activator inhibitor antigen type 1 (PAI-1), tissue inhibitor metalloproteinases 1 
(TIMP-1)), and smoking pack-years that comprise GrimAge in order to identify individual 
components that may drive associations or that are more predictive than the overall measure 
itself.10 
Cardiometabolic risk factors 
Resting systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured 
by a random zero sphygmomanometer and a cuff appropriate for arm size. The second and third 
of three readings, after the participant sat for at least 5 minutes, were averaged for analysis.52  
Mean arterial pressure (MAP) was calculated as the weighted average of SBP and DBP 
(1/3*SBP + 2/3*DBP) and pulse pressure (PP) was calculated as the difference between SBP and 
DBP (SBP – DBP). Information on current anti-hypertensive medication use and lipid-lowering 
statin medication use were collected. Hypertension was defined as SBP ≥ 140 mmHg, DBP ≥ 90 
mmHg, or antihypertensive medication use. Smoking was categorized as current, former, or 
never. Blood glucose and insulin levels were measured for participants fasting for at least 10 
hours. Serum total cholesterol, HDL-C, and triglycerides (TGs) were measured by standard 
enzymatic methods on a Hitcahi 911 Chemistry Analyzer (Roche Diagnostics, Indianapolis, IN). 
LDL-C was calculated using the Friedewald formula [LDL in mg/dl = TC – HDL-C – (TGs/5)]53 
and individuals with triglycerides levels ≥ 400 mg/dl were excluded from LDL-C association 
analysis. Type 2 diabetes was defined as fasting serum glucose concentration > 126 mg/dl or 
self-reported physician-diagnosed diabetes and current medication use (insulin or hypoglycemic 
agents). Educational attainment was based on self-reported years of education. Alcohol 
consumption was calculated as the number of drinks per week based on aggregated 
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measurements of a variety of alcoholic drinks. Height was measured by stadiometer and weight 
by electronic balance and body mass index (BMI) was calculated as weight in kilograms divided 
by the square of height in meters. 
CVD events and risk scores 
Framingham risk score (FRS), predicting the 10-year risk of a CVD (defined as coronary 
death, myocardial infarction, coronary insufficiency, angina, ischemic stroke, hemorrhagic 
stroke, transient ischemic attack, peripheral artery disease, and heart failure), was estimated 
using age, sex, total cholesterol, HDL-C, anti-hypertensive medication use, SBP, smoking status, 
and type 2 diabetes status after limiting the sample to individuals aged between 30 – 74 years 
(N= 945, events = 69, person-years = 7874.9).25 While FRS was developed in participants of 
European ancestry, ASCVD was developed using a pooled community-based population cohort 
with a higher proportion of African Americans and has been validated for prediction of clinical 
events in more race/ethnically-diverse cohorts. 26 It is based on the same covariates as FRS and 
predicts the 10-year risk of developing a first ASCVD event, defined as nonfatal myocardial 
infarction or coronary heart disease death or fatal or nonfatal stroke. Using sex- and race-specific 
parameters, we estimated the ASCVD risk equation, after limiting the sample those between the 
ages of 20 – 79 years (N = 988, events = 71, person-years = 8115.5). Risk scores were modeled 
as continuous variables and as categorical predictors where they were used to group participants 
into low risk (10-year risk ≤ 7.5%) or high risk (> 7.5%) groups.26  
Information about CVD, as reported by participants, was collected at baseline and at each 
subsequent follow-up phase. An event was defined as myocardial infarction, coronary 
revascularization (stenting, balloon angioplasty, or coronary artery bypass grafting), stroke 
(ischemic or hemorrhagic events), or surgical carotid artery revascularization. Participants only 
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reported the year of CVD events. Time to CVD was modeled by setting the CVD event time at 
the mid-point of the year in which participants reported an event. For censored participants, 
follow-up time was set at the time point they were last interviewed.   
Statistical analysis 
Outliers at more than 5 standard deviations from the mean were removed for the 
cardiometabolic outcomes and the epigenetic age acceleration measures. Glucose, insulin, HDL-
C and triglycerides were natural log-transformed as ln(measure +1). Linear mixed models that 
account for familial relatedness were used to assess the cross-sectional univariate association 
between each epigenetic age acceleration measure (predictor) and each cardiometabolic risk 
factors (outcome) at Phase I. Base models were adjusted for age and sex (Model 1). In 
subsequent models, we additionally adjusted for education, smoking status, body mass index, 
and alcohol consumption (Model 2) and white blood cell counts for PhenoAA and GrimAA to 
assess confounding by changes in cell composition (Model 3). For LDL-C and triglycerides, we 
performed sensitivity analyses excluding participants who were not fasting for at least 10 hours 
before the blood draw.  
After excluding participants with baseline CVD events, associations with time to first 
CVD event (incident CVD) were assessed using Cox proportional hazards models, and hazard 
ratios (HR) and 95% confidence intervals were estimated. A simple random effects (frailty) term 
in the Cox model was included to take into account family structure.54 We next adjusted for 
traditional CVD risk factors (age, sex, education, body mass index, alcohol consumption, total 
cholesterol, HDL-C, anti-hypertensive medication use, SBP, smoking status, and type 2 diabetes 
status). Finally, we adjusted for white blood cell counts. The proportional hazard assumption was 
evaluated using Schoenfeld residuals, and all models satisfied the assumption. As a sensitivity 
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analysis, we additionally modeled time to CVD using interval censoring using the iceReg 
package.55 
Likelihood ratio (LR) testing of nested models (addition of epigenetic age acceleration to 
a base model with either FRS or ASCVD) was used to assess improvement in model fit. For 
measures with P < 0.05, we assessed improvement in risk prediction of incident CVD by adding 
the epigenetic age acceleration measure to the base model with the clinical risk scores. We 
assessed the improvement in CVD risk prediction using C-statistics computed from Cox 
proportional hazards models of time to CVD events and risk scores as continuous predictors.56 
We additionally used the net reclassification index (NRI) to assess net improvement in 
reassignment of the risk categories.28 Categorized CVD risk scores were used in the base model 
and improvement in risk reassignment was then assessed after the addition of epigenetic 
acceleration measures. For this analysis, we also examined the associations excluding individuals 
taking lipid-lowering statin medications (N = 40).  
Statistical tests were two-sided and a P value of < 0.05 was considered nominally 
significant. We also applied a Bonferroni threshold for statistical significance (0.05/10 = adjusted 
P < 0.005) to account for multiple testing in assessing the association between epigenetic 
acceleration measures and the 10 cardiometabolic traits. For NRI, bootstrapping (10,000 
iterations) was used to compute 95% confidence intervals, and an empirical P < 0.05 was 
considered significant. Analyses were performed using R (Version 4.0.2)57 and the following 




Baseline characteristics of the participants are shown in Table 1. The 1,100 participants 
from 530 sibships had a mean age of 57.1 years, and 71% were women. About 60% were never 
smokers and mean alcohol consumption was 0.66 drinks per week. About 70% of the 
participants had hypertension and 20% had type 2 diabetes at baseline. At baseline, 91 
participants had prevalent CVD and another 72 developed incident CVD over 8,161 person-years 
of follow-up. The mean Framingham risk score (FRS) was 14.4% and the mean of the 
atherosclerotic cardiovascular disease (ASCVD) risk equation was 11.6%. FRS and ASCVD 
were positively and significantly correlated (r = 0.94, P = 2.2 × 10-16). Supplemental Figure 1 
shows the scatterplots for each of the DNAm age measures with chronological age.  As 
previously reported, all of the DNAm age measures were strongly and significantly correlated 
with chronological age (all r > 0.8, Supplemental Table 1).27 The means of the age acceleration 
measures ranged between 0.11 years for GrimAA and 0.38 years for PhenoAA. The acceleration 
measures were not strongly correlated with each other (r range: 0.19 – 0.50), nor where they 
correlated with chronological age (Supplemental Table 1, Supplemental Figure 2). 
Association between epigenetic age acceleration and cardiometabolic risk factors 
Table 2 shows the regression results from linear mixed models for the univariate 
associations between the epigenetic age acceleration measures and cardiometabolic risk factors 
with beta coefficients for 1-year increase in epigenetic age acceleration after adjusting for age, 
sex, and familial relatedness. Effect sizes are also reported below per 5-year increase, which is 
equivalent to approximately one standard deviation of the epigenetic acceleration measures. At P 
< 0.05, IEAA, EEAA, and PhenoAA were each associated with four cardiometabolic risk factors, 
while GrimAA was associated with five. 
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IEAA was associated with higher systolic blood pressure (SBP), and both EEAA and 
GrimAA were associated with higher pulse pressure after accounting for multiple testing. A 5-
year increase in IEAA was associated with an approximately 1.85 mmHg increase in SBP (95% 
CI 0.55–3.14). For EEAA and GrimAA, a 5-year increase was associated with a 1.20 mmHg 
(95% CI 0.41–2.0) and a 1.75 mmHg (95% CI 0.73–2.72) increase in pulse pressure, 
respectively. 
GrimAA was associated with higher fasting glucose levels and EEAA was associated 
with higher fasting insulin levels after accounting for multiple testing. A 5-year increase in 
GrimAA was associated with a 4.08% increase (95% CI 1.51%–6.18%) in glucose levels. EEAA 
was the only measure associated with insulin, where a 5-year increase was associated with a 
5.13% increase (95% CI 2.53%–10.5%).  
Only GrimAA was associated with any of the lipid traits examined after accounting for 
multiple testing. A 5-year increase in GrimAA was associated with a 3.85 mg/dl (95% CI -6.50 
to -1.20) decrease in low density lipoprotein (LDL-C) and a 5.13% (95% CI 3.05%–8.87%) 
increase in triglyceride levels. The associations between the lipid measures and GrimAA 
remained significant after excluding participants who were not fasting for at least 10 hours (β = -
1.01, P = 0.001, N = 863 for LDL-C and β = 0.011, P = 0.001, N = 881 for triglycerides).  
Supplemental Table 2 shows the adjusted linear mixed model regression results for associations 
significant at P < 0.05 from Table 2. Although some of the nominally significant associations 
fully attenuated after adjusting for education, smoking status, body mass index (BMI), and 
alcohol consumption (Model 2), all of the associations that were significant after multiple testing 
in the base model (Bonferroni-corrected P < 0.05) remained significant at P < 0.05. When we 
further adjusted PhenoAA and GrimAA associations for white blood cell counts (Model 3), all of 
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the associations became less significant, and the associations between PhenoAA and glucose and 
GrimAA and pulse pressure were fully attenuated (P = 0.100 and P = 0.054, respectively). 
GrimAA, however, remained significantly associated with glucose, LDL-C, and triglycerides (P 
< 0.05). 
Epigenetic age acceleration associations with clinical cardiovascular risk scores and 
incident CVD  
All epigenetic age acceleration measures were significantly associated with the FRS and 
the ASCVD risk equation, except for IEAA with FRS. The effect estimates from the linear 
mixed models were in the expected direction with increased biological aging associated with an 
increase in the predicted 10-year risk of CVD (Table 3). The largest effect estimate was 
observed for GrimAA, where a 5-year increase in epigenetic age acceleration was associated 
with a 2.9% (95% CI 2.2%–3.6%) and a 2.2% (95% CI 1.7%–2.8%) increase in the 10-year 
CVD risk using FRS and ASCVD equations, respectively.  
When we examined whether epigenetic acceleration measures were associated with time 
to first CVD event, a similar trend emerged with GrimAA showing the only significant 
association with incidence of CVD events. Table 4 shows the hazard ratios (HR) and 95% 
confidence intervals estimated from Cox proportional hazards models with a frailty term for the 
associations of the four epigenetic age acceleration measures with incident CVD. A 5-year 
increase in GrimAA was associated with a HR of 1.54 (95% CI 1.22–2.01) in the base model 
(adjusted for age, sex, and family structure). Further adjusting for traditional CVD risk factors 
(education, alcohol consumption, body mass index, total cholesterol, HDL-C, anti-hypertensive 
medication use, SBP, smoking status, and type 2 diabetes status) only slightly attenuated the 
association (HR per 5-year increase in GrimAA: 1.47, 95% CI 1.05–2.01, P = 0.024). 
Additionally adjusting for white blood cell counts did not attenuate the association (HR per 5-
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year increase in GrimAA: 1.54, 95% CI 1.10–2.19, P = 0.01). Findings were similar when time 
to CVD was modeled using interval censoring. Last, we examined the association between the 
individual components comprising GrimAge and incident CVD to identify components that may 
be driving the association between GrimAA and CVD or outperform the overall GrimAA 
measure itself (Supplemental Table 3). Adrenomedullin (ADM), smoking pack-years, and 
plasminogen activator inhibitor antigen type 1 (PAI-1) were associated with incident CVD (P < 
0.05) in the base model after further adjustment for white blood cell types, with HRs only 
slightly lower than that of GrimAA. Figure 1 shows the box plots of the standardized DNAm 
surrogate measures of the 7 plasma protein and smoking pack-years in GrimAge by incident 
CVD status. The means of ADM, smoking pack-years, and PAI-1 were higher among those with 
incident CVD.  
Evaluating the performance of epigenetic age acceleration measures in CVD prediction 
Likelihood ratio (LR) tests of nested models showed that GrimAA improved model fit 
when added to a model with age, sex, and FRS (HR per 1-year increase in GrimAA: 1.07, 95% 
CI 1.02–1.13, P for LR test of model fit = 0.013) or the ASCVD equation (HR per 1-year 
increase in GrimAA: 1.08, 95% CI 1.02–1.13, P for LR test = 0.008) (Table 5). None of the 
other age acceleration measures improved model fit.  
Since GrimAA improved model fit, we next evaluated whether it could improve CVD 
risk prediction compared with the FRS and ASCVD risk equations using the C-statistic and the 
net reclassification index (NRI). The C-statistic is the probability that a randomly selected 
participant who experienced the CVD event will have a higher predicted probability of having 
the event compared to a randomly selected participant who did not experience the event. Table 6 
shows the C-statistics for the performance of GrimAA in predicting incident CVD. The addition 
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of GrimAA to a model with each risk score increased the C-statistic to 0.698 for FRS and to 
0.685 for the ASCVD risk equation (all P > 0.05). Supplementary Figure 3 shows the receiver 
operator characteristic (ROC) curves for the risk scores before and after adding GrimAA to the 
model.  
Next, we compared the classification of CVD events with and without GrimAA using the 
net reclassification index (NRI). The NRI is an index of the net improvement in reassignment of 
the risk categories.28 The FRS categorized 36.5% of the GENOA cohort as low risk (≤ 7.5%) 
while the ASCVD equation categorized 47.2% of the cohort as low risk. Net reclassification for 
CVD was small but significant with the addition of GrimAA to a model of age, sex, and FRS 
(NRI: 0.055, 95% CI 0.040–0.071, P < 0.0001), and for a similar model of age, sex, and the 
ASCVD equation (NRI: 0.029, 95% CI 0.006–0.064, P = 0.0011). Supplemental Figure 4 
shows the reclassification tables of predicted CVD based on the NRI for models with FRS or 
ASCVD and GrimAA. The improvement in risk prediction was driven by the classification of 
CVD nonevents as low risk.  
When we excluded participants taking lipid-lowering statin medications, improvement in 
risk prediction in models with GrimAA was almost identical to that of the full sample. GrimAA 
remained associated with incident CVD after adding it to a base model with FRS and ASCVD 
(HR = 1.08 in both models, P = 0.004 and P = 0.003, respectively). As in the full sample, 
addition of GrimAA to a model with FRS or the ASCVD equation increased the C-statistics, but 
the increases were not significant at P < 0.05. The NRIs with the addition of GrimAA to the risk 
scores were also similar (NRI = 0.052 for FRS, NRI = 0.030 for the ASCVD equation).  
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3.5 Discussion 
In this study of primarily hypertensive African American participants from GENOA, we 
showed that increased biological aging is associated with a worse cardiometabolic risk profile, 
although the associations with specific cardiometabolic risk factors varied across the age 
acceleration measures. All of the epigenetic acceleration measures were correlated with risk of 
CVD onset as modeled by clinical CVD risk scores (FRS and ASCVD equation). GrimAA 
outperformed IEAA, EEAA, and PhenoAA in predicting CVD incidence, and the association 
remained significant after adjusting for traditional CVD risk factors. The addition of GrimAA to 
FRS or ASCVD did not improve the C-statistics of CVD risk prediction; however, the NRIs 
showed small but significant improvement in the reassignment of risk categories.  
Differences in the cardiometabolic risk factor and CVD incidence associations among the 
various epigenetic clocks may be attributed to a number of factors. IEAA, EEAA, and PhenoAA 
share only between 5 and 36 CpG sites.9 Information on the CpGs included in GrimAge are not 
publicly available, so we cannot assess how many CpG sites this measure shares with the other 
three. In addition to differences in training algorithms (chronological age for IEAA and EEAA 
vs. aging correlates and outcomes for PhenoAA and GrimAA), the second generation of 
epigenetic measures (PhenoAA and GrimAA) were trained using longitudinal data.29 This is 
particularly relevant for studies assessing their prediction of aging related outcomes. The use of 
cross-sectional training data may have biased the algorithm as individuals with accelerated aging 
rates will have a higher morality burden and may have been selected out from the training 
samples.29,30 Nevertheless, an analysis of the transcriptional profiles of IEAA, EEAA, and 
PhenoAge shows that they have relatively similar transcriptional signatures.11 
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Our study found cross-sectional associations between epigenetic age acceleration and a 
number of cardiometabolic risk factors. Out of the 10 cardiometabolic risk factors examined in 
the base model, GrimAA was associated with 4 measures, EEAA with 2 measures, and IEAA 
and PhenoAA with 1 measure after accounting for multiple testing. Some of the associations 
were unique to one specific cardiometabolic feature such as the association between GrimAA 
and lipid traits. For the significant associations between the acceleration measures and 
cardiometabolic risk factors, the effect directions were as expected with the exception of the 
association between GrimAA and LDL-C. Higher epigenetic acceleration, indicative of tissue 
aging faster than expected by chronological age, was associated with worsening outcomes as 
measured by cardiometabolic risk factors. Increased tissue aging in blood is accompanied by 
changes in cell-type composition.31 However, the associations between GrimAA and 
cardiometabolic risk factors were not attenuated after adjusting for blood cell composition, with 
the exception of the association between GrimAA and pulse pressure. This suggests that the 
associations observed are not due to age-related changes in blood cell composition and that 
GrimAA is capturing cell-intrinsic properties or innate changes related to aging rather than 
changes in immune cell composition.  
In our study, IEAA was associated with SBP, and both EEAA and GrimAA were associated with 
pulse pressure. Previous studies on the association between IEAA and EEAA and 
cardiometabolic phenotypes show inconsistent findings.13,20,32,33 A previous study of IEAA and 
EEAA in the Women’s Health initiative (WHI) found no associations with systolic or diastolic 
blood pressure after adjusting for diet and metabolic syndrome symptoms.32 However, in a 
smaller sample of African Americans from the Bogalusa Heart Study (N=288), both IEAA and 
EEAA were associated with hypertension.20 Another study of approximately 5,000 individuals 
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from the Generation Scotland: Scottish Family Health Study found evidence of an association 
between EEAA and high blood pressure, but not IEAA.34 A previous analysis in GENOA found 
no association between blood pressure measured at Phase II and IEAA or EEAA,35 although 
significant associations were detected in this study using concurrently measured blood pressure 
(Phase I). PhenoAA and GrimAA were more recently developed, so fewer studies have assessed 
their associations with cardiometabolic risk factors. However, in WHI, both PhenoAA and 
GrimAA were significantly correlated with SBP but not DBP.9,10   
In this study, we also found evidence of associations between PhenoAA and GrimAA and 
glucose, and EEAA and insulin. GrimAA was the only measure associated with any of the lipid 
traits. In WHI, no associations between measures of insulin resistance and dyslipidemia (HDL-C 
and triglycerides) were detected with IEAA or EEAA, except for an association between EEAA 
and triglycerides (β = 0.004, P value = 0.04).20 However, other studies have reported an inverse 
association between fasting HDL-C levels and EEAA13 and IEAA.34 Cross-sectional 
examination of WHI revealed correlations between both PhenoAA and GrimAA and insulin, 
glucose, triglycerides, and HDL-C.9 PhenoAA, but not GrimAA, was also correlated with LDL-
C.10 As in our study, GrimAA was associated with lower total cholesterol and LDL-C in a cross-
sectional analyses of 709 individuals from the Lothian Birth Cohort.36 Another study in the 
Methyl Epigenome Network Association and a Spanish cohort found significant correlations 
between GrimAA and glucose levels, HDL-C, and triglycerides.37 
In our analyses, higher GrimAA was the only measure associated with CVD incidence in 
GENOA African Americans independent of CVD risk factors. Adjustment for white blood cell 
counts did not attenuate the association. Neither EEAA nor IEAA were associated with incident 
coronary heart disease in WHI.20 However, among Black participants from the Atherosclerosis 
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Risk in Communities (ARIC) study, epigenetic age acceleration based on the Horvath and 
Hannum measures were both associated with increased hazard of fatal coronary heart disease 
(HR: 1.17, 95% CI 1.02–1.33 and HR: 1.22, 95% CI 1.04–1.44, respectively).17 A German case-
cohort study reported an increase in the hazard of cardiovascular mortality associated with 
Horvath age acceleration,38 while a study in the Melbourne Collaborative Cohort found no 
association with the Horvath or Hannum measures.16 Increased PhenoAA, but not HorvathAA, 
was also associated with increased risk of cardiovascular mortality in 500 males from the US 
Normative Aging Study.39  
Our findings are in line with the literature in cohorts of European ancestry showing that 
GrimAA outperforms other measures in its association with CVD incidence.21,22 The effect size 
of GrimAA on CVD incidence appears to be remarkably similar across studies in European 
ancestry, and similar to our estimate in African Americans. Comparing the same four measures 
of epigenetic acceleration that we investigated, Hillary et al. found that over thirteen years of 
follow-up, GrimAA outperforms the other measures in terms of its association with incidence of 
heart disease (HR: 1.41, 95% CI 1.18–1.68,  per 1 SD).21 Wang et al. found that a 1 SD increase 
in GrimAA was associated with elevated risk of myocardial infarction (HR: 1.44, 95% CI 1.16–
1.79) and stroke (HR: 1.42, 95% CI 1.06–1.91) in a study of elderly participants from the 
Normative Ageing Study and the Cooperative Health Research in the Region Augsburg (KORA) 
study.22  
To our knowledge, no previous study has assessed the performance of the epigenetic age 
acceleration measures in improving the predictive accuracy of clinical risk scores of CVD. 
GrimAA appears to marginally improve prediction of CVD events beyond traditional risk factors 
when assessed using NRI but not using changes in the area of the ROC curves. The net gains in 
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risk prediction were mostly due to the down-classification of non-cases as low risk, with fewer 
up-classification of non-cases as high risk. More studies are needed to validate and replicate 
these findings and assess their utility in clinical settings. In addition, each of our clinical score 
measures predict a different set of outcomes. FRS is a predictor of total CVD, including coronary 
death, peripheral artery disease and heart failure. The ASCVD, on the other hand, predicts 
outcomes related to coronary heart disease and stroke. Further studies are needed to fully 
investigate the predictive performance of GrimAA in relation to different cardiovascular 
outcomes. However, GrimAA may be a promising biomarker since it is a composite measure of 
multiple plasma proteins, some of which have been shown to be independent biomarkers that can 
improve CVD prediction.40-43 Additionally, for some of the components of GrimAge (PAI-1, 
TIMP-1, and cystatin C), DNAm-based surrogates were found to outperform the observed 
biomarkers.10 Lu et al. found that DNAm smoking pack-years was a more significant predictor of 
lifespan than self-reported smoking and that it predicted mortality even among non-smokers. 
This may be related to errors in self-reporting or because DNAm pack-years may capture 
intrinsic variation across individuals with lasting biological damage related to smoking.10  
Our study has a number of limitations. Our findings were based on self-reported events, 
with only the year of the event reported, which could be subject to recall bias. We also note that 
there was loss to follow-up between baseline and Phases II and III. Those lost to follow-up 
between baseline and Phase III were 1.63 years older and had 3.5 mmHg higher systolic blood 
pressure on average (P = 0.014). Additionally, individuals lost to follow up had higher GrimAA, 
FRS, and ASCVD risk scores (all P < 0.05). This indicates that participants at greater risk of 
CVD events were more likely to be lost to follow-up. Another limitation is that although we 
adjusted for a number of important confounders, we lacked information on dietary data in 
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GENOA African Americans. Finally, our sample is predominantly hypertensive and has an 
overrepresentation of women, so our findings may not be representative of other cohorts. A 
strength is that our study provides insights on the association between four different epigenetic 
aging measures and cardiometabolic risk factors and CVD in a relatively large cohort of older 
African Americans. In addition, we also explored improvement of CVD risk prediction by 
incorporating epigenetic aging measures in clinical risk equations and investigated potential 
molecular drivers of the observed associations. 
Epigenetic information is an important molecular readout of lifetime exposures. We have 
shown that epigenetic aging measures are associated with some cardiometabolic risk factors in 
this relatively large cohort of African Americans. GrimAge acceleration was the only measure 
associated with CVD incidence after adjusting for CVD risk factors. Further studies are needed 
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Table 3-1: Descriptive characteristics of GENOA African Americans (N = 1,100) † 
  
Mean (SD) or N (%) 
Female 781 (71.0%) 
Age (years) 57.1 (10.6) 
Education (years) 12.3 (3.5) 
Smoking status  
     Never 666 (60.5%) 
     Former 255 (23.2%) 
     Current 179 (16.3%) 
Alcohol consumption (drinks/week) 0.66 (2.6) 
BMI (kg/m2) 31.20 (6.6) 
Type 2 diabetes 216 (19.6%) 
Anti-hypertensive medication use 649 (59.0%) 
Hypertension 771 (70.1%) 
Epigenetic age acceleration  
IEAA (years) (N = 1099) 0.15 (4.8) 
EEAA (years) 0.27 (5.9) 
PhenoAA (years) (N = 1099) 0.38 (7.2) 
GrimAA (years) (N = 1099) 0.11 (5.0) 
Cardiometabolic parameters  
Systolic blood pressure (mmHg) 133.8 (21.6) 
Diastolic blood pressure (mmHg) 77.7 (11.9) 
Mean arterial pulse pressure (mmHg) 96.4 (13.5) 
Pulse pressure (mmHg) 56.2 (17.7) 
Glucose (mg/dl) (N = 883) 109.2 (42.1) 
Insulin (mIU/l) (N = 882) 11.5 (13.4) 
Total cholesterol (mg/dl)  (N = 1098) 204.3 (45.2) 
HDL-C (mg/dl) 55.2 (17.9) 
LDL-C (mg/dl) (N = 1076) 120.8 (41.5) 
Triglycerides (mg/dl) (N = 1099) 146.0 (82.1) 
CVD 10-year risk scores  
Framingham risk score (%) (N = 945) 14.4 (12.7) 
ASCVD risk equation (%) (N = 988) 11.6 (11.1) 
Prevalent CVD at baseline 91 (8.3%) 
Incident CVD at follow-up 72 (8.8 per 1000 person-years) 
Abbreviations: SD, standard deviation; IEAA, intrinsic epigenetic age acceleration; EEAA, extrinsic 
epigenetic age acceleration; BMI, body mass index; HDL-C, high density lipoprotein; LDL-C, low 
density lipoprotein; CVD, cardiovascular disease; ASCVD, Atherosclerotic cardiovascular disease. 
Cardiovascular disease (CVD) was defined as self-reported myocardial infarction, coronary artery 
revascularization, cerebrovascular events, or surgical carotid artery revascularization. 
†Total N = 991 at Phase II and N = 496 at Phase III with DNAm measures. 
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Table 3-2: Association between epigenetic age acceleration and cardiometabolic risk factors in GENOA African Americans 
Abbreviations: IEAA, intrinsic epigenetic age acceleration; EEAA, extrinsic epigenetic age acceleration; SBP, systolic blood pressure; DBP, diastolic 
blood pressure; MAP, mean arterial pressure; PP, pulse pressure; HDL-C, high density lipoprotein; LDL-C, low density lipoprotein. 
Models are adjusted for age, sex and familial relatedness. 
Effect sizes (β) correspond to the change in the cardiometabolic risk factor associated with a 1-year increase in the epigenetic age acceleration measure. 
Associations significant at P < 0.05 are shown in bold; †Associations significant at Bonferroni adjusted P < 0.005.




β 95% CI P value  β 95% CI P value  β 95% CI P value  β 95% CI P value 
SBP  0.37 0.109, 0.627 0.005†  0.27 0.055, 0.485 0.014  0.22 0.050, 0.395 0.012  0.36 0.093, 0.627 0.008 
DBP  0.16 0.009, 0.303 0.037  0.04 -0.083, 0.160 0.534  0.07 -0.033, 0.163 0.195  0.02 -0.133, 0.170 0.809 
MAP  0.23 0.056, 0.393 0.009  0.11 -0.026, 0.253 0.112  0.12 0.004 0.229 0.042  0.13 -0.042, 0.305 0.138 
PP  0.22 0.026, 0.414 0.027  0.24 0.082, 0.403 0.003†  0.16 0.033, 0.293 0.014  0.35 0.145, 0.544 0.001† 
Log glucose  2 × 10-3 -0.002, 0.006 0.280  3 × 10-3 0, 0.007 0.049  4 × 10-3 0.001, 0.007 0.004†  8 × 10-3 0.003, 0.012 4.0 × 10-4† 
Log insulin  2 × 10-3 -0.008, 0.011 0.724  0.01 0.005, 0.020 0.002†  0.01 0, 0.012 0.056  2 × 10-3 -0.008, 0.011 0.722 
Total 
cholesterol 
 -0.22 -0.778, 0.332 0.430  -0.17 -0.627, 0.291 0.473  -0.06 -0.431, 0.309 0.748  -0.49 -1.057, 0.080 0.092 
Log HDL-C  -3 × 10-4 -0.004, 0.003 0.855  -1 × 10-3 -0.004, 0.002 0.475  1 × 10-3 -0.001, 0.003 0.444  -2 × 10-3 -0.005, 0.002 0.328 
LDL-C  -0.38 -0.894, 0.144 0.157  -0.15 -0.579, 0.281 0.498  -0.23 -0.576, 0.120 0.199  -0.77 -1.303, -0.236 0.005† 
Log 
Triglycerides 




Table 3-3: Association between epigenetic age acceleration and clinical CVD risk scores in 
GENOA African Americans 
 
Framingham risk score 
(FRS)  
(N = 945) 
 
Atherosclerotic cardiovascular disease 
equation (ASCVD)  





β (95% CI) P value 
 
β (95% CI) P value 
IEAA 0.12 (-0.02 – 0.26) 0.088  0.17 (0.06 – 0.29) 0.004 
EEAA 0.21 (0.10 – 0.32) 3.77 × 10-4  0.23 (0.13 – 0.33) 3.85 × 10-6 
PhenoAA 0.15 (0.06 – 0.24) 0.001  0.18 (0.10 – 0.26) 4.78 × 10-6 
GrimAA 0.58 (0.44 – 0.71) 4.53 × 10-16  0.44 (0.33 – 0.56) 2.38 × 10-13 
Abbreviations: IEAA, intrinsic epigenetic age acceleration; EEAA, extrinsic epigenetic age acceleration. 
Models are adjusted for age, sex and familial relatedness. 
FRS and ASCVD are modeled as continuous predictors. 
Effect sizes (β) correspond to the change in predicted 10-year risk of CVD using the FRS or ASCVD risk 
equation associated with 1-year increase in the epigenetic age acceleration measure. 
Cardiovascular disease (CVD) was defined as self-reported myocardial infarction, coronary artery 
revascularization, cerebrovascular events, or surgical carotid artery revascularization. 








HR (95% CI) P value 
IEAA 0.97 (0.93 – 1.02) 0.300 
EEAA 1.04 (1.00 – 1.08) 0.057 
PhenoAA 1.00 (0.97 – 1.04) 0.810 
GrimAA 1.09 (1.04 – 1.15) 4.20 × 10-4 
Abbreviations: CVD, cardiovascular disease; HR, hazard ratio; IEAA, intrinsic epigenetic 
age acceleration; EEAA, extrinsic epigenetic age acceleration. 
Models are adjusted for age, sex and familial relatedness. 
Hazard ratios correspond to the risk of a CVD event associated with a 1-year increase in 
the epigenetic age acceleration measure. 
Cardiovascular disease (CVD) was defined as self-reported myocardial infarction, 
coronary artery revascularization, cerebrovascular events, or surgical carotid artery 
revascularization. 




Table 3-5: Incident CVD hazard ratios for GrimAA and clinical CVD risk scores in GENOA African Americans 
 
Adjusted HR (95% CI) 
Predictor 
FRS only 
(N = 945) 
ASCVD only 
(N = 988) 
FRS + GrimAA 
(N = 945) 
ASCVD + GrimAA 
(N = 988) 
FRS 
1.03 (1.02 - 1.05) 
P = 9.5 × 10-6 
-- 
1.03 (1.01 – 1.05) 
P = 4.7 × 10-4 
-- 
ASCVD -- 
1.04 (1.02 – 1.06) 
P = 2.7 × 10-5 
-- 
1.03 (1.01 – 1.05) 
P = 9.8 × 10-4 
GrimAA -- -- 
1.07 (1.02 – 1.13) 
P = 0.011 
1.08 (1.02 – 1.13) 
P = 0.007 
Abbreviations: CVD, cardiovascular disease; HR, hazard ratio; FRS, Framingham risk score; ASCVD, atherosclerotic cardiovascular disease. 
Models consisted of clinical risk scores with and without GrimAA. All models were adjusted for age, sex and familial relatedness. 
Adjusted hazard ratios correspond to the risk of a CVD event associated with a 1-unit increase in the clinical risk score or the epigenetic age acceleration 
measure. 

























Abbreviations: CVD, cardiovascular disease; FRS, Framingham risk score; ASCVD, atherosclerotic cardiovascular disease. 
The C statistics associated with a set of nested models for time to CVD events are shown. All models are adjusted for familial relatedness. 
Cardiovascular disease (CVD) was defined as self-reported myocardial infarction, coronary artery revascularization, cerebrovascular events, or surgical carotid 
artery revascularization 
Model C-statistic 95% CI 
N = 945     
Base model (age + sex) 0.595 0.525 – 0.664 
Age + sex + GrimAA 0.643 0.576 – 0.709 
Age + sex + FRS 0.687 0.624 – 0.749 
Age + sex + FRS + GrimAA 0.698 0.637 – 0.759 
N = 988     
Base model (age + sex) 0.588 0.521 –  0.656 
Age + sex + GrimAA 0.636 0.571 –  0.701 
Age + sex + ASCVD 0.670 0.606 –  0.728 
Age + sex + ASCVD + GrimAA 0.685 0.625 –  0.746 
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3.8 Figures 
Figure 3-1: Boxplots of standardized GrimAge components by incident CVD status 
 
CVD, cardiovascular disease. 
Cardiovascular disease (CVD) was defined as self-reported myocardial infarction, coronary artery 
revascularization, cerebrovascular events, or surgical carotid artery revascularization. 
† GrimAge components significantly associated with incident CVD in models adjusted for age, sex, and 
familial relatedness (P < 0.05). 
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3.9 Supplementary Material 
Table SM 3-1: Pearson correlations between age, DNA methylation age, and epigenetic age acceleration in GENOA African 
Americans 
 
 Age HorvathAge HannumAge PhenoAge GrimAge IEAA EEAA PhenoAA 
HorvathAge  0.86***        
HannumAge  0.90*** 0.90***       
PhenoAge  0.82*** 0.84*** 0.85***      
GrimAge  0.85*** 0.78*** 0.81*** 0.80***     
IEAA   0.02 0.51*** 0.24*** 0.28*** 0.12***    
EEAA   0.00 0.28*** 0.43*** 0.30*** 0.15*** 0.43***   
PhenoAA   -0.01 0.23*** 0.20*** 0.56*** 0.16*** 0.44*** 0.50***  
GrimAA   -0.02 0.07* 0.07* 0.17*** 0.50*** 0.19*** 0.27*** 0.32*** 
*** p < .0001; ** p < .01; * p < .05 




Table SM 3-2: Adjusted associations between epigenetic age acceleration and cardiometabolic 
risk factors for associations with P < 0.05 in the base model (Model 1) in GENOA African 
Americans 
IEAA, intrinsic epigenetic age acceleration; EEAA, extrinsic epigenetic age acceleration; SBP, systolic blood 
pressure; DBP, diastolic blood pressure; HDL-C, high density lipoprotein; LDL-C, low density lipoprotein. 
Model 1 (base model) is adjusted for age, sex, and familial relatedness. Results for Model 1 are shown in Table 2. 
Only associations that were significant in Model 1 (P<0.05) were further evaluated and reported in this table.  
Model 2 is adjusted for Model 1 and years of education, smoking status, body mass index, and alcohol consumption.  
Model 3 is adjusted for Model 2 and white blood cell counts.  
Effect sizes (β) correspond to the change in the cardiometabolic risk factor associated with a 1-year increase in the 
epigenetic age acceleration measure. 
Associations significant at P < 0.05 are shown in bold. 
  
 











β 95% CI P value 
 




IEAA  0.33 0.075, 0.594   0.012     
EEAA  0.23 0.012, 0.443   0.039     
PhenoAA  0.17 -0.002, 0.347   0.053  0.14 -0.047, 0.329   0.141 
GrimAA  0.31 -0.024, 0.638   0.069  0.29 -0.070, 0.639   0.115 
DBP IEAA  0.16 0.010, 0.305   0.037     
Mean arterial 
pressure 
IEAA  0.22 0.0459, 0.385   0.013     
PhenoAA  0.10 -0.018, 0.210  0.100  0.10 -0.019, 0.226   0.099 
Pulse 
pressure 
IEAA  0.18 -0.010, 0.378   0.063     
EEAA  0.20 0.043, 0.365   0.013     
PhenoAA  0.12 -0.011, 0.25 0.073  0.06 -0.080, 0.200 0.403 
GrimAA  0.34 0.095, 0.588   0.007  0.26 -0.004, 0.523   0.054 
Log glucose 
EEAA  2 × 10-3 -0.001, 0.006  0.137     
PhenoAA  3 × 10-3 0, 0.005  0.047  2 × 10-3 -0.001, 0.005   0.100 
GrimAA  8 × 10-3 0.003, 0.013   0.001  8 × 10-3  0.003, 0.013   0.004 
Log insulin EEAA  0.010 0.003, 0.017  0.004     
LDL-C GrimAA  -1.05 -1.709, -0.383   0.002  -0.74 -1.444, -0.025 0.043 
Log 
Triglycerides 
GrimAA  0.01 0.001, 0.015   0.026 
 
0.01 0.0002, 0.015   0.045 
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Table SM 3-3: Incident CVD hazard ratios for GrimAge components in GENOA African Americans 
GrimAge component  
(Predictor) 
HR (95% CI) P value 
Adrenomedullin (ADM) 1.45 (1.07 – 1.98) 0.017 
Beta-2-microglobulim (B2M) 1.04 (0.77 – 1.41) 0.780 
Cystatin C  1.38 (0.95 – 1.99) 0.089 
Growth differentiation factor 15 (GDF-15) 1.21 (0.92 – 1.59) 0.170 
Leptin 1.38 (0.91 – 2.10) 0.130 
Smoking pack-years 1.36 (1.09 – 1.72) 0.0076 
Plasminogen activator inhibitor antigen type 1 (PAI-1)  1.48 (1.17 – 1.87) 0.0012 
Tissue inhibitor metalloproteinases 1 (TIMP-1) 1.59 (0.97 – 2.60) 0.068 
Abbreviations: CVD, cardiovascular disease; HR, hazard ratio. 
Models adjusted for age, sex, white blood cell counts, and familial relatedness. 
Hazard ratios significant at P < 0.05 are shown in bold font. 
Hazard ratios correspond to the risk of a CVD event associated with a one-standard deviation increase in the GrimAge component. 
Cardiovascular disease (CVD) was defined as self-reported myocardial infarction, coronary artery revascularization, cerebrovascular events, or 
surgical carotid artery revascularization. 





Figure SM 3-1: Scatterplots of DNA methylation age measures against 
chronological age in GENOA African Americans 
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  Figure SM 3-2: Scatterplots of epigenetic age acceleration measures against chronological 
age in GENOA African Americans 
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(A) Receiver operator curves for time to CVD for models of Framingham risk score (blue line) vs. Framingham risk score + GrimAA (red line) (N = 945). 
(B) Receiver operator curves for time to CVD for models of ASCVD score (blue line) vs. ASCVD + GrimAA (red line) (N = 988). 
Models are adjusted for age, sex and familial relatedness. 
Cardiovascular disease (CVD) was defined as self-reported myocardial infarction, coronary artery revascularization, cerebrovascular events, or surgical carotid 
artery revascularization. 
CVD, cardiovascular disease; FRS, Framingham risk score; ASCVD, atherosclerotic cardiovascular disease.  
Figure SM 3-3: Receiver operator characteristic (ROC) curves for incident CVD in GENOA African Americans 
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Columns and rows refer to categories of predicted risk using (A) FRS and GrimAA and (B) ASCVD and GrimAA. The counts in the cells represent the number of individuals assigned to 
the indicated risk category.  
Blue shaded cells represent correctly reclassified individuals, and orange shaded cells represent incorrectly classified individuals.  
NRI = P(up|case) – P(down|case) – P(up|noncase) + P(down|noncase) 
In the model with FRS and GrimAA (A), 1 individual was incorrectly up-classified and 49 individuals were correctly down-classified (NRI = 49/876 – 1/876) 
In the model with ASCVD and GrimAA (B), 1 individual was correctly-up classified. 9 individuals were incorrectly up-classified, and 23 individuals were correctly down-classified (NRI 
= 1/71 – 9/917 + 23/917) 
Abbreviations: CVD, cardiovascular disease; FRS, Framingham risk score; ASCVD, atherosclerotic cardiovascular disease  
Models are adjusted for age, sex and familial relatedness. 
Cardiovascular disease (CVD) was defined as self-reported myocardial infarction, coronary artery revascularization, cerebrovascular events, or surgical carotid artery revascularization 
FRS 
model 
Standard CVD Model + GrimAA 
≤ 7.5% > 7.5% 









 ≤ 7.5% 7 0 7 
> 7.5% 0 62 62 
Total no. (%) 
of participants 











≤ 7.5% 337 1 338 
> 7.5% 49 489 538 
Total no. (%) 
of participants 
386 (44.1) 490 (55.9) 876 
ASCVD  
model 
Standard CVD Model + GrimAA 
≤ 7.5% > 7.5% 









 ≤ 7.5% 14 1 15 
> 7.5% 0 56 56 
Total no. (%) 
of participants 











≤ 7.5% 442 9 451 
> 7.5% 23 443 466 
Total no. (%) 
of participants 
465 (49.7) 452 (50.3) 917 
(A)  FRS + GrimAA (B)  ASCVD + GrimAA 
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Chapter 4.  Epigenetics of Single and Multisite Atherosclerosis in African Americans from 
the Genetic Epidemiology Network of Arteriopathy (GENOA) 
4.1 Abstract 
DNA methylation, an epigenetic mechanism modulated by lifestyle and environmental 
factors, may be an important biomarker of complex diseases including cardiovascular diseases 
(CVD) and subclinical atherosclerosis. Novel biomarkers of CVD may help to improve risk 
prediction and advance precision medicine. DNA methylation in blood samples from 391 
African Americans from the Genetic Epidemiology Network of Arteriopathy (GENOA) was 
assessed at baseline, and atherosclerosis was assessed 5 and 12 years later. Using linear mixed 
models, we examined the association between previously-identified CpGs for coronary artery 
and carotid artery calcification, both individually and aggregated into methylation risk scores 
(MRSCAC and MRScartoid), and four measures of atherosclerosis (coronary artery calcification 
(CAC), abdominal aorta calcification (AAC), ankle brachial index (ABI), and a multi-
atherosclerosis score combining the three measures). We also examined the association between 
four epigenetic age acceleration measures (IEAA, EEAA, PhenoAge acceleration, and GrimAge 
acceleration) and the four atherosclerosis measures. Finally, we characterized the temporal 
stability of the potential epigenetic markers for atherosclerosis (epigenetic age acceleration and 
MRSs) using longitudinal measures of DNA methylation measured five years after baseline for a 
subset of 193 participants. One and six CpGs were associated with AAC and multisite 
atherosclerosis, respectively, after adjusting for age, sex, and traditional CVD risk factors at false 
discovery rate (FDR) < 0.1. A one-unit increase in MRScarotid was associated with an 
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approximately 1.6-fold increase in the Agatston score of CAC and AAC, and a 0.7 units increase 
in the multisite atherosclerosis score (score range 0-12) after adjusting for CVD risk factors 
(Bonferroni adjusted P < 0.05). The MRScarotid explained 5.3%, 2.7%, and 5.5% of the variability 
of CAC, AAC, and multisite atherosclerosis. A 5-year increase in GrimAA (~1 SD) was 
associated with a 1.6-fold (95% CI 1.11–2.25) increase in the Agatston score of AAC and 0.7 
units (95% CI 0.33–1.07) increase in multisite atherosclerosis score after adjusting for CVD risk 
factors (Bonferroni adjusted P < 0.05). All epigenetic measures were relatively stable,with the 
highest intraclass correlation coefficients observed for MRScarotid and GrimAge acceleration 
(0.82 and 0.89, respectively). Our study found evidence of an association between a number of 
CpGs and two epigenetic measures, an atherosclerosis methylation risk score (MRScarotid) and 
GrimAge acceleration, and atherosclerosis at multiple vascular sites in a sample of African 
Americans. These epigenetic measures were relatively stable over time. These findings deepen 
our understanding of the relationship between aging and atherosclerosis and suggest that further 




Cardiovascular diseases (CVD), including coronary heart disease, myocardial infarction, 
stroke, and peripheral artery disease, are the leading cause of death in the US.1 In African 
Americans, the CVD mortality burden is 21% higher compared to whites despite modest 
decreases in racial disparities at the national level since 2005.2 Genetic factors, along with non-
genetic risk factors, such as age, smoking, and hypertension contribute to CVD. However, much 
of the variability in CVD, as well as the persistent causes of CVD disparities, remains 
unexplained. 
Vascular calcification can occur in either the intimal or medial layers of the arterial wall.3 
The intima is the innermost layer consisting of a smooth endothelium layer covered by elastic 
tissue. The aorta is associated with atherosclerosis.3 Atherosclerosis is a chronic inflammatory 
age-related condition that develops over several decades and is a precursor for CVD.4-6 Coronary 
artery calcification (CAC) is a strong predictor of incident CVD and coronary heart disease 
beyond traditional CVD risk factors.7-10 Medial calcification occurs in the tunica media which 
consists of smooth muscles cells and elastic fibers. It affects lower limb arteries, in addition to 
the aorta, and is typically associated with peripheral artery disease.3 Medial lesions are thought to 
calcify earlier than intimal ones and result in vascular stiffness and reduced vessel 
compliance,11,12 and they may be also associated with CVD.8,13 Medial calcification increases 
with aging and is prevalent in individuals with chronic kidney disease and diabetes mellitus. In 
the peripheral arteries, it can be assessed the using ankle-brachial pressure index ratio.11  
Epigenetics, which captures both genetic influences as well as imprints of lifestyle and 
environmental exposures throughout the life course, may help identify biological mechanisms 
contributing to CVD pathogenesis and atherosclerosis. As such, epigenetic markers may have 
 109 
potential as biomarkers of CVD risk. Similarly, epigenetic age acceleration measures, including 
first generation measures (Horvath14 and Hannum15), which were trained on chronological age, 
and more recent measures trained on a number of biological and physiological markers and 
chronological age, such as PhenoAge16 and GrimAge,17 are DNA methylation-based markers of 
biological aging that are associated with late-life onset diseases and mortality.14,15,17-19 Previous 
studies of genome-wide DNA methylation patterns or epigenetic age acceleration measures have 
reported significant associations between epigenetic markers and CVD,20-26 however, a majority 
of these studies were in cohorts of European ancestry and/or were cross-sectional rather than 
longitudinal. 
Only a few epidemiological studies have examined the association between DNA 
methylation and subclinical CVD or atherosclerosis.27,28 A recent cross-sectional transcriptome 
and epigenome analyses of atherosclerosis in 1,208 participants from the Multi-Ethnic Study of 
Atherosclerosis (MESA) identified 82 differentially methylated CpGs associated with either 
CAC or carotid plaque score at false discovery rate (FDR) ≤ 0.1.27 The sample was comprised of 
45.9% Caucasians, 21.5% African Americans, and 32.6% Hispanics. Race-specific analyses 
showed that the directions of the methylation changes were generally consistent across 
ethnicities, although some sites were not significant for African Americans and Hispanics.27 The 
most significant CpG associated with carotid plaque, cg05575921, is located in the AHRR gene 
body and is a well-documented smoking marker.29-32 
In this study, we evaluated the association between potential epigenetic markers of 
atherosclerosis and single- or multi-site atherosclerosis in 391 African Americans from the 
Genetic Epidemiology Network of Arteriopathy (GENOA) during a mean follow-up of 12 years. 
Our definition of atherosclerosis included both intimal and medial calcification measures: CAC, 
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abdominal aorta calcification (AAC), and ABI. Epigenetic markers included the previously-
identified CpGs for atherosclerosis,27 methylation risk scores (MRSs) derived from these CpGs, 
and four epigenetic age acceleration measures (Horvath (IEAA),14 Hannum (EEAA),15 
PhenoAge (PhenoAA),16 and GrimAge (GrimAA)).17 Finally, we characterized the temporal 
stability of the epigenetic age acceleration measures and the MRSs using longitudinal measures 
of DNA methylation for a subset of the sample (N=129).   
4.3 Methods 
Study sample  
Genetic Epidemiology Network of Arteriopathy (GENOA) is a community-based study 
in Rochester, MN and Jackson, MS that was established to identify genes influencing blood 
pressure.33 In the first phase of GENOA (Phase I: 1996 – 2001), sibships with at least two adults 
with clinically diagnosed essential hypertension before age 60 were recruited, and all siblings in 
the sibship were invited to participate regardless of hypertension status. Exclusion criteria 
included secondary hypertension, alcoholism or drug abuse, pregnancy, insulin-dependent 
diabetes mellitus, or active malignancy. 
At baseline (Phase I), a total of 1,583 non-Hispanic whites (Rochester, MN) and 1,854 
African Americans (Jackson, MS) were enrolled. In the second phase (Phase II: 2001 – 2005), all 
participants were invited for a second examination. Eighty percent of African Americans (N = 
1,482) and 75% of non-Hispanic whites (N = 1,213) from Phase 1 returned. At Phase III (2009-
2011), 752 African Americans returned for a third examination. Demographic information, 
medical history, clinical characteristics, lifestyle factors, and blood samples were collected in 
each phase. This study includes 391 African American participants from 277 sibships who had 
their DNA methylation measured in whole blood samples collected at Phase I and were seen in 
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Phase III. For a subset of 129 participants that were seen in Phase III, DNA methylation was 
measured at both Phase I and Phase II. Written informed consent was obtained from all 
participants and approval was granted by participating institutional review boards (University of 
Michigan, University of Mississippi Medical Center, and Mayo Clinic). 
Study measurements 
Height was measured by stadiometer and weight by electronic balance. Body mass index 
(BMI) was calculated as weight in kilograms divided by the square of height in meters. Smoking 
was categorized as current, former, or never. Resting systolic (SBP) and diastolic blood pressure 
(DBP) were measured by a random zero sphygmomanometer and a cuff appropriate for arm size. 
The second and third of three readings, after the participant sat for at least 5 minutes, were 
averaged for analysis.34 Information on current anti-hypertensive medication and statin use were 
collected. Hypertension was defined having an average SBP ≥ 140 mmHg or DBP ≥ 90 mmHg, 
or current anti-hypertensive medication use. Type 2 diabetes status (T2D) was defined as having 
fasting blood glucose levels ≥ 126 mg/dL or self-reported physician diagnosed diabetes and 
current diabetes medications use. Serum total cholesterol (TC), HDL-C, and triglycerides (TGs) 
were measured by standard enzymatic methods on a Hitcahi 911 Chemistry Analyzer (Roche 
Diagnostics, Indianapolis, IN). TC was adjusted for statin use as TC/0.8. LDL-C was calculated 
using the Friedewald formula for individuals with triglycerides below 400 mg/dl.35 
DNA methylation, epigenetic age acceleration and methylation risk scores 
Genomic DNA from 1,106 African American participants from Phase I and 304 from 
Phase II was extracted from stored peripheral blood leukocytes using AutoGen FlexStar 
(AutoGen, Holliston, MA) and DNA methylation was measured using the Infinium 
MethylationEPIC BeadChip. DNA methylation processing procedures have been previously 
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described.36 Briefly, Sex mismatches and outliers were excluded using the shinyMethyl R 
package.37 Probes with detection P-value < 10-16 were considered to be successfully detected.38 
Samples and probes that failed a detection rate of at least 10% were removed. The Noob method 
was used for individual background and dye-bias normalization.39 Regression on Correlated 
Probes method was used to adjust for the probe-type bias in the data.40 White blood cell type 
proportions within the blood sample were estimated using Houseman’s method.41A total of 1,100 
samples from Phase I and 294 from Phase II were available after quality control. 
We derived two methylation risk scores based on the regression coefficients for CpG 
sites associated with CAC and/or carotid plaque at FDR≤ 0.1 in MESA.27 At FDR of ≤ 0.1, 16 
CpG sites were associated with CAC in MESA, 15 of which were available in GENOA. For 
carotid plaque, 68 CpG sites were reported in the MESA study, 62 of which were available in 
GENOA, and two of which overlapped with those associated with CAC (cg07033253 and 
cg23661483). Methylation M-values were adjusted for batch effects (modeled as random effects 
of plate, row and column) and white blood cell counts modeled as fixed effects. The adjusted 
means plus residuals were then used to calculate two methylation risk scores, MRSCAC and 
MRScarotid. The MRSs were scored so that higher values correspond to greater risk of 
atherosclerosis.  
Methylation beta values for Phase I and Phase II DNA methylation were uploaded to the 
online Horvath epigenetic age calculator to calculate DNAm Age.42 Four measures of epigenetic 
age – HorvathAge, HannumAge, PhenoAge and GrimAge – were estimated. Intrinsic epigenetic 
age acceleration (IEAA) is based on the regression residuals from a model of chronological age 
and blood cell counts and Horvath age as the outcome.14,15 Extrinsic epigenetic age acceleration 
(EEAA) is derived similarly based on the Hannum epigenetic age measure but incorporates 
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weighted averages of three white blood cell types (naïve cytotoxic T cells, exhausted cytotoxic T 
cells, and plasmablasts).15,43 PhenoAA is a residual measure from a model of phenotypic age, 
calculated based on clinical measures such as albumin, creatinine, and white blood cell counts, as 
well as chronological age.18 GrimAA is based on the residuals from a model of GrimAge and 
chronological age. GrimAge is a composite biomarker of smoking pack-years and 7 surrogate 
measures of plasma proteins selected for their significant association with time-to-death. The 
components are adrenomedullin (ADM), beta-2-microglobulin, cystatin C, GDF-15, leptin, 
plasminogen activator inhibitor antigen type 1 (PAI-1), and tissue inhibitor metalloproteinases 1 
(TIMP-1).17  
Atherosclerosis measurements 
Computed tomography (CT) imaging was used to quantify calcification in the coronary 
arteries and the abdominal aorta. CT images were read by trained technologists and the amount 
of calcified plaque was calculated by multiplying each lesion area are by a weighted attenuation 
score (Hounsfield units) on a TeraRecon Aquarius Workstation (TeraRecon, San Mateo, CA). 
The amount of calcification was quantified using the Agatston score. Both CAC and abdominal 
aorta calcification (AAC) were natural log-transformed as ln (measure +1) when examined 
individually as outcomes.  
The ankle-brachial index was used to quantify atherosclerosis in the peripheral arteries. 
Details about the ABI measurement has been previously described.44 Briefly, a Doppler 
ultrasonic instrument (Medisonics, Minneapolis, MN) was used to detect the pulse at each arm 
and ankle using appropriately sized blood pressure cuffs. ABI was calculated as the systolic 
blood pressure at each ankle site divided by the higher of the two brachial pressures. The lower 
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of the average ABIs from both legs was used. Individuals with ABI > 1.50 were excluded as they 
may have non-compressible arteries and medial arterial calcification.  
Multisite atherosclerosis score was defined similarly to that described by Zhao et al.45 Both CAC 
and AAC were scored separately as follows: 0 if absent, or for those with calcification as a score 
between 1 and 4 according to gender-specific quartiles of each measure. ABI was scored 
between 1 and 4 for the highest to lowest gender-specific quartiles for ABI < 1.0; 0 for 1 ≤ ABI 
< 1.4, and 1 if ABI ≥ 1.4 and ≤ 1.50. The multisite atherosclerosis score was then calculated as 
the sum of the three measures (range: 0-12) and was modeled as a continuous outcome.  
Statistical analysis 
Outliers beyond 5 standard deviations from the mean of the outcome and epigenetic 
measures were removed. We calculated the Pearson correlation coefficients between the single 
site atherosclerosis measures, and among the epigenetic age acceleration measures and MRSs. 
We also calculated the correlations between the individual GrimAge components and the MRSs. 
We use linear mixed models that account for familial relatedness to assess the association 
between the previously identified atherosclerosis-associated CpGs in MESA and MRSs derived 
from these CpGs (predictors) and the single- or multi-site atherosclerosis measures (outcomes). 
The minimally adjusted model (Model 1) was adjusted for age at baseline, sex, first 4 genetic 
principal components (PCs), and time between the measures. The time covariate was calculated 
based on the age difference of the participants at the time of atherosclerosis assessment (Phase II 
or Phase III) and DNA methylation assessment (Phase I). For models of multisite atherosclerosis, 
we included two time covariates – the age difference between Phase III and Phase I, and an 
additional covariate for the age difference between Phase III and Phase II – to account for the 
differences in the assessment times of ABI (at Phase II) and CAC and AAC (at Phase III). Model 
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2 was additionally adjusted for smoking status, and Model 3 was further adjusted for 
cardiovascular risk factors (T2D status, hypertension status, BMI, and statin-adjusted total 
cholesterol levels).  
We used a similar procedure as described above to assess the association between the 
four epigenetic age acceleration measures and atherosclerosis without including the PCs. This 
approach of not adjusting for genetic PCs is consistent with other studies and allow for 
comparability of findings. As sensitivity analysis, we also performed this analysis after adjusting 
for the first four genetic PCs. We additionally carried out sensitivity analyses adjusting for white 
blood cell counts for significant associations with PhenoAA and GrimAA to assess confounding 
by changes in blood cell composition.16,17,46 For GrimAA, we investigated the association 
between the individual GrimAge components and atherosclerosis to identify components that 
may be driving the association between GrimAA and atherosclerosis or that outperform the 
overall GrimAA measure itself. For this analysis, GrimAge components were scaled and 
centered. Models were adjusted for age, sex, and white blood cell counts.  
For the subset of individuals with repeated DNA methylation measurements, we used 
chi-square and t-tests as appropriate to compare the demographic and clinical characteristics of 
the subset to the full sample. We used linear mixed-effect models adjusted for age and sex to 
calculate the intraclass correlation coefficients (ICC) between Phases I and II for the methylation 
risk scores and the epigenetic age acceleration measures. Parametric bootstrapping (1000 
iterations) was used to calculate the 95% confidence intervals of the ICC coefficients.47,48 
Additionally, for these participants, we assessed the associations between all of the epigenetic 
biomarkers at Phase II and atherosclerosis after adjusting for age at Phase II, sex, time between 
measures, and the first 4 PCs (Model 1). Finally, we used generalized estimating equation (GEE) 
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models to assess the intra-individual changes in the epigenetic predictors during follow-up in 
models adjusted for age and sex.   
Statistical tests were two-sided. False discovery rate (FDR)49 of 0.1 was considered 
significant for the associations between the individual CpGs and the atherosclerosis measures. A 
Bonferroni adjusted P value of < 0.025 (for MRS association analyses) and P < 0.0125 (for 
epigenetic age acceleration association analyses) were considered significant. Analyses were 
conducted in R (Version 3.4.1),50 using the lme4,51 rptR,48 and geepack 52 packages.  
4.4 Results 
Sample characteristics 
Baseline characteristics of the participants are shown in Table 1. The mean age of the 
participants was 56 years (SD = 9.0) at Phase I. Women comprised about 76% of the sample. 
Phase III was on average 12 years (SD = 1.2) after Phase I. About 64% of the participants had 
hypertension and 16% had T2D at Phase I. Distributions of the atherosclerosis measures and 
MRSs are shown in Supplemental Figures 1 and 2, respectively. For MRSCAC, one outlier 
beyond 5 SD from the mean was removed from the analysis. 
Correlations among the methylation risk scores, epigenetic age acceleration measures, and 
atherosclerosis measures 
CAC and AAC were correlated at r = 0.57 (P < 2.2 × 10-16). ABI was negatively 
correlated with AAC (r = -0.14, P = 0.004), but only weakly correlated with CAC (r = -0.08, p = 
0.09). Supplemental Table 1 shows the correlation between the epigenetic predictors. The two 
MRSs were correlated at r = 0.39 (P = 6 × 10-16). The correlation between the acceleration 
measures was weak to moderate (r range: 0.21 – 0.46). The epigenetic age acceleration measures 
and MRSs were weakly correlated (r range: 0.08 – 0.25), with the exception of GrimAA and 
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MRScarotid which were correlated at r = 0.62 (P = 2.2 × 10
-16). Supplemental Figure 3 shows the 
scatterplots of the MRSs against the epigenetic age acceleration measures. Of the GrimAge 
components, smoking pack years slightly more correlated with MRScarotid than the overall 
GrimAA measure (r = 0.68, P = 2.2 × 10-16), with the second highest correlation between 
MRScarotid and PAI-1 (r = 0.24, P = 1.1 × 10
-6).  
Associations between previously identified atherosclerosis-associated CpGs and 
atherosclerosis 
CAC, AAC, ABI, and multisite atherosclerosis were associated with 11, 17, 4, and 21 
CpGs in Model 1, respectively (FDR < 0.1). The regression results are shown in Supplemental 
Table 2. One CpG, cg05246522, was a CAC-associated CpG in MESA and the remainder of the 
significant CpGs in GENOA were carotid plaque-associated CpGs in MESA. Supplemental 
Table 3 shows the regression results for the CpGs that remained significantly associated with 
atherosclerosis after adjustment for cardiovascular risk factors (Model 3) in GENOA. After 
adjusting for cardiovascular risk factors, 6 CpGs (cg05575921 (AHRR), cg04761231 (RPL35), 
cg08958747 (RAB26), cg09935388 (GFI1), cg16661609 (LILRB4), and cg21161138 (AHRR)) 
remained significantly associated with multisite atherosclerosis, and cg05575921 was also 
associated with AAC (FDR < 0.1). All of these CpGs were carotid plaque-associated CpGs in 
MESA. Hypermethylation at all of the significant CpGs (FDR < 0.1 in Model 3) was associated 
with decreased multisite atherosclerosis. Significant CpG,s in Model 3 explained between 0.3% 
and 6.5% of the variability of multisite atherosclerosis, and cg05575921 explained 2.7% of the 
variability of AAC.  
Given the previous reports of an association between three of the identified CpGs 
(cg05575921, cg21161138, and cg09935388) and smoking, we examined their methylation 
levels by smoking status in GENOA. As expected, the plots show a dose response effect where 
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current smokers had the lowest methylation levels and never smokers had the highest 
methylation levels (Supplemental Figure 4).  
Associations between methylation risk scores and atherosclerosis  
Table 2 shows the associations between MRSCAC and MRScarotid and single or multisite 
atherosclerosis measures. The beta coefficients shown in the tables correspond to the change in 
the atherosclerosis measures associated with a 1-unit increase in the MRS. In Model 1, MRSCAC 
was associated with log-transformed CAC (Beta = 0.421, 95%CI 0.080–0.762, P = 0.016) but 
the association was not significant after adjusting for CVD risk factors (Models 2 and 3). 
MRScarotid was associated with both log-transformed CAC (Beta = 0.778, 95%CI 0.433–1.12, P = 
1.26 × 10-5) and log-transformed AAC (Beta = 1.062, 95%CI 0.688–1.44, P = 5.13 × 10-8). 
Associations remained associated after adjusting for smoking (Model 2) and other traditional 
CVD risk factors (Model 3), where a one unit increase in MRScarotid was associated with a 0.479 
units increase in log transformed CAC (95%CI 0.083–0.875, P = 0.018) and a 0.551 units 
increase in log-transformed AAC (95%CI 0.118–0.984). This is equivalent to an approximately 
1.6-fold increase in the Agatston score of CAC and AAC. A one unit increase in MRScarotid was 
associated with a 0.7 units (95%CI 0.21–1.13) increase in the multisite atherosclerosis score after 
adjusting for CVD risk factors (Model 3). The MRScarotid explained 5.3%, 2.7%, 0.29%, and 
5.5% of the variability of CAC, AAC, ABI, and multisite atherosclerosis after adjusting for CVD 
risk factors.  
Associations between epigenetic age acceleration and atherosclerosis 
Associations between the epigenetic age acceleration measures and atherosclerosis are 
shown in Table 3. PhenoAA was associated with multisite atherosclerosis in Model 1, but the 
association attenuated after adjusting for CVD risk factors. GrimAA was positively associated 
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with all measures of atherosclerosis in the minimally adjusted model (Model 1) and remained 
significant after adjusting for CVD risk factors for AAC and multisite atherosclerosis. A 5-year 
increase in GrimAA (~1 SD) was associated with a 1.6-fold (95% CI 1.11–2.25) increase in the 
Agatston score of AAC and a 0.7 units (95% CI 0.33–1.07) increase in multisite atherosclerosis 
score in Model 3. Increased GrimAA was nominally associated with lower ABI (higher 
atherosclerosis), but the association was not significant after accounting for multiple testing. The 
effect estimates were unchanged after adjusting for the first 4 genetic PCs. Supplemental Table 
4 shows the associations for PhenoAA and GrimAA after adjusting for white blood cell counts. 
The associations between GrimAA and AAC and multisite atherosclerosis in Model 3 slightly 
attenuated after adjusting for white blood cells counts but remained significant at P < 0.05. 
The associations between the DNA methylation based surrogate measures comprising GrimAge 
and atherosclerosis are shown in Supplemental Table 5. Associations were adjusted for age, 
sex, time between measures, and white blood cell counts. All components were associated with 
at least one single or multi-site atherosclerosis measure, with the exception of leptin and TIMP-1 
(P < 0.05). DNAm smoking pack years was associated with each of the atherosclerosis measures 
and was the most significant predictor of CAC, AAC and multisite atherosclerosis, with 
consistent effect directions across all of the measures. Compared to the corresponding model 
using GrimAA (Supplemental Table 3; Model 1), DNAm smoking pack years was more 
significantly associated with single- and multi-site atherosclerosis, with greater magnitude of 
effects, than the overall GrimAA measure.  
Longitudinal correlation of methylation risk scores and epigenetic age acceleration 
measures between Phases I and II 
Compared to the remaining sample, the 129 individuals with longitudinal measures of 
DNA methylation were younger (mean age of 53.4 vs. 57.3 years, P < 0.001), had a lower 
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multisite atherosclerosis score (mean of 4.51 vs. 5.26, P = 0.026) and a lower PhenoAA (mean of 
-1.11 vs. 0.41, P = 0.043). All the remaining epigenetic and atherosclerosis measures were 
similar across both samples (P > 0.05). The mean time difference between the DNA methylation 
measurements was 5.5 years (standard deviation = 1.1 years). All of the epigenetic measures 
were relatively stable between Phases I and II, with both MRScarotid and GrimAA showing the 
highest stability (ICC > 0.8), and MRSCAC showing the lowest stability (ICC = 0.519) (Table 4). 
MRScarotid derived at Phase II was associated with consistent effect direction but reduced effect 
magnitude for log-transformed AAC (Beta = 0.894, 95% CI 0.241–1.55, P = 0.008) and multisite 
atherosclerosis (Beta = 0.891, 95% CI 0.238–1.54, P = 0.009) compared to the full sample 
analysis using Phase I MRSs (Table 2, Model 1). Neither MRS was associated with CAC or 
ABI at Phase II (Supplemental Table 6). For the epigenetic age acceleration measures from 
Phase II, only GrimAA was associated with multisite atherosclerosis score (Beta = 0.123, 95%CI 
0.015–0.231, P = 0.028 in Model 1). Supplemental Figure 5 shows the change MRSs and 
epigenetic age acceleration measures by age. As expected, both MRSs were significantly and 
positively associated with age (p<0.05), while the epigenetic acceleration measures were not.  
4.5 Discussion 
In this study of African Americans, we examined the association between whole blood 
DNA methylation patterns, measured at baseline, and multisite atherosclerosis assessed 5 and 12 
years later. After adjusting for CVD risk factors, six CpGs were associated with multisite 
atherosclerosis and an aggregate risk score (MRScarotid) was associated with CAC, AAC, and 
multisite atherosclerosis. The mean of MRScarotid was negative, indicative of a general trend of 
hypomethylation at the individual CpGs associated with carotid plaque. GrimAA was the only 
epigenetic age acceleration measure associated with atherosclerosis. GrimAA and MRScarotid 
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were moderately correlated with each other, and both measures were relatively stable over 5 
years in a small subset of participants with repeated DNA methylation measurement. Although 
our findings cannot establish causality, the relatively long time period between the DNA 
methylation and atherosclerosis assessments help establish temporal patterning between changes 
in DNA methylation and the development of subclinical markers of CVD. Our findings 
additionally highlight the role of age-related methylation changes, as measured by the epigenetic 
clocks, and vascular calcification.  
After adjusting for CVD risk factors, 1 CpG was associated with AAC, and another 5 
were also associated with multisite atherosclerosis at FDR < 0.1. The direction of effects 
between the individual CpG sites and atherosclerosis in our study were consistent with MESA, 
where hypomethylation was associated with increased carotid plaque. Three of the significant 
CpGs (cg05575921, cg21161138, and cg09935388) were previously found to be associated with 
smoking.29-32 Both cg05575921 and cg21161138 are located in the AHRR gene body. AHRR is an 
aryl hydrocarbon receptor repressor, which among other roles, inhibits the metabolism of 
polycyclic aromatic hydrocarbons and dioxins by competing with AHR.53,54 The significant 
association between these CpGs and atherosclerosis after adjusting for smoking status in our 
study could potentially be related to residual confounding, errors in self-reporting of smoking, 
and/or interindividual sensitivities to smoking with lasting biological effects. In a previous 
analysis in MESA that used a candidate gene approach to assess the association between CpG 
sites in AHRR and atherosclerosis, hypomethylation at cg05575921 (P = 3.08×10−10) and 
cg21161138 (P = 7.73×10−8) was significantly associated with carotid plaque score.55 Similar to 
our findings, the association with cg05575921 remained significant after adjusting for self-
reported smoking exposure, urinary cotinine, and other CVD risk factors, and remained 
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significant in stratified analysis of former smokers and current smokers but not never smokers. 
Other studies have also reported evidence of cg05575921 differential methylation by air 
pollution in adults,56 by maternal smoking in neonates,57,58 and by smoking in atherosclerotic 
plaque specimens.59  
Similarly, cg09935388 located in the GFI1 gene body has been found to be associated 
with smoking 32,60,61 and exposure to maternal smoking in fetuses.62,63 The growth factor 
independent 1 transcriptional repressor gene, GFI1, encodes a nuclear zinc finger protein that 
plays a role in hematopoiesis, oncogenesis, and in controlling histone modification as part of a 
complex with other cofactors.64,65 cg04761231 is located in the gene body of RPL35, which 
encodes a ribosomal protein, and was also associated with smoking.66,67 cg08958747 is located in 
the gene body region of RAB26, a member of the RAB protein family which are important 
regulators of vesicular fusion and trafficking.68 cg16661609 is located upstream of a 
transcription start site of the LILRB4 gene. LILRB4 (leukocyte immunoglobulin like receptor B4) 
is a member of the leukocyte immunoglobulin-like receptor family. The receptor is expressed on 
immune cells where it transduces a negative signal that inhibits stimulation of an immune 
response and controls inflammatory responses and cytotoxicity to help focus the immune 
responses. One notable finding in MESA was that both the transcriptome signature of AT-rich 
interaction domain 5B (ARID5B) and a cg25953130 site in the gene were associated with CAC 
and carotid plaque atherosclerosis measures.27 In GENOA, cg25953130 was only nominally 
associated with multisite atherosclerosis after adjusting for CVD risk factors (Beta = -0.625, 
95%CI 0.17–1.23, P = 0.044), but the effect direction was consistent across studies. 
In our study, MRSCAC was associated only with CAC, and the association became non-
significant after adjusting for CVD risk factors. MRScarotid was associated with CAC, AAC, and 
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the derived multisite atherosclerosis score. Two of the significant CpGs in MRScarotid explained a 
slightly higher percent of the variability of multisite atherosclerosis compared to that explained 
by MRScarotid, potentially due to added noise generated by including CpGs not as strongly 
associated with atherosclerosis in African Americans. It is not clear why in our sample, carotid 
plaque-associated CpGs were better predictors of atherosclerosis than CAC-associated ones. In 
MESA, out of 7 CpGs associated with CAC (FDR < 0.05) in the full sample, only 3 were 
significant in the African American sub-sample, although the magnitude and direction of effect 
were consistent across ancestry groups. Also, despite having similar age distributions, MESA 
multi-ethnic participants had a higher median CAC score than African Americans in GENOA, 
and MESA also had a lower percentage of females. The prevalence of CAC in GENOA was low 
(median: 18.7 and IQR: 0 – 195.7) with about 40% of the sample having an Agatston score of 
zero while in MESA, participants had a median CAC score of 46 (IQR: 0 – 305), and the 
proportion with no CAC was not reported. This is consistent with evidence from epidemiological 
studies showing that African Americans tend to have lower calcification in the coronary arteries 
compared to whites.69-71 Hence, the CpGs included in the MRSCAC could be related to a more 
extreme form of the trait versus the lower atherosclerosis burden seen in GENOA. Another 
difference between MESA and GENOA is that the methylation signature in MESA was 
measured in monocytes, which have a well-established role in atherogenesis,72,73 while the DNA 
methylation in GENOA was measured in all white blood cells. This could have the effect of 
diluting the associations observed in MESA if some cell types have different methylation 
patterns compared to monocytes.27 Additionally, the ICC of MRSCAC was low, which could 
indicate a lower stability of methylation at these sites. This could be particularly relevant to 
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GENOA, as we assessed the association with CAC 12 years after DNA methylation 
measurement, while in MESA methylation and atherosclerosis were assessed concurrently. 
GrimAA was the only epigenetic age acceleration measure associated with 
atherosclerosis in GENOA. Increased GrimAA, indicative of increased biological aging, was 
associated with higher atherosclerosis. Very few other studies have examined epigenetic age 
associations with subclinical measures of CVD. In a cross-sectional analysis of 2,500 African 
Americans from the Atherosclerosis Risk in Communities (ARIC) study, a 5-year increase in 
both Horvath and the Hannum acceleration measures was associated with an approximately 0.01 
mm increase in carotid intima thickness.28 We did not find associations between the Horvath and 
Hannum measures we evaluated (IEAA and EEAA) and atherosclerosis, and in general our 
findings were varied across our four epigenetic age acceleration measures. These measures 
include different CpG sites, differ in how they were trained, and are hypothesized to capture 
different biological processes and aspects of aging.18,46 Both GrimAA and PhenoAA were 
trained using longitudinal data, making them better predictors of aging-related outcomes.74,75 
Two recent studies of participants of European ancestry have additionally shown that GrimAA 
outperforms the other acceleration measures in its association with incident CVD 25,26 and all-
cause mortality.25,76 Our reported associations attenuated slightly after adjusting for white blood 
cell counts but remained significant, suggesting that the effects were not mediated by blood cell 
composition. In our study, GrimAA was correlated with MRScarotid, with the smoking pack-years 
component of GrimAge being slightly more correlated with MRScarotid than the overall GrimAA 
measure. While we do not know individual the CpGs comprising GrimAge, we know of one 
CpG overlap, cg05575921,17 between GrimAge and MRScarotid, and potentially other smoking 
related CpGs, which partially explains the observed correlations.  
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Our results show that the epigenetic measures most strongly associated with 
atherosclerosis, GrimAA and MRScarotid, had moderate stability (ICC: 0.822 and 0.888, 
respectively) across repeated samples taken approximately 5 years apart. The characteristic of 
reliability over time is an important consideration for biomarkers that may be used for risk 
prediction. Further studies are needed to fully characterize the longitudinal patterns of DNA 
methylation, especially in response to known drivers of DNA methylation changes, such as 
smoking. In GENOA, smoking status was unchanged for the majority of the sample between 
Phases I and III, with only 27 current smokers becoming former smokers. One study that looked 
at the longitudinal changes of fetal DNA methylation in response to maternal smoking using 
serial samples at birth, age 7, and age 17 found evidence of reversible methylation changes at 
cg09935388 (GFI1) and persistent methylation changes at cg05575921 (AHRR).63 An 
epigenome-wide study of adult smoking reported that out of approximately 2,600 CpGs that 
were differentially methylated between current versus never smokers, 185 CpGs showed patterns 
of persistent methylation changes between former versus never smokers, including cg05575921, 
cg09935388, and cg21161138 CpGs.66 Most recently, Dugue et al. reported a reversibility 
coefficient (ratio of regression coefficients comparing former to current smokers and never to 
current smokers) between 69% and 75% at cg05575921, cg09935388, and cg21161138.77 Little 
is known regarding the longitudinal trends of GrimAA; however, a longitudinal trend of 
increased GrimAA with increasing age has been observed in one study.78 
One strength of our study is that we examined atherosclerosis at multiple vascular sites 
which reflect both intimal and medial vascular changes that may manifest differentially over 
time. CAC has been more extensively studied because it appears in a more clinically relevant 
vascular site 79 and is more strongly associated with coronary disease compared to carotid intima 
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thickness.80 Abdominal aorta atherosclerosis has been less extensively studied, yet recent 
evidence suggests that the associations of CAC and AAC with CVD are independent and 
additive.8,13 AAC starts earlier in life and is more prevalent than CAC and may be associated 
with an increased risk of onset and progression of CAC and/or lower ABI.81,82 Given the low 
prevalence of CAC and previous findings that it may not carry the same pathobiologic 
significance in African Americans,83 incorporating extracoronary calcification may be more 
informative and useful for risk assessment. A limitation of our study is the attrition of 
participants between Phases I and III. In a previous work, we have noted that participants who 
were lost to follow-up had higher epigenetic age acceleration and higher CVD risk.84 
Additionally, we did not have measures of carotid plaque which was included in the multisite 
atherosclerosis score that we used as a model for our score in GENOA,45 and the GENOA 
atherosclerosis measures were not all assessed concurrently. Furthermore, seven significant 
CpGs from MESA were not available in GENOA because of the different arrays used.  
In conclusion, our study found evidence of associations between DNA methylation and 
atherosclerosis at multiple vascular sites after accounting for traditional CVD risk factors. DNA 
methylation changes were at CpGs with inflammatory and smoking-related regulatory functions, 
which further highlights the relevance of inflammation and smoking in atherosclerosis. Despite 
being derived from CpGs associated with carotid plaque, MRScarotid was associated with 
atherosclerosis in the coronary arteries and abdominal aorta suggesting common pathobiological 
mechanisms of atherosclerosis on a systemic level. GrimAA was also associated with multisite 
atherosclerosis beyond traditional CVD risk factors. This is one of the very few studies to 
examine the DNA methylation signature of multiple atherosclerosis measures in a population-
based cohort. These results further our understanding of the relationship between aging and 
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Table 4-1: Descriptive characteristics of GENOA African Americans 
 Characteristicsa Overall (N = 391) 
Females (%) 297 (76.0%) 
Age at Phase I (years) 56.0 ± 9.0 
Age at Phase III (years) 68.0 ± 8.4 
Cardiovascular risk factors at Phase I  
Smoking status  
     Never (%) 241 (61.6%) 
     Former (%) 93 (23.8%) 
     Current (%) 57 (14.6%) 
Body mass index (kg/m2) 31.4 ± 6.2 
Hypertension 249 (63.7%) 
Type 2 diabetes 63 (16.1%) 
Total cholesterolb (mg/dl) 208.56 ± 50.4  
Low density lipoproteinc (mg/dl) 121.8 (42.8) 
Statin use (%) 18 (4.6%) 
Atherosclerosis measures at Phase III  
Coronary artery calcium score, median (IQR) 18.7 (0 – 195.7) 
Abdominal aorta calcium score, median (IQR) 500.8 (18.9 – 1800.5) 
Ankle-brachial index, median (range)d 0.985 (0.474 – 1.274) 
Multisite atherosclerosis score, median (IQR) (range: 0 – 12) 5 (2 – 7) 
Methylation risk scores at Phase I  
MRSCAC 
e 0.86 ± 0.71 
MRScarotid -3.60 ± 0.71 
Epigenetic age acceleration at Phase I  
Horvath (years) 52.8 ± 8.9 
Hannum (years) 46.2 ± 9.5 
PhenoAge (years) 42.7 ± 11.5 
GrimAge (years) 52.8 ± 7.9 
, intrinsic epigenetic age acceleration; EEAA, extrinsic epigenetic age acceleration; IQR, interquartile 
range 
a Means ± standard deviation 
b Adjusted for statin use as total cholesterol/0.8 
c Calculated using the Freidwald formula for participants with triglycerides < 400 mg/dl (N=386) 
d Measured at Phase II (mean: 5.2 ± 1.3 years from Phase I)   




Table 4-2: Association between methylation risk scores and atherosclerosis measures in GENOA African Americans 
  
  








MRSCAC 0.421 0.174 0.016 
 0.330 0.173 0.057  0.290 0.165 0.079 
MRScarotid 0.778 0.176 1.26 × 10-5 
 0.484 0.211 0.022  0.479 0.202 0.018 




MRSCAC 0.448 0.191 0.020 
 0.268 0.184 0.145  0.267 0.180 0.138 
MRScarotid 1.062 0.191 5.13 × 10-8 
 0.527 0.224 0.019  0.551 0.221 0.013 
             
Ankle-brachial 
index (ABI) 
MRSCAC 0.012 0.007 0.074 
 0.014 0.007 0.041  0.014 0.007 0.042 
MRScarotid -0.012 0.007 0.085 
 -0.005 0.008 0.586  -0.003 0.008 0.717 




MRSCAC 0.443 0.204 0.030  0.295 0.196 0.134  0.283 0.193 0.143 
MRScarotid 1.196 0.202 7.58 × 10-9   0.679 0.238 0.005   0.669 0.236 0.005 
Model 1 is adjusted for age, sex, time between measures, and 4 genetic principal components  
Model 2 is adjusted for Model 1 covariates and smoking status 
Model 3 is adjusted for Model 2 covariates, hypertension status, diabetes status, body mass index, and total cholesterol levels adjusted for statin use 
Beta is the change in the atherosclerosis measure associated with a 1 unit increase in the MRS. 
P-values significant after Bonferroni correction (P < 0.025) are shown in bold font 




Table 4-3: Associations between epigenetic age acceleration and atherosclerosis measures in GENOA African Americans 
  








IEAA 0.016 0.027 0.555  0.008 0.026 0.750  -0.008 0.025 0.741 
EEAA 0.018 0.023 0.436  0.012 0.022 0.589  0.003 0.021 0.901 
PhenoAA 0.034 0.018 0.056  0.023 0.017 0.191  0.010 0.017 0.532 
GrimAA 0.149 0.028 2.04 × 10-7  0.105 0.034 0.002  0.074 0.033 0.025 





IEAA -0.016 0.029 0.591  -0.025 0.028 0.366  -0.040 0.027 0.139 
EEAA 0.027 0.025 0.285  0.024 0.024 0.311  0.018 0.024 0.437 
PhenoAA 0.046 0.019 0.018  0.033 0.018 0.073  0.028 0.018 0.133 
GrimAA 0.188 0.031 2.94 × 10-9  0.106 0.036 0.004  0.092 0.036 0.012 




IEAA -0.001 0.001 0.562  0 0.001 0.644  -0.001 0.001 0.580 
EEAA 0 0.001 0.649  0 0.001 0.755  0 0.001 0.795 
PhenoAA -0.001 0.001 0.076  -0.001 0.001 0.133  -0.001 0.001 0.149 
GrimAA -0.004 0.001 0.002  -0.003 0.001 0.024  -0.003 0.001 0.026 




IEAA 0.021 0.031 0.489  0.011 0.029 0.713  -0.002 0.029 0.942 
EEAA 0.027 0.027 0.318  0.021 0.026 0.417  0.013 0.025 0.613 
PhenoAA 0.067 0.020 0.001  0.052 0.020 0.008  0.044 0.019 0.023 
GrimAA 0.231 0.032 4.59 × 10-12   0.158 0.038 4.58 × 10-5   0.140 0.038 3.01  × 10-4 
IEAA: intrinsic epigenetic age acceleration; EEAA: extrinsic epigenetic age acceleration; PhenoAgeAccel: PhenoAge acceleration; GrimAgeAccel: 
GrimAge acceleration 
Model 1 is adjusted for age, sex, and time between measures 
Model 2 is adjusted for Model 1 covariates and smoking status 
Model 3 is adjusted for Model 2 covariates, hypertension status, diabetes status, body mass index, and total cholesterol levels adjusted for statin use 
Beta is the change in the atherosclerosis measure associated with a 1 unit increase in the epigenetic age acceleration measure 
P-values significant after Bonferroni correction (P < 0.0125) are shown in bold font 




Table 4-4: Inter-individual correlations for methylation risk scores and epigenetic age 
acceleration measures between Phases I and II in GENOA African Americans (N=129) 
Measures Intraclass correlation coefficient (95%CI) 
MRSCAC 0.519 (0.385 – 0.645) 
MRSCarotid 0.822 (0.764 – 0.874) 
IEAA 0.726 (0.635 – 0.802) 
EEAA 0.799 (0.726 – 0.854) 
PhenoAA 0.676 (0.569 – 0.758) 
GrimAA 0.888 (0.848 – 0.921) 
IEAA: intrinsic epigenetic age acceleration; EEAA: extrinsic epigenetic age acceleration; 





5.1 Supplementary material 
Table SM 4-1: Pearson correlations between epigenetic age acceleration measures and methylation risk scores in GENOA African 
Americans 
  IEAA EEAA AgeAccelPheno AgeAccelGrim MRSCAC 
IEAA           
EEAA 0.39****         
AgeAccelPheno 0.44**** 0.46****       
AgeAccelGrim 0.21**** 0.27**** 0.31****     
MRSCAC 0.08 0.20*** 0.15** 0.19****   
MRScarotid 0.19*** 0.25**** 0.21**** 0.62**** 0.39**** 
*** p < .0001; ** p < .01; * p < .05 






Table SM 4-2: Association between previously-identified atherosclerosis-associated CpGs and atherosclerosis measures in GENOA 
African Americans a 
  
Multisite atherosclerosis 
Coronary artery calcium score 
 (CAC)b 




CpGs Beta SE P FDR Beta SE P FDR Beta SE P FDR Beta SE P FDR 
cg05575921 -1.109 0.160 1.64E-11 8.75E-10† -0.570 0.141 6.32E-05 0.005 -1.050 0.150 1.16E-11 8.32E-10† 0.019 0.006 0.001 0.039 
cg21161138 -2.495 0.435 1.93E-08 5.14E-07† -1.382 0.381 3.26E-04 0.008 -2.168 0.412 2.34E-07 8.37E-06 0.047 0.015 0.002 0.039 
cg09935388 -1.158 0.212 8.67E-08 1.54E-06† -0.676 0.184 2.81E-04 0.008 -1.013 0.201 6.83E-07 1.63E-05 0.023 0.007 0.001 0.039 
cg21566642 -1.525 0.353 1.97E-05 2.63E-04 -0.759 0.306 0.013 0.092 -1.520 0.331 6.05E-06 1.08E-04 0.017 0.012 0.161  
cg01940273 -1.530 0.398 1.41E-04 0.001 -0.614 0.343 0.075  -1.519 0.374 5.79E-05 0.001 0.017 0.014 0.204  
cg08958747 -1.869 0.488 1.49E-04 0.001† -1.310 0.420 0.002 0.036 -0.818 0.466 0.080  0.032 0.017 0.054  
cg24859433 -1.224 0.340 3.69E-04 0.003 -0.860 0.295 0.004 0.057 -1.064 0.322 0.001 0.009 0.015 0.011 0.186  
cg14753356 -1.511 0.447 0.001 0.005 -1.069 0.384 0.006 0.063 -1.143 0.422 0.007 0.046 0.022 0.015 0.138  
cg19572487 -1.325 0.390 0.001 0.005 -0.707 0.340 0.038  -1.479 0.364 0.000 0.001 0.021 0.013 0.108  
cg04761231 -2.169 0.676 0.001 0.007† -0.945 0.581 0.104  -1.420 0.640 0.027  0.030 0.023 0.200  
cg25953130 -1.019 0.319 0.001 0.007 -0.509 0.274 0.064  -0.759 0.301 0.012 0.061 0.021 0.011 0.057  
cg03636183 -0.841 0.273 0.002 0.010 -0.597 0.232 0.011 0.079 -0.767 0.258 0.003 0.025 0.010 0.009 0.286  
cg18168448 -1.076 0.369 0.004 0.016 -0.872 0.316 0.006 0.063 -0.627 0.349 0.073  0.012 0.012 0.348  
cg15342087 -1.070 0.375 0.005 0.017 -0.865 0.322 0.008 0.063 -0.926 0.354 0.009 0.055 0.018 0.013 0.151  
cg18446336 -0.658 0.275 0.017 0.061 -0.462 0.235 0.050  -0.903 0.257 0.000 0.005 0.000 0.009 0.961  
cg16661609 -1.386 0.603 0.022 0.070† -0.250 0.519 0.631  -1.312 0.568 0.021 0.090 0.010 0.020 0.619  
cg19979108 -0.988 0.429 0.022 0.070 -0.683 0.369 0.065  -0.497 0.406 0.222  0.023 0.014 0.119  
cg09646173 -1.115 0.497 0.025 0.075 -0.502 0.430 0.244  -0.211 0.470 0.653  0.023 0.017 0.177  
cg05246522 -0.838 0.386 0.030 0.085 -0.658 0.334 0.050  -0.612 0.363 0.093  -0.007 0.013 0.599  
cg15501219 -1.820 0.878 0.039 0.099 -1.090 0.753 0.148  0.157 0.831 0.850  0.056 0.029 0.056  
cg21271420 -1.345 0.650 0.039 0.099 -1.008 0.560 0.073  -0.612 0.614 0.320  0.025 0.022 0.262  
cg03295554 -0.649 0.328 0.049  -0.439 0.281 0.119  -0.763 0.308 0.014 0.061 -0.002 0.011 0.878  
cg03738331 0.979 0.492 0.047  0.165 0.424 0.697  1.144 0.461 0.014 0.061 -0.034 0.016 0.040  
cg12547807 -1.191 0.598 0.047  -0.375 0.514 0.466  -0.792 0.565 0.162  0.057 0.020 0.005 0.070 
cg15344028 -0.480 0.308 0.120  -0.371 0.261 0.156  -0.832 0.287 0.004 0.029 -0.005 0.010 0.619  
cg20507228 0.303 0.351 0.389  0.805 0.299 0.007 0.063 0.844 0.327 0.010 0.057 0.028 0.012 0.016  
Model 1 is adjusted for age, sex, time between measures, and 4 genetic principal components 
Beta is the change in the atherosclerosis measure associated with a 1 unit increase in the CpG methylation. 
FDR > 0.10 are left blank 
a Only associations with FDR<0.1 in Model 1 for any of the four measures of atherosclerosis are shown. 
b Coronary artery calcium score and abdominal aorta calcification score were transformed as ln[(CAC+1)] and ln[(AAC+1)] 
†Associations that remained significant in Model 3 (adjusted for Model 1 plus smoking status, type 2 diabetes status, hypertension status, BMI, and statin-






Table SM 4-3: Association between previously-identified atherosclerosis-associated CpGs and atherosclerosis measures in GENOA 













Model 3 is adjusted for age, sex, time between measures, 4 genetic principal components, smoking, T2D status, hypertension status, BMI, and statin-adjusted 
total cholesterol levels. 
Beta is the change in the atherosclerosis measure associated with a 1 unit increase in the CpG methylation. 
FDR > 0.10 are left blank 
a Only associations with FDR<0.1 in Model 3 for any of the four measures of atherosclerosis are shown.  
b Coronary artery calcium score and abdominal aorta calcification score were transformed as ln[(CAC+1)] and ln[(AAC+1)
    
Multisite atherosclerosis  
Coronary artery calcium 
score (CAC)b 
 Abdominal aorta calcification 
score (AAC)b 
 Ankle-brachial index  
(ABI) 
CpGs  Beta SE P FDR  Beta SE P FDR  Beta SE P FDR  Beta SE P FDR 
cg05575921  -0.806 0.223 3.38E-04 0.020  -0.390 0.193 0.044   -0.760 0.208 2.88E-04 0.019  0.016 0.008 0.040  
cg04761231  -1.710 0.646 0.008 0.091  -0.812 0.550 0.141   -1.169 0.604 0.054   0.017 0.023 0.469  
cg08958747  -1.267 0.474 0.008 0.091  -0.841 0.404 0.038   -0.338 0.446 0.449   0.022 0.017 0.199  
cg09935388  -0.609 0.232 0.009 0.091  -0.323 0.198 0.104   -0.482 0.217 0.027   0.018 0.008 0.027  
cg16661609  -1.583 0.570 0.006 0.091  -0.496 0.487 0.309   -1.541 0.531 0.004   0.011 0.021 0.577  





Table SM 4-4: Association between epigenetic age acceleration measures and single and multisite atherosclerosis after adjusting for 
white blood cell counts in GENOA African Americans 








PhenoAA 0.041 0.019 0.030  0.024 0.019 0.202  0.010 0.018 0.595 
GrimAA 0.149 0.029 2.85 × 10-7  0.108 0.036 0.003  0.073 0.035 0.036 





PhenoAA 0.052 0.020 0.012  0.029 0.020 0.149  0.020 0.019 0.300 
GrimAA 0.194 0.031 1.07 × 10-9  0.106 0.038 0.005  0.087 0.038 0.023 




PhenoAA -0.001 0.001 0.069  -0.001 0.001 0.135  -0.001 0.001 0.135 
GrimAA -0.003 0.001 0.002  -0.003 0.001 0.016  -0.004 0.001 0.016 




PhenoAA 0.074 0.022 0.001  0.050 0.021 0.019  0.040 0.021 0.054 
GrimAA 0.231 0.033 7.25 × 10-11  0.157 0.040 1.08 × 10-4  0.137 0.040 7.87 × 10-4 
PhenoAgeAccel: PhenoAge acceleration; GrimAgeAccel: GrimAge acceleration 
Model 1 is adjusted for age, sex, time between measures, and 5 white blood cell counts 
Model 2 is adjusted for Model 1 covariates and smoking status 
Model 3 is adjusted for Model 2 covariates, hypertension status, diabetes status, body mass index, and total cholesterol levels adjusted for lipid lowering 
medications  
Beta is the change in the atherosclerosis measure associated with a 1 year increase in the epigenetic age acceleration measure.  
Association with P < 0.05 are shown in bold font 






Table SM 4-5: Association between components of GrimAge and single and multisite atherosclerosis in GENOA African Americans 
 
 
Coronary artery calcium 
score 
(CAC)a 




Ankle brachial index 
(ABI) 
 
Multisite atherosclerosis score 
GrimAge component 
(Predictor)  
Beta SE P 
 
Beta SE P 
 
Beta SE P 
 




 0.333 0.182 0.068 
 
0.037 0.2 0.853 
 
-0.012 0.007 0.104 
 
0.472 0.211 0.026 
DNAm Beta-2-
microglobulim (B2M) 
 0.372 0.167 0.026 
 
0.582 0.184 0.002 
 
-0.013 0.007 0.052 
 
0.557 0.195 0.005 
DNAm Cystatin C  0.558 0.23 0.016 
 
0.393 0.256 0.126 
 
-0.035 0.009 1.12E-04 
 
0.859 0.269 0.002 
DNAm 
Growth Differentiation 
Factor 15 (GDF15) 
 0.354 0.158 0.026 
 
0.512 0.174 0.003 
 
-0.003 0.006 0.579 
 
0.431 0.185 0.021 
DNAm Leptin  0.424 0.238 0.076 
 
0.175 0.26 0.502 
 
4.68E-04 0.009 0.959 
 
0.281 0.276 0.31 
DNAm Smoking pack-
years 
 0.569 0.132 2.21E-05 
 
1.05 0.139 3.19E-13 
 
-0.012 0.005 0.024 
 
1.021 0.149 3.23E-11 
DNAm Plasminogen 
activator inhibitor 
antigen type 1 (PAI1) 
 0.457 0.127 3.48E-04 
 
0.282 0.141 0.046 
 
0.001 0.005 0.892 
 
0.447 0.148 0.003 
DNAm Tissue inhibitor 
metalloproteinases 1 
(TIMP1) 
 0.413 0.216 0.058 
 
-0.013 0.241 0.958 
 
-0.009 0.009 0.288 
 






Table SM 4-6: Association between methylation risk scores at Phase II and atherosclerosis 
measures in GENOA African Americans (N = 129) 
Outcome Epigenetic measure Beta SE P 
Coronary artery calcium 
score  
(CAC) a 
MRSCAC 0.156 0.315 0.621 
MRSCarotid 0.297 0.306 0.333 
         
Abdominal aorta 
calcification score  
(AAC) a 
MRSCAC 0.154 0.353 0.663 
MRSCarotid 0.894 0.333 0.008 
         
Ankle Brachial Index  
(ABI) 
MRSCAC 0 0.011 0.949 
MRSCarotid -0.010 0.011 0.596 
         
Multisite atherosclerosis 
score 
MRSCAC 0.133 0.354 0.707 
MRSCarotid 0.891 0.333 0.009 
Model is adjusted for age, sex, time between measures, and 4 genetic principal components  
Beta is the change in the atherosclerosis measure associated with a 1 unit increase in the MRS. 
P-values significant after Bonferroni correction (P < 0.025) are shown in bold font 






















Figure SM 4-1: Distribution of single- and multi-site atherosclerosis measures in GENOA African Americans 








Figure SM 4-2: Distribution of MRSCAC and MRScarotid in GENOA African Americans 





 IEAA, intrinsic epigenetic age acceleration; EEAA, extrinsic epigenetic age acceleration. 
B 
Figure SM 4-3: Scatterplots and Pearson correlation coefficients for MRSCAC (A) and MRScarotid (B) and epigenetic age acceleration 




















Figure SM 4-4: Methylation at the cg05575921 (A), cg21161138 (B) and cg09935388 (C) by 









IEAA, intrinsic epigenetic age acceleration; EEAA, extrinsic epigenetic age acceleration. 
Blue lines indicate the mean change of the methylation risk scores or epigenetic age acceleration measures by age using generalized estimating equation (GEE) 
models adjusted for sex. 
 
Figure SM 4-5: Spaghetti plots for the change in participant methylation risk scores (MRSCAC and MRScarotid) and epigenetic age 
acceleration (IEAA, EEAA, PhenoAA, and GrimAA) between Phase I and Phase II in GENOA African Americans 
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Chapter 5.  Conclusions 
5.1 Summary and Implications of Main Findings 
The primary goals of this dissertation were to: (1) examine the epigenome wide 
association between DNA methylation and 5 TOD measures of functional and structural changes 
in the heart, kidneys and brain using univariate and multivariate models; (2) evaluate whether 
epigenetic age acceleration measures are associated with cardiometabolic markers and CVD 
incidence; and (3) examine the association between epigenetic age acceleration measures and 
previously-identified CpGs for atherosclerosis, both individually and aggregated into MRSs, and 
single- or multi-site atherosclerosis. Findings from this work advance our knowledge about the 
relationship between DNA methylation, aging, and CVD, highlighting the important role of 
epigenetics in subclinical and clinical CVD and TOD.  
In Chapter 2, we addressed whether DNA methylation sites are associated with eGFR, 
albuminuria, left ventricular mass index, relative wall thickness, and white matter hyperintensity 
in GENOA African Americans. For TOD traits related to the heart and kidneys, we used a 
multivariate (pleiotropy) model that leverages the correlation between those traits to identify 
differentially methylated CpGs. Using this model, we successfully identified seven CpGs: 
cg21134922, cg04816311 near C7orf50, cg09155024, cg10254690 near OAT, cg07660512, 
cg12661888 near IFT43, and cg02264946 near CATSPERD at FDR < 0.1. Three CpGs remained 
significant after adjusting for hypertension, BMI, and type 2 diabetes. DNA methylation was 
associated with proximal gene expression for some CpGs, but we did not find evidence of 
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mediation by gene expression. Mendelian randomization analyses suggested causality between 
three CpGs and eGFR (cg04816311, cg10254690, and cg07660512). In a replication analysis in 
an independent cohort of 614 African Americans from the Hypertension Genetic Epidemiology 
Network (HyperGEN), One site, cg04816311, was significantly associated with eGFR (P = 
0.0003), LVMI (P = 0.0003), and RWT (P = 0.002).  
Our study findings are important because they fill in the gap in the current literature on 
the role of epigenetics in TOD. To date, very few studies have examined the association between 
genome-wide DNA methylation and TOD traits.1 Our sample which was comprised of largely 
hypertensive African Americans is representative of the population group most burdened by 
hypertension and downstream TOD. We have additionally showed the utility of using a 
pleiotropy informed analysis to increase statistical power and improve detection of significant 
DNA methylation sites. Finally, our conclusions were further supported by our ability to adjust 
for important comorbidities to delineate potentially important biological TOD pathways, the use 
of Mendelian randomization to assess causality, and the replication of some of our findings in an 
independent cohort of African Americans.   
In Chapter 3, we investigated the association between four DNAm-based epigenetic age 
acceleration measure and ten cardiometabolic risk factors and CVD incidence in GENOA 
African Americans. Overall, increased epigenetic age acceleration, indicative of faster biological 
aging was associated with a worse cardiometabolic risk profile, although the associations with 
specific cardiometabolic risk factors varied across the age acceleration measures.  All of the 
epigenetic acceleration measures were correlated with risk of CVD onset as modeled by clinical 
CVD risk scores (FRS and ASCVD equation). The direction of association was as expected (i.e. 
increased biological aging was associated with increased risk of CVD as predicted by FRS 
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and/or ASCVD). GrimAA outperformed IEAA, EEAA, and PhenoAA in predicting CVD 
incidence, and the association remained significant after adjusting for traditional CVD risk 
factors. A 5-year increase in GrimAA, was associated with a hazard ratio of 1.47 (95% CI: 1.05 
– 2.01, P = 0.024) for incident CVD. Finally, we examined whether GrimAA could be used to 
improve the predictive accuracy of clinical CVD risk scores. GrimAA improved model fit over 
clinical risk scores using likelihood ratio tests (P = 0.013 for FRS, P = 0.008 for ASCVD), did 
not improve C statistics (P > 0.05), and marginally improved the net reclassification index (NRI 
= 0.055, 95% CI: 0.040 – 0.071 for FRS; 0.029, 95% CI: 0.006 – 0.064 for ASCVD). 
The results of this study are important because they add to the growing literature 
examining the associations between epigenetic age acceleration measures, CVD, and its risk 
factors. Our study included two “first generation” and two “second generations” measures. The 
observation that GrimAA, a “second generation” measure, outperforms the other 3 measures in 
predicting incident CVD has also been observed in two large cohorts with participants of 
Europeans/Caucasian ancestry.2,3 Our findings suggest that the association between GrimAA and 
CVD incidence is shared across these two racial groups, with similar effect sizes across the three 
studies. Our study was the first to go beyond evaluating statistical associations by assessing the 
predictive utility of epigenetic age acceleration measures to improve CVD risk prediction. Our 
findings highlight the potential relevance of epigenetic markers for the improvement of risk 
stratification of CVD beyond traditional risk factors and CVD risk scores currently used 
clinically.  
In Chapter 4, we build upon our findings in Chapter 3 where we found evidence of 
association between epigenetic age acceleration measures and CVD. In this study, we examined 
the association between previously identified atherosclerosis-associated CpGs (individually and 
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aggregated into MRSs), epigenetic age acceleration measures, and subclinical CVD. To quantify 
subclinical CVD, we used three measures of atherosclerosis in the coronary arteries (CAC), 
abdominal aorta (AAC), and peripheral arteries (ABI). We additionally derived a multisite 
atherosclerosis score combining these three measures. When we examined the association with 
previously-identified CpGs, one and six CpGs were associated with AAC and multi-site 
atherosclerosis, respectively (FDR < 0.1). A one unit increase in the MRS for carotid artery 
calcification was associated with a 1.6-fold increase in AAC and 0.7 units increase in multi-site 
atherosclerosis (score range: 0-12) after adjusting for CVD risk factors (Bonferroni-adjusted P < 
0.05). As we expected based on our findings in Chapter 3, GrimAA was the only measure 
associated with AAC and multisite atherosclerosis after adjustment for CVD risk factors 
(Bonferroni-adjusted P < 0.05). We also observed that the epigenetic measures most strongly 
associated with atherosclerosis, GrimAA and MRScarotid, had moderate stability (ICC: 0.822 and 
0.888, respectively) across repeated samples taken approximately 5 years apart. 
To our knowledge, this is one of the few studies to examine the whole blood DNA 
methylation signature of multiple atherosclerosis measures in a population-based cohort. It is 
also one of the few studies to use a prospective design where DNA methylation was measured 
approximately 5 and 12 years prior to the assessment of atherosclerosis. Our finding that 
GrimAA, but not other measures of epigenetic age, is associated with subclinical CVD supports 
our previously reported association between GrimAA and CVD incidence. We also found that 
some associations between DNA methylation and atherosclerosis are consistent across African 
Americans in GENOA and white participants in other studies. Finally, our results support the 
notion that associations between epigenetic biomarkers and atherosclerosis have similarities 
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across vascular sites and suggests common underlying biological mechanisms of atherosclerosis 
at these sites. 
More studies are needed to better elucidate the biological pathways implicated in the 
associations described in this dissertation and fully explore regulatory and downstream gene 
expression changes. In Chapter 2, our multivariate model and subsequent univariate models 
confirm our hypothesis that common biological mechanisms underly the TOD measures of 
multiple organ systems. For the identified CpGs, we only investigated proximal gene expression 
changes and lacked the power to detect mediating effects. However, our findings shed light on 
the potential role of pathways related to nitric oxide (NO) as an underlying mechanism of TOD. 
NO is an important messenger molecule that regulates blood vessel dilation and has other 
thrombotic and inflammatory effects.4 Further, one identified CpG, cg04816311 near C7orf50, 
has been previously associated with type 2 diabetes and BMI. This suggests the possibility of 
common biological mechanisms underlying comorbidities in multiple organ systems.    
In Chapter 3, we found a significant association between GrimAA and CVD incidence. 
Since information about the individual CpGs comprising GrimAge are not available, we 
explored the association between each component of GrimAge and CVD incidence to understand 
potential biological pathways leading to the observed association. Of the GrimAge components, 
we found that adrenomedullin, plasminogen activator inhibitor antigen type 1, and smoking 
pack-years are associated with CVD incidence. Adrenomedullin is a free-circulating peptide that 
is an important vasodilator and has other biological functions, especially involving the heart.5 
Studies suggest that adrenomedullin levels are increased in acute myocardial infarction and in 
hypertrophied and failing hearts as a protective mechanism against cardiac dysfunction, 
myocardial remodeling, or both.5 Plasminogen activator inhibitor antigen type I (PAI-1) is a 
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biomarker of fibrinolysis, the degradation of fibrin as a result of complex interaction among 
multiple plasminogen activators and inhibitors. PAI-1 is one of the most important inhibitors of 
plasma fibrinolytic activity. In vivo, PAI-1 expression suppresses fibrinolysis leading to 
pathological fibrin deposition resulting in atherothrombosis and tissue damage.6-8 PAI-1 
expression has been found to play an important role in subclinical and clinical conditions related 
to aging including increased inflammation, atherosclerosis, and obesity.6  
Smoking is a well-established risk factor for CVD. Evidence from animal and clinical 
studies show that a number of mechanisms precipitate the effects of smoking on CVD. Smoking 
has been reported to reduce flow-mediated dilatation in the systemic arteries which is an early 
marker for endothelial dysfunction.9 It has also been associated with quantitative and qualitative 
modulation of lipids leading to increased levels of total cholesterol, LDL-C, and triglycerides in 
addition to increased lipid oxidation.9 Furthermore, smoking is associated with increased 
activation of the immune system, both systematically and locally, which is an important 
constituent of atherogenesis. The increased inflammation results in increased white blood cell 
counts, changes in the vascular wall leading to increased expression of matrix 
metalloproteinases, and increased endothelial adhesion molecules leading to leukocyte 
recruitment.9 Hence, our findings lend further evidence to the potential role of these components 
in shaping cardiovascular health and risk. Finally, it is important to note that the DNAm-based 
surrogate measures of these components may be more strongly associated than the measures 
themselves.10 In the case of smoking, this may be due to inaccurate reporting or exposure to 
secondhand smoking, but it can also be due to DNAm capturing the intrinsic variations 
associated with long-term biological changes related to the plasma proteins and/or smoking. 
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In Chapter 4, we found similar evidence of the role of smoking in atherosclerosis, which 
was evident in the hypomethylation signature at a number of CpGs in the AHRR and GFI1 genes. 
Additionally, we found evidence of an association between hypomethylation at cg16661609, 
located upstream of a transcription start site of the LILRB4, and atherosclerosis. This gene 
encodes a protein belonging to the subfamily B class of the leukocyte immunoglobulin-like 
receptors and is expressed on immune cells. This receptor binds to antigen-presenting cells and 
transduces a negative signal that inhibits stimulation of an immune response. We additionally 
found evidence of association between increased biological aging, as measured by GrimAge, and 
atherosclerosis. Each of the GrimAge components was associated with multisite atherosclerosis 
with the exception of Leptin and Tissue inhibitor metalloproteinases 1 (TIMP1). Smoking pack-
years was the most strongly associated component, and it was associated with all the 
atherosclerosis measures in GENOA. 
While it is well known that atherosclerosis is an aging disease, it is not clearly understood 
how the association between aging and atherosclerosis unfolds. DNA methylation, under both 
genetic and environmental control, may be an important link by which increased aging leads to 
atherosclerosis. Epigenetic changes with chronological age are currently recognized to be either 
age-related methylation changes or epigenetic drift.11,12 Age-related methylation refers to the 
predictable, direction-specific changes in DNA methylation levels that occur with chronological 
age.13,14 This concept is linked to epigenetic age acceleration measures or clocks. Epigenetic 
drift, on the other hand, is a reflection of deficient maintenance of epigenetic marks leading to 
the loss of hypomethylation in hypermethylated regions and gains in hypomethylated ones. 
These changes in the epigenome are thought to be stochastic, bidirectional, and to have varying 
contribution to the epigenome across the life course.14 Recently, Kochmanski and colleagues 
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coined the term “environmental deflection” to refer to a process by which an environment can 
increase or decrease age-related methylation and epigenetic drift.14 Our study found evidence of 
association between age-related DNA methylation changes (GrimAA), other CpGs combined 
into MRSs, and atherosclerosis. It is possible that the epigenetic biomarkers associated with 
atherosclerosis in our study could be showing evidence of environmental deflection, potentially 
due to traditional CVD risk factors including smoking. Evidence of epigenetic deflection due to 
smoking has been observed, for example, in our most significant CpG, cg05575921 in the AHRR 
gene region.15 
Collective findings from this dissertation advance our knowledge about the associations 
between DNA methylation changes and DNA methylation based aging measures and CVD risk 
factors, subclinical and clinical disease in African Americans. Replication studies are needed to 
characterize whether our findings generalize to other cohorts of African Americans, as well as 
other African and non-African ancestries. Our GENOA cohort was recruited from Jackson, 
Mississippi, and most African ancestry individuals in this area are from coastal Western African 
and Nigerian origins.16,17 Ancestry analysis of GENOA African Americans using genetic 
principal components confirms that this is a population with relatively homogenous ancestry. 
Both genetic variation and environmental factors impact DNA methylation.18 Hence, our 
findings may not generalize to other African American cohorts of similar genetic ancestry due to 
differences in environmental exposures which can influence the epigenome during the early 
stages of embryo development and later in life.17-20 Likewise, it remains unclear whether our 
findings are generalizable to other cohorts of different ancestries. Future studies with multiethnic 
participants and repeated DNA methylation measurements, including early in life, may elucidate 
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the differences in DNA methylation between different groups and improve our understanding of 
the contribution of differential DNA methylation to human variation and phenotypes. 
5.2 Strengths and Limitations 
While this dissertation contributes to our understanding of the role of DNA methylation 
in CVD, TOD, and their risk factors, it has several important limitations. First, our sample is 
comprised of individuals from sibships with a strong family history of hypertension. This may 
limit the generalizability of our findings. To address these concerns, we have adjusted our 
findings for hypertension or blood pressure measurements when appropriate. Second, we note 
the attrition of participants between Phase I and the follow-up visits (Phases II and III). We 
addressed concerns regarding selection bias by comparing the baseline characteristics of those 
lost to follow up and those who returned for later Phases. We noted that loss to follow-up may 
have biased the associations towards the null. Third, CVD events were defined based on 
participant reports, and were not validated using medical records examination. Given this, our 
findings regarding CVD risk prediction should be validated in studies with access to medical 
records. Last, although we used longitudinal data and Mendelian randomization for some of the 
reported associations, it remains difficult to establish causality between changes in the 
epigenome and CVD or TOD. 
This dissertation has several strengths. First, we used a prospective design where DNA 
methylation was assessed prior to our outcomes of interest. For CVD and TOD, it is difficult to 
determine the timeline of true onset. However, our study design partially addresses concerns 
related to reverse causation and offers further validation of previous cross-sectional reports. 
Second, our rich phenotyping, which included a number of lifestyle and clinical measures in 
addition to genetic and transcriptomic data, allowed us to control for important confounders, 
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explore the causality of our associations using Mendelian randomization analysis, and 
characterize potential functional effects by assessing gene expression changes. Third, our 
findings further our understanding of the role of DNAm in CVD in African Americans who are 
underrepresented in previous literature. Finally, we employed multiple methods to assess the 
associations between DNA methylation and related outcomes. In Aim 1, we used multivariate 
modelling that leverages the correlation between TOD measures and increases statistical power 
and decreases the burden of multiple testing. In Aim 3, we took a different approach by creating 
a multisite atherosclerosis score based on three single site atherosclerosis measures. This 
approach allowed us to model the associations with the different atherosclerosis measures and 
draw conclusions on the presence of multisite atherosclerosis. Such conclusions would not have 
been possible using multivariate approaches which would have allowed us to only test whether 
DNA methylation is associated with at least one of the single site atherosclerosis measures.  
5.3 Future Directions 
This dissertation builds upon previous work that identified DNAm to be an important 
mechanism that captures the imprints of lifestyle and environmental exposures throughout the 
life course. The collective results generated from this dissertation have important implications 
that may be leveraged to improve risk stratification and prediction of CVD and TOD. Our 
findings emphasize that the etiology of these complex disease is intricate and is a result of 
interaction between different “omic” layers and environmental factors. Future studies that are 
able to more fully integrate “omic” data, including transcriptomics, proteomics, and 
metabolmics, can answer important questions regarding underlying biological mechanisms and 
processes for the associations identified. Furthermore, closer examination of downstream gene 
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expression changes due to DNAm changes can answer important questions on the proximal and 
distal regulatory effects of DNAm on gene expression in relation to CVD and TOD.  
Additionally, beyond identification of significant CpGs and/or biomarkers, future studies 
with the capacity to delineate pathways of associations are of utmost importance. This could be 
achieved by using Mendelian randomization to identify causal effects of DNAm on CVD and its 
risk factors white controlling for confounding and reverse causation. DNAm associations with 
CVD and TOD could be due to causal pathways that can be targeted for potential interventions. 
Mendelian randomization could be used to refute causality where the DNAm patterns in the 
white blood cells are reflective of early signs of disease onset and elevated disease risk. Hence, 
DNAm offers the potential for identifying and quantifying key epigenetic modifications that may 
help to improve risk stratification and prediction of CVD and TOD.  Combined with other 
precision medicine efforts, this may translate into tailored interventions based on genomic and 
molecular profiles, in addition to environmental exposures, of individuals. 
Finally, larger studies with longer follow-up periods and repeated DNA methylation 
measurement would be better powered to investigate the role of DNA methylation in these age-
related outcomes. Such studies would be less biased by reverse causality and are better powered 
to detect associations with health conditions that have long onset durations. In this dissertation, 
our outcome measures were assessed after DNA methylation, which helped establish temporal 
patterning for our associations. We additionally used Mendelian randomization to help further 
investigate the causality of our findings when possible. Repeated DNA methylation measurement 
was also essential to help further our understanding of DNA methylation changes over time. In 
Aim 3, we used a small sample of about 130 participants with repeated DNA methylation 
measurements to investigate the temporal stability of our epigenetic predictors. GEE models 
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allow us to model the methylation as repeated measures while incorporating within-subject and 
between-subject variations into model fitting. However, a larger sample size would have allowed 
us to further investigate trends and increased our statistical power. Hence, future adequately 
powered studies with repeated measures are essential to further our understanding of the role of 
DNA methylation in CVD and TOD.  
5.5 Conclusion 
Together, these studies support the premise that DNAm plays an important role in CVD 
and TOD and is a promising biomarker that may improve risk assessment in African Americans. 
Chapter 2 identified seven CpGs associated with TOD with suggestive evidence of causality. 
Findings from Chapters 3 and 4 shed important insights on the role of DNAm in atherosclerosis, 
CVD risk factors, and subsequent CVD incidence. Our findings contribute to the rapidly 
evolving picture of the role of epigenetics in CVD and TOD in African Americans. Insights from 
this dissertation can chart a new path forward for improved risk prediction, advances in precision 
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